{
    "questions": [
        {
            "body": "Which micro-RNAs (miR) are associated with the human cycloxygenase-2 (COX-2) gene promoter?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28182010",
                "http://www.ncbi.nlm.nih.gov/pubmed/22049153",
                "http://www.ncbi.nlm.nih.gov/pubmed/24616567",
                "http://www.ncbi.nlm.nih.gov/pubmed/29945115",
                "http://www.ncbi.nlm.nih.gov/pubmed/29404887",
                "http://www.ncbi.nlm.nih.gov/pubmed/29511456",
                "http://www.ncbi.nlm.nih.gov/pubmed/24472607",
                "http://www.ncbi.nlm.nih.gov/pubmed/27900011",
                "http://www.ncbi.nlm.nih.gov/pubmed/29524580",
                "http://www.ncbi.nlm.nih.gov/pubmed/28678919",
                "http://www.ncbi.nlm.nih.gov/pubmed/25907560"
            ],
            "ideal_answer": [
                "MicroRNA-16, miRNA-128, miR-26b, icroRNA-26a, MicroRNA-146b-3p, microRNA-137, mi R-146a, mir-143-5p,microRNA-101, microRNAs-142-3 p, mi r-146p, mir-128 and miR -128 were found to be associated with the human cycloxygenase-2 (COX-2) gene promoter.",
                "miR-146a, miR-203, miRNA-124a, microRNA-155, miRS-146b, miS-146c, miG-145, miRP-148a, let-7b, siRNA-181, miRNAs-152, miN-182, mir-223, myosin heavy chain, are associated with the human cycloxygenase-2 (COX-2) gene promoter We also report the following miRNA associations with the COX- 2 gene promoters: miCENP-1,",
                "Recently, the human cycloxygenase-2 (COX-2) gene promoter has a microRNA (miR) promoter region that is highly expressed in non-cancer cells and is associated with the cell cycle. MicroRNA-16, miRNA-128, microRNA-26a, miRNAs-142-3p, miR-144, mi R-146b-3 p, mir-146a, icroRNA- 26a, -26b,microRNA-137, mi r-146 a, mir-143-5p,",
                "miR-16 was shown to bind the COX-2 3'-UTR and inhibit COX-2 expression by promoting rapid mRNA decay.  miR-143-5p directly targets COX-2. The NF-kB family member RelB regulates microRNA miR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts. TargetScan analysis predicted COX-2 as a target of miR-26a and miR-26b. miR-26a/-26b decreased luciferase activity associated with COX-2-3'-UTR. microRNA-142-3p inhibits apoptosis and inflammation induced by bleomycin through down-regulation of Cox-2 in MLE-12 cells. MicroRNA-144 is regulated by CP2 and decreases COX-2 expression and PGE2 production in mouse ovarian granulosa cells. The down-regulation of microRNA-137 contributes to the up-regulation of retinoblastoma cell proliferation and invasion by regulating COX-2/PGE2 signaling. MicroRNA-128 inhibits proliferation and invasion of glioma cells by targeting COX-2. Altered expression of miR-146b-3p is closely related to the progression and development of DCMI mediating the RAF/P38MAPK/COX-2 signal transduction pathway. MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.",
                "The following micro-RNAs (miRNAs) have been associated with the human cycloxygenase-2 (COX-2) gene promoter: microRNA-16, miRNA-128, micro RNA-26a, miR-142-3p, mir-144, mi r-146b-3 p, mir-16), mir-26b, icroRNA-26 a, MicroRNA-146 b-3P, mir-146a, mir -143-5p, mir microRNA-137, mir--MicroRNA"
            ],
            "exact_answer": [
                [
                    "miR-16"
                ],
                [
                    "miR-143-5p"
                ],
                [
                    "miR-146a"
                ],
                [
                    "miR-26a"
                ],
                [
                    "miR-26b"
                ],
                [
                    "miR-142-3p"
                ],
                [
                    "miR-144"
                ],
                [
                    "miR-137"
                ],
                [
                    "miR-128"
                ],
                [
                    "miR-146b-3p"
                ],
                [
                    "miR-101"
                ]
            ],
            "type": "list",
            "id": "5d38673da1e1595105000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22049153",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 431,
                    "offsetInEndSection": 538,
                    "text": ". We identified miR-16 to bind the COX-2 3'-UTR and inhibit COX-2 expression by promoting rapid mRNA decay.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22049153",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1812,
                    "offsetInEndSection": 1930,
                    "text": "However, miR-143-5p alone directly targets COX-2, and it exhibits a stronger tumor suppressive effect than miR-143-3p.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24616567",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "The NF-\u03baB family member RelB regulates microRNA miR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24472607",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 375,
                    "text": "TargetScan analysis predicted COX-2 as a target of miR-26a and miR-26b. miR-26a/-26b decreased luciferase activity associated with COX-2-3'-UTR.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25907560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 163,
                    "text": "icroRNA-26a/-26b-COX-2-MIP-2 Loop Regulates Allergic Inflammation and Allergic Inflammation-promoted Enhanced Tumorigenic and Metastatic Potential of Cancer Cells",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25907560",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27900011",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "microRNA-142-3p inhibits apoptosis and inflammation induced by bleomycin through down-regulation of Cox-2 in MLE-12 cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28678919",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1120,
                    "offsetInEndSection": 1318,
                    "text": " Up-regulation of Cox-2 and inactivation of PI3K/AKT/mTOR were found in bleomycin-pretreated cells, while these abnormal regulations were partially abolished by miR-142-3p overexpression and NS-398.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28678919",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "MicroRNA-144 is regulated by CP2 and decreases COX-2 expression and PGE2 production in mouse ovarian granulosa cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182010",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 815,
                    "text": "overexpression of miR-144 significantly decreased the luciferase reporter activity under the control of the cyclooxygenase-2 (COX-2) or mothers against decapentaplegic homologue 4 (Smad4) 3'-untranslated region (3'-UTR) and suppressed COX-2 and Smad4 expression. In contrast, a miR-144 inhibitor increased COX-2 and Smad4 expression in mouse granulosa cells (mGCs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182010",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "The down-regulation of microRNA-137 contributes to the up-regulation of retinoblastoma cell proliferation and invasion by regulating COX-2/PGE2 signaling.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945115",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 532,
                    "offsetInEndSection": 837,
                    "text": "Bioinformatic analysis predicted that cyclooxygenase-2 (COX-2) was a potential target gene of miR-137, which was validated by a dual-luciferase reporter assay. Moreover, our results showed that miR-137 negatively regulated the expression of COX-2 and the production of prostaglandin E2 (PGE2) in RB cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945115",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "MicroRNA-128 inhibits proliferation and invasion of glioma cells by targeting COX-2.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524580",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 750,
                    "text": " the inhibitory effects of miR-128 mimics on the invasion and proliferation of glioma cells were reversed by overexpression of cyclooxygenase-2 (COX-2). Our data showed that COX-2 was a candidate target of miR-128. Luciferase activity of 3'-UTR of COX-2 was reduced in the presence of miR-128",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524580",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 1040,
                    "text": "miR-128 obviously decreased COX-2 mRNA stability determined by real time PCR. Contrarily, we found that miR-128 inhibitor significantly increased the COX-2 mRNA expression, and elevated the protein expression of MMP9 and ki67, and promoted the proliferation of glioma cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524580",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "MicroRNA-146b-3p regulates the development and progression of cerebral infarction with diabetes through RAF1/P38MAPK/COX-2 signaling pathway",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29511456",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1565,
                    "offsetInEndSection": 1748,
                    "text": "Our data have implied that altered expression of miR-146b-3p is closely related to the progression and development of DCMI mediating the RAF/P38MAPK/COX-2 signal transduction pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29511456",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404887",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1150,
                    "offsetInEndSection": 1292,
                    "text": "Our results suggest that modulating miR-101 and COX-2 levels or their activity may be a potential therapeutic strategy for endometrial cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404887",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the most frequent syndromes associated with inherited bone marrow failure?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16304365",
                "http://www.ncbi.nlm.nih.gov/pubmed/20022637"
            ],
            "ideal_answer": [
                "The inherited bone marrow failure syndromes (IBMFS) are a heterogeneous group of genetic disorders that share the inability of the bone marrow to produce an adequate number of blood cells. The 4 most frequent syndromes are Fanconi anemia (FA), dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA), and Shwachman-Diamond syndrome (SDS)  ",
                "The inherited bone marrow failure syndromes (IBMFS) are a heterogeneous group of genetic disorders that share the inability of the bone marrow to produce an adequate number of blood cells. The 4 most frequent syndromes are Fanconi anemia (FA), dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA), and Shwachman-Diamond syndrome (SDS)."
            ],
            "exact_answer": [
                [
                    "Fanconi anemia"
                ],
                [
                    "Dyskeratosis congenita"
                ],
                [
                    "Diamond-Blackfan anemia"
                ],
                [
                    "Shwachman-Diamond syndrome"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001853",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001855",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019046",
                "http://www.disease-ontology.org/api/metadata/DOID:4961"
            ],
            "type": "list",
            "id": "55031270e9bde6963400001a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20022637",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 349,
                    "text": "The inherited bone marrow failure syndromes (IBMFS) are a heterogeneous group of genetic disorders that share the inability of the bone marrow to produce an adequate number of blood cells. The 4 most frequent syndromes are Fanconi anemia (FA), dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA), and Shwachman-Diamond syndrome (SDS)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20022637",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 635,
                    "text": "The major inherited bone marrow failure syndromes associated with development of pancytopenia include Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304365",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 634,
                    "text": "The major inherited bone marrow failure syndromes associated with development of pancytopenia include Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304365",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which organs are primarily damaged in SLE?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9458204",
                "http://www.ncbi.nlm.nih.gov/pubmed/26936891",
                "http://www.ncbi.nlm.nih.gov/pubmed/23229448"
            ],
            "ideal_answer": [
                "The patients with SLE are mostly affected by renal, peripheral vascular, musculoskeletal and neurological damage. The skin and heart are also damaged very frequently.",
                "In systemic lupus erythematosus (SLE), brain and kidney are the most frequently damaged organs. The heart is one of the most commonly damaged organs in SLE. Any part of the heart can be affected, including the pericardium, myocardium, coronary arteries, valves, and the conduction system"
            ],
            "exact_answer": [
                [
                    "kidney"
                ],
                [
                    "skin"
                ],
                [
                    "vascular organs"
                ],
                [
                    "heart"
                ],
                [
                    "musculoskeletal organs"
                ],
                [
                    "brain"
                ]
            ],
            "type": "list",
            "id": "5c70273c7c78d69471000061",
            "snippets": [
                {
                    "offsetInBeginSection": 879,
                    "offsetInEndSection": 1045,
                    "text": "The patients with SLE and SS had the greatest renal, peripheral vascular, and musculoskeletal damage (24, 19, 38% of patients, respectively) followed by the SLE group",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9458204",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 385,
                    "text": "Observations from lupus centres worldwide revealed that the prevalence of damage occurring in the cardiovascular system in patients with SLE has increased over the past four decades.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 475,
                    "offsetInEndSection": 642,
                    "text": "lupus-related organ damage involving the neuropsychiatric and renal systems also remains a major factor that limits survival improvement in patients with this disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 947,
                    "offsetInEndSection": 1376,
                    "text": "This Review discusses the pattern and trend of organ damage in patients with SLE worldwide, the potential serological and genetic mechanisms of organ damage, and the advances in research on potential tools for early detection of lupus-related organ damage, such as functional brain imaging techniques, measurement of endothelial function, identification of biomarkers from body fluids, and development of risk calculation models.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1942,
                    "offsetInEndSection": 2201,
                    "text": " Patients with SLE treated with long-term belimumab plus SoC had a low incidence of organ damage accrual and no unexpected AEs. High-risk patients with pre-existing organ damage also had low accrual, suggesting a favorable effect on future damage development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936891",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List the four most important interferonopathies",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27863149",
                "http://www.ncbi.nlm.nih.gov/pubmed/28844088",
                "http://www.ncbi.nlm.nih.gov/pubmed/27678529",
                "http://www.ncbi.nlm.nih.gov/pubmed/27821552",
                "http://www.ncbi.nlm.nih.gov/pubmed/28519900",
                "http://www.ncbi.nlm.nih.gov/pubmed/28585220",
                "http://www.ncbi.nlm.nih.gov/pubmed/28578473",
                "http://www.ncbi.nlm.nih.gov/pubmed/28089741"
            ],
            "ideal_answer": [
                "Aicardi-Gouti\u00e8res syndrome\nchilblain lupus\nubiquitin specific peptidase 18 (USP18)-deficiency\nSingleton-Merten syndrome",
                "Inappropriate upregulation of type I IFN signaling and interferon-stimulated gene expression have been linked to several CNS diseases termed \"interferonopathies\" including Aicardi-Goutieres syndrome, ubiquitin specific peptidase 18 (USP18)-deficiency, haploinsufficiency in A20, otulipenia, familial chiblain lupus."
            ],
            "exact_answer": [
                [
                    "Aicardi-Gouti\u00e8res syndrome"
                ],
                [
                    "chilblain lupus"
                ],
                [
                    "ubiquitin specific peptidase 18 (USP18)-deficiency"
                ],
                [
                    "Singleton-Merten syndrome"
                ]
            ],
            "type": "list",
            "id": "5a882b5761bb38fb24000013",
            "snippets": [
                {
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 326,
                    "text": "As defined, the type I interferonopathies represent discrete examples of a disturbance of the homeostatic control of this system caused by Mendelian mutations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821552",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 166,
                    "text": "Familial chilblain lupus belongs to the group of type I interferonopathies and is characterized by typical skin manifestations and acral ischaemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28844088",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 165,
                    "text": "interferonopathies such as Aicardi-Gouti\u00e8res syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27863149",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 924,
                    "offsetInEndSection": 1178,
                    "text": "Inappropriate upregulation of type I IFN signaling and interferon-stimulated gene expression have been linked to several CNS diseases termed \"interferonopathies\" including Aicardi-Goutieres syndrome and ubiquitin specific peptidase 18 (USP18)-deficiency.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28519900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 789,
                    "text": " interferonopathies (Singleton-Merten syndrome)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28585220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Aicardi-Gouti\u00e8res syndrome (AGS) is an inflammatory disorder belonging to the recently characterized group of type I interferonopathies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28089741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 924,
                    "offsetInEndSection": 1179,
                    "text": "Inappropriate upregulation of type I IFN signaling and interferon-stimulated gene expression have been linked to several CNS diseases termed \"interferonopathies\" including Aicardi-Goutieres syndrome and ubiquitin specific peptidase 18 (USP18)-deficiency. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28519900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 928,
                    "text": "Then, major players driving autoinflammation, such as type-1 interferonopathies (including the recently described haploinsuffiency in A20 and otulipenia), TNF-associated periodic syndromes, defects in ubiquitination, and SAID with overlapping features of autoimmunity or immunodeficiency. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28578473",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 167,
                    "text": "Familial chilblain lupus belongs to the group of type I interferonopathies and is characterized by typical skin manifestations and acral ischaemia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28844088",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List features of the Perry syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23628468",
                "http://www.ncbi.nlm.nih.gov/pubmed/19136952",
                "http://www.ncbi.nlm.nih.gov/pubmed/24881494",
                "http://www.ncbi.nlm.nih.gov/pubmed/20702129",
                "http://www.ncbi.nlm.nih.gov/pubmed/24676999",
                "http://www.ncbi.nlm.nih.gov/pubmed/24484619",
                "http://www.ncbi.nlm.nih.gov/pubmed/24343258",
                "http://www.ncbi.nlm.nih.gov/pubmed/20437543"
            ],
            "ideal_answer": [
                "Perry syndrome is a familial parkinsonism associated with central hypoventilation, mental depression, and weight loss."
            ],
            "exact_answer": [
                [
                    "parkinsonism"
                ],
                [
                    "central hypoventilation"
                ],
                [
                    "depression"
                ],
                [
                    "weight loss"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
                "http://www.disease-ontology.org/api/metadata/DOID:225"
            ],
            "type": "list",
            "id": "56c1f034ef6e394741000050",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "BACKGROUND: Depression, parkinsonism, and hypoventilation (Perry syndrome) or familial motor neuron disease have been linked to mutations in dynactin P150(Glued) (DCTN1).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "BACKGROUND: Perry syndrome (PS) caused by DCTN1 gene mutation is clinically characterized by autosomal dominant parkinsonism, depression, severe weight loss, and hypoventilation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24484619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1150,
                    "offsetInEndSection": 1431,
                    "text": "CONCLUSIONS AND RELEVANCE: Mutations of the DCTN1 gene have been previously associated with amyotrophic lateral sclerosis and with Perry syndrome, a rare autosomal dominant disorder characterized by weight loss, parkinsonism, central hypoventilation, and psychiatric disturbances. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24343258",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "OBJECTIVES: Perry syndrome consists of autosomal dominant Parkinsonism, depression, weight loss, and central hypoventilation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24881494",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 277,
                    "text": "A patient with a mood disorder and a Parkinsonian syndrome with frontal cognitive impairment thought to resemble progressive supranuclear palsy defied precise diagnosis until the development of respiratory compromise, prompting consideration of the diagnosis of Perry syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628468",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Perry syndrome is a familial parkinsonism associated with central hypoventilation, mental depression, and weight loss. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702129",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "Perry syndrome (PS) caused by DCTN1 gene mutation is clinically characterized by autosomal dominant parkinsonism, depression, severe weight loss, and hypoventilation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24484619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Perry syndrome is a familial parkinsonism associated with central hypoventilation, mental depression, and weight loss",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702129",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20437543",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 445,
                    "text": "Perry syndrome consists of early-onset parkinsonism, depression, severe weight loss and hypoventilation, with brain pathology characterized by TDP-43 immunostaining. We carried out genome-wide linkage analysis and identified five disease-segregating mutations affecting the CAP-Gly domain of dynactin (encoded by DCTN1) in eight families with Perry syndrome; these mutations diminish microtubule binding and lead to intracytoplasmic inclusions. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19136952",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Where can we find the protein lacritin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22918641",
                "http://www.ncbi.nlm.nih.gov/pubmed/23425695",
                "http://www.ncbi.nlm.nih.gov/pubmed/16982797",
                "http://www.ncbi.nlm.nih.gov/pubmed/22956620",
                "http://www.ncbi.nlm.nih.gov/pubmed/19770725",
                "http://www.ncbi.nlm.nih.gov/pubmed/19714880",
                "http://www.ncbi.nlm.nih.gov/pubmed/17850790",
                "http://www.ncbi.nlm.nih.gov/pubmed/11419941",
                "http://www.ncbi.nlm.nih.gov/pubmed/16865190",
                "http://www.ncbi.nlm.nih.gov/pubmed/22871838",
                "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
                "http://www.ncbi.nlm.nih.gov/pubmed/14574570",
                "http://www.ncbi.nlm.nih.gov/pubmed/18334948",
                "http://www.ncbi.nlm.nih.gov/pubmed/23422824",
                "http://www.ncbi.nlm.nih.gov/pubmed/21087963",
                "http://www.ncbi.nlm.nih.gov/pubmed/16923831",
                "http://www.ncbi.nlm.nih.gov/pubmed/20375347",
                "http://www.ncbi.nlm.nih.gov/pubmed/15952718",
                "http://www.ncbi.nlm.nih.gov/pubmed/23482462",
                "http://www.ncbi.nlm.nih.gov/pubmed/22300579"
            ],
            "ideal_answer": [
                "The protein lacritin can be found in lacrimal and salivary glands as well as in tear fluid and in the thyroid."
            ],
            "exact_answer": [
                [
                    "lacrimal gland"
                ],
                [
                    "salivary glands"
                ],
                [
                    "thyroid"
                ],
                [
                    "tear fluid"
                ]
            ],
            "concepts": [
                "http://www.uniprot.org/uniprot/LACRT_HUMAN"
            ],
            "type": "list",
            "id": "515b30d8d24251bc050000b0",
            "snippets": [
                {
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 258,
                    "text": "Lacritin, a glycoprotein secreted from lacrimal acinar cells,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23482462",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 389,
                    "text": "Essential for the viability of the surface epithelium of the eye and for normal vision is the thin, but protein-rich, tear film in which the small tear glycoprotein lacritin appears to play a prominent prosecretory, cytoprotective, and mitogenic role",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425695",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 140,
                    "text": "Lacritin is a prosecretory mitogen in tears and, although a tear protein, it promotes basal tearing and lacrimal gland secretion.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422824",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11419941",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 717,
                    "text": "Lacritin mRNA and protein are highly expressed in human lacrimal gland, moderately in major and minor salivary glands and slightly in thyroid. No lacritin message or protein is detected elsewhere among more than 50 human tissues examined.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11419941",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1155,
                    "offsetInEndSection": 1198,
                    "text": "and tear-specific proteins such as lacritin",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16865190",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 303,
                    "text": "This study assessed lacritin levels in tears from healthy individuals",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22918641",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1109,
                    "text": "The lipocalin 1, lactotransferrin, lacritin, lysozyme C, lipophilin A and immunoglobulin lambda chain were identified as possible biomarker candidates with significantly higher relative levels in the tear of patients with diabetic retinopathy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300579",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 54,
                    "text": "Lacritin is a novel human tear glycoprotein",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21087963",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1483,
                    "offsetInEndSection": 1569,
                    "text": "In primates, lacritin was produced in the lacrimal gland and secreted into tear fluid.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17850790",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 708,
                    "offsetInEndSection": 1069,
                    "text": "Here we show by quantitative real-time PCR that lacritin is expressed in human breast tumors, breast cancer cell lines, and normal breast. The previously reported restricted expression pattern of lacritin is therefore incorrect. Lacritin transcripts were not detected in peripheral blood which makes lacritin a potential candidate as a breast cancer marker gene",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574570",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Which human genes are more commonly related to craniosynostosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12407713",
                "http://www.ncbi.nlm.nih.gov/pubmed/19530187",
                "http://www.ncbi.nlm.nih.gov/pubmed/16258006",
                "http://www.ncbi.nlm.nih.gov/pubmed/20643727",
                "http://www.ncbi.nlm.nih.gov/pubmed/10914960",
                "http://www.ncbi.nlm.nih.gov/pubmed/9934984",
                "http://www.ncbi.nlm.nih.gov/pubmed/18000908",
                "http://www.ncbi.nlm.nih.gov/pubmed/11428324",
                "http://www.ncbi.nlm.nih.gov/pubmed/17042739",
                "http://www.ncbi.nlm.nih.gov/pubmed/11746040",
                "http://www.ncbi.nlm.nih.gov/pubmed/17955513",
                "http://www.ncbi.nlm.nih.gov/pubmed/14672347",
                "http://www.ncbi.nlm.nih.gov/pubmed/10951518",
                "http://www.ncbi.nlm.nih.gov/pubmed/9917362",
                "http://www.ncbi.nlm.nih.gov/pubmed/15964893",
                "http://www.ncbi.nlm.nih.gov/pubmed/9042914",
                "http://www.ncbi.nlm.nih.gov/pubmed/11820058",
                "http://www.ncbi.nlm.nih.gov/pubmed/8106171",
                "http://www.ncbi.nlm.nih.gov/pubmed/9600744",
                "http://www.ncbi.nlm.nih.gov/pubmed/11484208",
                "http://www.ncbi.nlm.nih.gov/pubmed/11197897",
                "http://www.ncbi.nlm.nih.gov/pubmed/11341328"
            ],
            "ideal_answer": [
                "The genes that are most commonly linked to craniosynostoses are the members of the Fibroblast Growth Factor Receptor family FGFR3 and to a lesser extent FGFR1 and FGFR2. Some variants of the disease have been associated with the triplication of the MSX2 gene and mutations in NELL-1. NELL-1 is being regulated bu RUNX2, which has also been associated to cases of craniosynostosis. Other genes reported to have a role in the development of the disease are RECQL4, TWIST, SOX6 and GNAS."
            ],
            "exact_answer": [
                [
                    "FGFR3"
                ],
                [
                    "FGFR2"
                ],
                [
                    "FGFR1"
                ],
                [
                    "MSX2"
                ],
                [
                    "NELL1"
                ],
                [
                    "RUNX2"
                ],
                [
                    "RECQL4"
                ],
                [
                    "TWIST"
                ],
                [
                    "SOX6"
                ],
                [
                    "GNAS"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018566",
                "http://www.disease-ontology.org/api/metadata/DOID:2340",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003398"
            ],
            "type": "list",
            "id": "513ce3c8bee46bd34c000008",
            "snippets": [
                {
                    "offsetInBeginSection": 635,
                    "offsetInEndSection": 721,
                    "text": "The FGFR3 P250R mutation was the single largest contributor (24%) to the genetic group",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20643727",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1416,
                    "offsetInEndSection": 1521,
                    "text": "FGFR3 P250R and FGFR2 exons IIIa/c) should be targeted to patients with coronal or multisuture synostoses",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20643727",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 845,
                    "text": "GNAS, the gene for guanine nucleotide-binding protein, alpha-stimulating activity polypeptide (gene for PHP1A), identified a de novo heterozygous 3 bp in frame deletion predicting a deletion of the asparagine residue at position 377 (deltaN377",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19530187",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 924,
                    "offsetInEndSection": 961,
                    "text": "craniosynostosis genes (FGFR2, FGFR3)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19530187",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Syndromic craniosynostosis due to complex chromosome 5 rearrangement and MSX2 gene triplication",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000908",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 782,
                    "offsetInEndSection": 898,
                    "text": "early fusion of cranial sutures commonly observed in the dup(5q) syndrome is caused by triplication of the MSX2 gene",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000908",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 52,
                    "offsetInEndSection": 123,
                    "text": "further evidence that extra copy of MSX2 gene leads to craniosynostosis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17955513",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 737,
                    "offsetInEndSection": 903,
                    "text": "Our results support the previous finding that distal 5q-trisomy together with an extra copy of the MSX2 gene leads to abnormal closure of sutures and craniosynostosis",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17955513",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 61,
                    "text": "Craniosynostosis-associated gene nell-1 is regulated by runx2",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042739",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 96,
                    "text": "We studied the transcriptional regulation of NELL-1, a craniosynostosis-related gene",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042739",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 2217,
                    "offsetInEndSection": 2377,
                    "text": "Runx2 directly binds to the OSE2 elements and transactivates the human NELL-1 promoter. These results suggest that Nell-1 is likely a downstream target of Runx2",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042739",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 907,
                    "offsetInEndSection": 1035,
                    "text": "The breakpoint on chromosome 11p15 disrupts the SOX6 gene, known to be involved in skeletal growth and differentiation processes",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16258006",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1037,
                    "offsetInEndSection": 1252,
                    "text": "SOX6 mutation screening of another 104 craniosynostosis patients revealed one missense mutation leading to the exchange of a highly conserved amino acid (p.D68N) in a single patient and his reportedly healthy mother",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16258006",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15964893",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "text": "Overexpression of Nell-1, a craniosynostosis-associated gene",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14672347",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 266,
                    "text": "Mutations in five genes (FGFR1-, -2, -3, TWIST, and MSX2) causing craniosynostosis as the main clinical feature were described.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12407713",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "One of the genes involved in craniosynostosis syndromes is the fibroblast growth factor receptor 2 (FGFR2) gene, a tyrosine kinase receptor gene",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11820058",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 221,
                    "text": "Most mutations in Crouzon, Pfeiffer, and Apert syndromes are in the extracellular, third immunoglobulin-like domain and adjacent linker regions (exons IIIa and IIIc) of the fibroblast growth factor receptor 2 (FGFR2) gene",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11484208",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Familial craniosynostosis due to Pro250Arg mutation in the fibroblast growth factor receptor 3 gene.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11428324",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Apert (Ap) syndrome is characterized by premature cranial suture ossification caused by fibroblast growth factor receptor 2 (FGFR-2) mutations",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11341328",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "text": "Recently, the substitution of proline 250 by arginine in the fibroblast growth factor receptor 3 (FGFR3) gene, has been identified in patients with craniosynostosis and defines a new syndrome on a molecular basis",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11197897",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Mutations in the fibroblast growth factor receptor 1, 2 and 3 (FGFR1, -2 and -3) and TWIST genes have been identified in several syndromic forms of craniosynostosis",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951518",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 472,
                    "text": "We describe a novel heterozygous mutation of FGFR2 (943G --> T, encoding the amino acid substitution Ala315Ser) in a girl with non-syndromic unicoronal craniosynostosis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951518",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "A unique Pro250Arg mutation in fibroblast growth factor receptor 3 (FGFR3) was recently found in patients with non-syndromic craniosynostosis",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10914960",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 188,
                    "text": "a possible mechanism for MSX2-mediated craniosynostosis in humans",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9917362",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 532,
                    "offsetInEndSection": 713,
                    "text": "We found previously that a single amino acid substitution in the homeodomain of the human MSX2 gene is associated with the autosomal dominant disorder craniosynostosis, Boston type.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9917362",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "Recently, a unique Pro250Arg point mutation in fibroblast growth factor receptor 3 (FGFR3) was reported in 61 individuals with coronal craniosynostosis from 20 unrelated families",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9600744",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1240,
                    "offsetInEndSection": 1409,
                    "text": "We identified a novel TWIST gene mutation in this patient, a Glu181Stop mutation predicting a premature termination of the protein carboxy-terminal to the helix 2 domain",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9934984",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9042914",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8106171",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "List the releases of tmVar",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28968638",
                "http://www.ncbi.nlm.nih.gov/pubmed/23564842"
            ],
            "ideal_answer": [
                "TmVar is a text mining approach for extracting sequence variants in biomedical literature. TmVar 2.0 integrates genomic variant information from literature with dbSNP and ClinVar for precision medicine."
            ],
            "exact_answer": [
                [
                    "TmVar"
                ],
                [
                    "TmVar 2.0"
                ]
            ],
            "type": "list",
            "id": "5c561da707647bbc4b00000f",
            "snippets": [
                {
                    "offsetInBeginSection": 702,
                    "offsetInEndSection": 1409,
                    "text": "Here, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society. By doing so, we cover several important types of mutations that were not considered in past studies. Using a novel CRF label model and feature set, our method achieves higher performance than a state-of-the-art method on both our corpus (91.4 versus 78.1% in F-measure) and their own gold standard (93.9 versus 89.4% in F-measure). These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "tmVar 2.0: integrating genomic variant information from literature with dbSNP and ClinVar for precision medicine.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "tmVar: a text mining approach for extracting sequence variants in biomedical literature.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1347,
                    "offsetInEndSection": 1850,
                    "text": "To our knowledge, this is the first large-scale study to analyze and integrate text-mined variant data with curated knowledge in existing databases. Our results suggest that databases can be significantly enriched by text mining and that the combined information can greatly assist human efforts in evaluating/prioritizing variants in genomic research.Availability and implementation: The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 964,
                    "text": "RESULTS\nHere, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1297,
                    "offsetInEndSection": 1410,
                    "text": "These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1413,
                    "offsetInEndSection": 1572,
                    "text": "AVAILABILITY\ntmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1703,
                    "offsetInEndSection": 1854,
                    "text": "Availability and implementation\nThe tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 964,
                    "text": "RESULTS Here, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1413,
                    "offsetInEndSection": 1572,
                    "text": "AVAILABILITY tmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1703,
                    "offsetInEndSection": 1854,
                    "text": "Availability and implementation The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 584,
                    "offsetInEndSection": 981,
                    "text": "As such, new automatic approaches are greatly needed for extracting different kinds of mutations with high accuracy.<br><b>RESULTS</b>: Here, we report tmVar, a text-mining approach based on conditional random field (CRF) for extracting a wide range of sequence variants described at protein, DNA and RNA levels according to a standard nomenclature developed by the Human Genome Variation Society.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1314,
                    "offsetInEndSection": 1602,
                    "text": "These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.<br><b>AVAILABILITY</b>: tmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1514,
                    "offsetInEndSection": 1923,
                    "text": "Our results suggest that databases can be significantly enriched by text mining and that the combined information can greatly assist human efforts in evaluating/prioritizing variants in genomic research.<br><b>Availability and implementation</b>: The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.<br><b>Contact</b>: zhiyong.lu@nih.gov.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1390,
                    "offsetInEndSection": 1536,
                    "text": "tmVar software and its corpus of 500 manually curated abstracts are available for download at http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/pub/tmVar",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1680,
                    "offsetInEndSection": 1799,
                    "text": "The tmVar 2.0 source code and corpus are freely available at https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1276,
                    "offsetInEndSection": 1389,
                    "text": "These results suggest that tmVar is a high-performance method for mutation extraction from biomedical literature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564842",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the main causes of fetal echogenic bowel?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20932506",
                "http://www.ncbi.nlm.nih.gov/pubmed/22378220",
                "http://www.ncbi.nlm.nih.gov/pubmed/14626795",
                "http://www.ncbi.nlm.nih.gov/pubmed/9664617",
                "http://www.ncbi.nlm.nih.gov/pubmed/10364670",
                "http://www.ncbi.nlm.nih.gov/pubmed/22990134",
                "http://www.ncbi.nlm.nih.gov/pubmed/17364293",
                "http://www.ncbi.nlm.nih.gov/pubmed/18577682",
                "http://www.ncbi.nlm.nih.gov/pubmed/14663844",
                "http://www.ncbi.nlm.nih.gov/pubmed/7474061",
                "http://www.ncbi.nlm.nih.gov/pubmed/21606744",
                "http://www.ncbi.nlm.nih.gov/pubmed/11169342",
                "http://www.ncbi.nlm.nih.gov/pubmed/1415421",
                "http://www.ncbi.nlm.nih.gov/pubmed/10550877",
                "http://www.ncbi.nlm.nih.gov/pubmed/8633653",
                "http://www.ncbi.nlm.nih.gov/pubmed/10590441",
                "http://www.ncbi.nlm.nih.gov/pubmed/8142051",
                "http://www.ncbi.nlm.nih.gov/pubmed/8538346",
                "http://www.ncbi.nlm.nih.gov/pubmed/11717628",
                "http://www.ncbi.nlm.nih.gov/pubmed/10912967",
                "http://www.ncbi.nlm.nih.gov/pubmed/18254450",
                "http://www.ncbi.nlm.nih.gov/pubmed/20059439",
                "http://www.ncbi.nlm.nih.gov/pubmed/12835583",
                "http://www.ncbi.nlm.nih.gov/pubmed/19921962",
                "http://www.ncbi.nlm.nih.gov/pubmed/10419606",
                "http://www.ncbi.nlm.nih.gov/pubmed/18417974",
                "http://www.ncbi.nlm.nih.gov/pubmed/22589170"
            ],
            "ideal_answer": [
                "Fetal echogenic bowel is mainly associated to feto-maternal, intramniotic bleeding but in several cases it is linked to cystic fibrosis, cytomegalovirus (CMV), herpes simplex virus and other viral infections and fetal aneuploidy.",
                "Fetal echogenic bowel (FEB) is a soft marker found on second trimester sonography. (PMID: 22990134) A disorder was diagnosed in 32.2% of the fetuses, cystic fibrosis being the most commonly identified (7.6%). We also found digestive malformations (7.0%), chromosomal abnormalities (3.7%), and maternofetal infections (3.7%). (PMID: 20932506) Brightly echogenic bowel in the second trimester was found to be associated with a significant risk of fetal aneuploidy. (PMID: 1415421) echogenic bowel does not uniformly herald an abnormal outcome. Echogenic bowel coexistent with other abnormalities (such as growth deficiency or structural malformations) may be a comarker for aneuploidy. (PMID: 8142051) 112 cases (57%) had a known etiology, which included chromosomal abnormality (7%), infection (4%), cystic fibrosis (1.5%), bowel abnormality (3%), bleeding or stained amniotic fluid (11%), Doppler abnormality (14%), malformation (16%) and miscellaneous (0.5%) (PMID: 12835583)"
            ],
            "exact_answer": [
                [
                    "Itramniotic bleeding"
                ],
                [
                    "CMV infection"
                ],
                [
                    "Cystic Fibrosis (CF)"
                ],
                [
                    "Fetal aneuploidy"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058535",
                "http://www.disease-ontology.org/api/metadata/DOID:9779"
            ],
            "type": "list",
            "id": "5131fa145274a5fb07000009",
            "snippets": [
                {
                    "offsetInBeginSection": 1054,
                    "offsetInEndSection": 1156,
                    "text": "In group 2 and 3, two anomalies, anorectal malformation and cystic fibrosis, were detected postnatally",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990134",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 671,
                    "offsetInEndSection": 774,
                    "text": "Six had chromosomal/genetic abnormalities, two had congenital cytomegalovirus, none had cystic fibrosis",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589170",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1325,
                    "offsetInEndSection": 1385,
                    "text": "Primary bowel pathology is rare following the finding of FEB",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589170",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 974,
                    "text": "Maternal serology for cytomegalovirus (CMV) was performed in 49 (78%) cases",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378220",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1066,
                    "offsetInEndSection": 1181,
                    "text": "Thirty-three pregnancies (53%) were tested for cystic fibrosis (CF) and 1 baby was confirmed to have CF postnatally",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378220",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1446,
                    "offsetInEndSection": 1618,
                    "text": "This study reiterates the increased prevalence of aneuploidy, CMV, CF and fetal growth restriction in pregnancies complicated by the midtrimester sonographic finding of FEB",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378220",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 616,
                    "text": "Primary outcomes were IUGR, defined as birth weight less than the 10th percentile for gestational age and intrauterine fetal demise at 20 weeks or more of gestatio",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606744",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 780,
                    "offsetInEndSection": 872,
                    "text": "Analyses were repeated after excluding cases of aneuploidy, cytomegalovirus (CMV) infection,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606744",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1969,
                    "offsetInEndSection": 2114,
                    "text": "The presence of echogenic bowel on ultrasonography is independently associated with an increased risk for both IUGR and intrauterine fetal demise",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606744",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1133,
                    "text": "This study highlights the importance of pregnancy ultrasound examinations and their efficiency in detecting cystic fibrosis",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20932506",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 836,
                    "text": "A disorder was diagnosed in 32.2% of the fetuses, cystic fibrosis being the most commonly identified (7.6%). We also found digestive malformations (7.0%), chromosomal abnormalities (3.7%), and maternofetal infections (3.7%).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20932506",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 887,
                    "text": "A potential association with placental abnormalities and a low prevalence of viral infections was observed",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20059439",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1405,
                    "offsetInEndSection": 1512,
                    "text": "Our data suggests an inverse relationship between the maternal BMI and the detection of fetal EIF and/or EB",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19921962",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Fetal echogenic bowel at 17 weeks' gestational age as the early and only sign of a very long segment of Hirschsprung disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577682",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 17,
                    "offsetInEndSection": 103,
                    "text": "fetal ultrasound findings associated with intrauterine cytomegalovirus (CMV) infection",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417974",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1109,
                    "offsetInEndSection": 1235,
                    "text": "the combination of hydrops fetalis, cerebral hemorrhage, and hyperechoic bowel should raise the possibility of a CMV infection",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417974",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 914,
                    "text": "strongly associated with adverse pregnancy outcome due to utero-placental insufficiency, particularly in women with elevated maternal serum alpha-fetoprotein concentration due to severe feto-maternal bleeding",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18254450",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Congenital cytomegalovirus infection presenting with echogenic bowel and oligohydramnios.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364293",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 515,
                    "text": "Five cases of trisomy 21 and one case of trisomy 18 were detected",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1415421",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 809,
                    "offsetInEndSection": 929,
                    "text": "Brightly echogenic bowel in the second trimester was found to be associated with a significant risk of fetal aneuploidy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1415421",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 922,
                    "offsetInEndSection": 1126,
                    "text": "echogenic bowel does not uniformly herald an abnormal outcome. Echogenic bowel coexistent with other abnormalities (such as growth deficiency or structural malformations) may be a comarker for aneuploidy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8142051",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Congenital cytomegalovirus infection with oligohydramnios and echogenic bowel at 14 weeks' gestation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7474061",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1220,
                    "text": "Parental CF carrier testing and amniocentesis to identify aneuploidy or fetal CF status has a high positive ascertainment rate in fetuses with echogenic bowel grades 2 and 3.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8538346",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1804,
                    "offsetInEndSection": 1968,
                    "text": "Swallowing of amniotic fluid after intraamniotic bleeding seems implicated in the etiology of second-trimester echogenic bowel in both euploid and aneuploid fetuses",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8633653",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Fetal echogenic bowel and a dilated loop of bowel associated with cystic fibrosis (CF) mutations delta F508 and 2183AA-->G",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9664617",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 385,
                    "text": "Fifteen cases (19%) were associated with maternal vaginal bleeding",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10364670",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 613,
                    "offsetInEndSection": 722,
                    "text": "Five fetuses (6.3%) had evidence of bowel obstruction or perforation not associated with cystic fibrosis (CF)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10364670",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 724,
                    "offsetInEndSection": 926,
                    "text": "Chromosomal aberrations were found in 5 fetuses (6.3%). Intrauterine infection with cytomegalovirus, herpes simplex virus, varicella-zoster virus, or parvovirus B-19 was documented in 5 patients (6.3%).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10364670",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Fetal echogenic bowel has been reported as a normal variant in the second trimester, and has also been associated with an adverse fetal outcome, including cystic fibrosis (CF)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10419606",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 918,
                    "offsetInEndSection": 969,
                    "text": "Intra-amniotic bleeding can lead to echogenic bowel",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10912967",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 808,
                    "text": "112 cases (57%) had a known etiology, which included chromosomal abnormality (7%), infection (4%), cystic fibrosis (1.5%), bowel abnormality (3%), bleeding or stained amniotic fluid (11%), Doppler abnormality (14%), malformation (16%) and miscellaneous (0.5%)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12835583",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Which kinases does baricitinib inhibit?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24965573",
                "http://www.ncbi.nlm.nih.gov/pubmed/25431052",
                "http://www.ncbi.nlm.nih.gov/pubmed/26137574",
                "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
                "http://www.ncbi.nlm.nih.gov/pubmed/23492738"
            ],
            "ideal_answer": [
                "Baricitinib is an inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2."
            ],
            "exact_answer": [
                [
                    "JAK1"
                ],
                [
                    "JAK2"
                ]
            ],
            "concepts": [
                "http://www.uniprot.org/uniprot/JAK2_PONAB",
                "http://www.uniprot.org/uniprot/JAK2_PIG",
                "http://www.uniprot.org/uniprot/JAK2_MOUSE",
                "http://www.uniprot.org/uniprot/JAK2_CHICK",
                "http://www.uniprot.org/uniprot/JAK2_RAT",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053613",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053612",
                "http://www.uniprot.org/uniprot/JAK2_HUMAN",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053614"
            ],
            "type": "list",
            "id": "56c8605b5795f9a73e000014",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 462,
                    "text": "A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 291,
                    "text": "Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965573",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 585,
                    "text": "A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 580,
                    "text": "Phase II data for four JAK inhibitors (baricitinib,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 1088,
                    "text": "Positive clinical trial results have also been reported for several other JAK inhibitors including baricitinib. Several other JAK inhibitors and other small molecular entities are also being developed in studies ranging from preclinical models to large clinical trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23492738",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the families of mammalian DNA-(cytosine-5)-methyltransferases?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21846773",
                "http://www.ncbi.nlm.nih.gov/pubmed/18367714",
                "http://www.ncbi.nlm.nih.gov/pubmed/22815530",
                "http://www.ncbi.nlm.nih.gov/pubmed/20838592",
                "http://www.ncbi.nlm.nih.gov/pubmed/23302691",
                "http://www.ncbi.nlm.nih.gov/pubmed/22133874",
                "http://www.ncbi.nlm.nih.gov/pubmed/23357425",
                "http://www.ncbi.nlm.nih.gov/pubmed/23393137",
                "http://www.ncbi.nlm.nih.gov/pubmed/21378119",
                "http://www.ncbi.nlm.nih.gov/pubmed/20679393",
                "http://www.ncbi.nlm.nih.gov/pubmed/18413740",
                "http://www.ncbi.nlm.nih.gov/pubmed/21559294",
                "http://www.ncbi.nlm.nih.gov/pubmed/17616512",
                "http://www.ncbi.nlm.nih.gov/pubmed/22737219",
                "http://www.ncbi.nlm.nih.gov/pubmed/22134929",
                "http://www.ncbi.nlm.nih.gov/pubmed/20071334",
                "http://www.ncbi.nlm.nih.gov/pubmed/22328086",
                "http://www.ncbi.nlm.nih.gov/pubmed/23033272",
                "http://www.ncbi.nlm.nih.gov/pubmed/22210859",
                "http://www.ncbi.nlm.nih.gov/pubmed/19173286",
                "http://www.ncbi.nlm.nih.gov/pubmed/19322801",
                "http://www.ncbi.nlm.nih.gov/pubmed/18437543",
                "http://www.ncbi.nlm.nih.gov/pubmed/17371843",
                "http://www.ncbi.nlm.nih.gov/pubmed/22140515",
                "http://www.ncbi.nlm.nih.gov/pubmed/17890317",
                "http://www.ncbi.nlm.nih.gov/pubmed/20547750",
                "http://www.ncbi.nlm.nih.gov/pubmed/16999741",
                "http://www.ncbi.nlm.nih.gov/pubmed/19626461",
                "http://www.ncbi.nlm.nih.gov/pubmed/22088914",
                "http://www.ncbi.nlm.nih.gov/pubmed/16236173",
                "http://www.ncbi.nlm.nih.gov/pubmed/15962389",
                "http://www.ncbi.nlm.nih.gov/pubmed/19576953",
                "http://www.ncbi.nlm.nih.gov/pubmed/19386473",
                "http://www.ncbi.nlm.nih.gov/pubmed/18974146",
                "http://www.ncbi.nlm.nih.gov/pubmed/17182866",
                "http://www.ncbi.nlm.nih.gov/pubmed/16575165",
                "http://www.ncbi.nlm.nih.gov/pubmed/17929180",
                "http://www.ncbi.nlm.nih.gov/pubmed/21549127",
                "http://www.ncbi.nlm.nih.gov/pubmed/18544619"
            ],
            "ideal_answer": [
                "DNA (cytosine-5)-methyltransferases catalyze the specific transfer of a methyl group  to the C5 position of cytosine residues in DNA. Three families of DNA (cytosine-5)-methyltransferases have been identified in mammals: DNMT1, DNMT2 and DNMT3 (including DNMT3a, DNMT3b and DNMT3L isoforms). All of them share homologous catalytic domains. DNMT1 is the \ufffd\ufffd\ufffdmaintenance\u201d methyltransferase family. DNMT1 is specific for hemi-methylated DNA and ensures the faithful transmission of DNA methylation patterns in every replication cycle. DNMT3 is required for de novo methylation of DNA. DNMT3 targets unmethylated DNA and is responsible for the establishment of new methylation patterns. Dnmt2, in contrast to all other mammalian DNA (cytosine-5)-methyltransferases, does not possess a large N-terminal regulatory domain. The DNA methylation activity of DNMT2 is still controversial."
            ],
            "exact_answer": [
                [
                    "DNMT1"
                ],
                [
                    "DNMT2"
                ],
                [
                    "DNMT3"
                ]
            ],
            "concepts": [
                "http://www.uniprot.org/uniprot/DNMT1_CHICK",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248",
                "http://www.uniprot.org/uniprot/CMT3_MAIZE",
                "http://www.uniprot.org/uniprot/DNM3A_RAT",
                "http://www.uniprot.org/uniprot/DNMT1_ARATH",
                "http://www.uniprot.org/uniprot/DNM3A_CHICK",
                "http://www.uniprot.org/uniprot/DNM3B_MOUSE",
                "http://www.uniprot.org/uniprot/CMT2_MAIZE",
                "http://www.biosemantics.org/jochem#4250454",
                "http://www.uniprot.org/uniprot/CMT1_DICDI",
                "http://www.uniprot.org/uniprot/DCM_ECOLI",
                "http://www.uniprot.org/uniprot/DNM3A_HUMAN",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015257",
                "http://www.uniprot.org/uniprot/DNMT1_RAT",
                "http://www.uniprot.org/uniprot/DNMT1_MOUSE",
                "http://www.uniprot.org/uniprot/DNMT1_HUMAN",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003596",
                "http://www.uniprot.org/uniprot/CMT1_MAIZE",
                "http://www.uniprot.org/uniprot/DNM3A_MOUSE",
                "http://www.uniprot.org/uniprot/DCM_ECO57",
                "http://www.uniprot.org/uniprot/DNMT_FRG3G",
                "http://www.biosemantics.org/jochem#4273977",
                "http://www.uniprot.org/uniprot/DNMT1_BOVIN",
                "http://www.uniprot.org/uniprot/DNM3B_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003886"
            ],
            "type": "list",
            "id": "516c3960298dcd4e51000073",
            "snippets": [
                {
                    "offsetInBeginSection": 449,
                    "offsetInEndSection": 529,
                    "text": "Of the DNMTs, DNMT1 and DNMT3a are most highly expressed in postmitotic neurons.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134929",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22133874",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Bovine DNA methylation imprints are established in an oocyte size-specific manner, which are coordinated with the expression of the DNMT3 family proteins.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088914",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "The DNMT3B de novo DNA methyltransferase (DNMT) plays a major role in establishing DNA methylation patterns in early mammalian development, but its catalytic mechanism remains poorly characterized.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549127",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "Dnmt2 proteins are the most conserved members of the DNA methyltransferase enzyme family, but their substrate specificity and biological functions have been a subject of controversy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20679393",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 456,
                    "text": "This promoter hypermethylation may be mediated not only by DNMT-1 but also by an entire family of de novo DNA-methyltransferases, such as DNA-methyltransferase-3a (DNMT-3a) and -3b (DNMT-3b).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19386473",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 494,
                    "text": "Within the family of DNA methyltransferases (Dnmts), Dnmt3a and 3b establish methylation marks during early development, while Dnmt1 maintains methylation patterns after DNA replication. The maintenance function of Dnmt1 is regulated by its large regulatory N-terminal domain that interacts with other chromatin factors and is essential for the recognition of hemi-methylated DNA.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19173286",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 324,
                    "text": "In this study, we examined a role for the DNA methyltransferase DNMT3B, in particular, the truncated isoform DNMT3B7, which is generated frequently in cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815530",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 741,
                    "offsetInEndSection": 908,
                    "text": "DNMT1 is a widely expressed DNA methyltransferase maintaining methylation patterns in development, and mediating transcriptional repression by direct binding to HDAC2.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22328086",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 106,
                    "offsetInEndSection": 337,
                    "text": "DNA methyltransferases (DNMTs) are a family of related proteins that both catalyze the de novo formation of 5-methylcytosine and maintain these methylation marks in cell-specific patterns in virtually all mitotic cells of the body.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134929",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 340,
                    "text": "This methylation is critical for imprinting; a reduction in the DNA methyltransferase DNMT1 causes a widespread loss of imprinting.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20547750",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 218,
                    "text": "DNA methyltransferase 3B (DNMT3B) is the key methyltransferase in DNA methylation regulations.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19576953",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 252,
                    "text": "DNA methyltransferases (DNMTs) are a family of enzymes that methylate DNA at the C5 position of cytosine residues, and their inhibition is a promising strategy for the treatment of various developmental and proliferative diseases, particularly cancers.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19322801",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 203,
                    "text": "DNA methylation is mediated by a family of DNA methyltransferases.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18437543",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1194,
                    "offsetInEndSection": 1357,
                    "text": "These results suggest that DNMT1 and DNMT3B regulate BAG-1 expression via insulator protein DNA-binding and chromatin dynamics by regulating histone dimethylation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18413740",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 336,
                    "offsetInEndSection": 468,
                    "text": "Here we show that human miR-148 represses DNA methyltransferase 3b (Dnmt3b) gene expression through a region in its coding sequence.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18367714",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "DNA methylation is catalyzed by a family of DNA methyltransferases (DNMTs) including the maintenance enzyme DNMT 1 and de novo methyltransferases DNMT 3a and DNMT 3b.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17929180",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 676,
                    "text": "Among the reported down-regulated miRNAs in lung cancer, the miRNA (miR)-29 family (29a, 29b, and 29c) has intriguing complementarities to the 3'-UTRs of DNA methyltransferase (DNMT)3A and -3B (de novo methyltransferases), two key enzymes involved in DNA methylation, that are frequently up-regulated in lung cancer and associated with poor prognosis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890317",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 797,
                    "text": "Furthermore, we have examined the roles of the de novo methyltransferases (Dnmt3a and Dnmt3b) and related protein (Dnmt3L) in this process.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17616512",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "DNA methyltransferase 1 (DNMT1) has been reported to interact with a wide variety of factors and to contain intrinsic transcriptional repressor activity.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17371843",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 690,
                    "text": "Inactivation of both Dnmt3a and Dnmt3b, DNA methyltransferases essential for the initiation of de novo DNA methylation, abolished the establishment of DNA methylation and the silencing of Rhox cluster genes in the embryo proper.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17182866",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 553,
                    "text": "Rather, in vitro analysis indicates that Dnmt3L stimulates DNA methylation by both Dnmt3a and Dnmt3b through direct binding to these proteins.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16999741",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235,
                    "text": "OBJECTIVE: To investigate the association between single nucleotide polymorphism (SNP) in promoter of the DNA methyltransferase 3B (DNMT3B) gene and risk for development and lymphatic metastasis of gastric cardiac adenocarcinoma (GCA).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15962389",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "text": "Methylation at the 5-position of DNA cytosine on the vertebrate genomes is accomplished by the combined catalytic actions of three DNA methyltransferases (DNMTs), the de novo enzymes DNMT3A and DNMT3B and the maintenance enzyme DNMT1.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23393137",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 303,
                    "text": "There are two major categories of DNA methyltransferases: de novo and maintenance.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357425",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 366,
                    "text": "Some, but not all, murine H1 subtypes interact with DNA methyltransferases DNMT1 and DNMT3B.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23302691",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "List the existing methods for genetic manipulation of cells.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24296066",
                "http://www.ncbi.nlm.nih.gov/pubmed/12719540",
                "http://www.ncbi.nlm.nih.gov/pubmed/19678910",
                "http://www.ncbi.nlm.nih.gov/pubmed/24269346",
                "http://www.ncbi.nlm.nih.gov/pubmed/24060313",
                "http://www.ncbi.nlm.nih.gov/pubmed/22675075",
                "http://www.ncbi.nlm.nih.gov/pubmed/24158830",
                "http://www.ncbi.nlm.nih.gov/pubmed/24048932",
                "http://www.ncbi.nlm.nih.gov/pubmed/21249368",
                "http://www.ncbi.nlm.nih.gov/pubmed/19594452",
                "http://www.ncbi.nlm.nih.gov/pubmed/16451554",
                "http://www.ncbi.nlm.nih.gov/pubmed/18556259",
                "http://www.ncbi.nlm.nih.gov/pubmed/24050263",
                "http://www.ncbi.nlm.nih.gov/pubmed/24055287",
                "http://www.ncbi.nlm.nih.gov/pubmed/18988631",
                "http://www.ncbi.nlm.nih.gov/pubmed/24222505",
                "http://www.ncbi.nlm.nih.gov/pubmed/24296044"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0086451",
                    "o": "U002966"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0025991",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0086451"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0025991",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0086451"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0086452",
                    "o": "Microinjections"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0483915",
                    "o": "microinjection"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0025991",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0086450"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0086450",
                    "o": "Microinjection"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0025991",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0483915"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0025991",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0086452"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#broader",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0040669",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0178659"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0319027",
                    "o": "genetic manipulation"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0040669",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0127589"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0040669",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0490756"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0040669",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0127588"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0127588",
                    "o": "Transfection"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0040669",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0127590"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0127590",
                    "o": "Transfections"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0040669",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0127590"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0490756",
                    "o": "transfection"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0040669",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7574200"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#broader",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0872089",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0040669"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0872089",
                    "o": "http://linkedlifedata.com/resource/umls/label/A1883737"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A1883737",
                    "o": "transfection/expression vector"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7574200",
                    "o": "NCI Thesaurus"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0490756",
                    "o": "CRISP Thesaurus"
                }
            ],
            "ideal_answer": [
                "Genetic engineering, also called genetic modification, is the direct manipulation of an organism's genome using biotechnology. New DNA may be inserted in the host genome by first isolating and copying the genetic material of interest using molecular cloning methods to generate a DNA sequence, or by synthesizing the DNA, and then inserting this construct into the host organism. Genes may be removed, or \"knocked out\", using a nuclease. Gene targeting is a different technique that uses homologous recombination to change an endogenous gene, and can be used to delete a gene, remove exons, add a gene, or introduce point mutations. Based on results there are developed many methods for genetic manipulation of cells such as Microinjection, electroporation, liposomes and via viral vectors.",
                "The existing methods for genetic manipulation of cells include Agrobacterium-mediated or direct delivery methods, as well as methods using plant artificial chromosomes, site-directed plasmid mutagenesis, combined use of Red/ET recombination and unique restriction site elimination, Bacterial artificial chromosomes (BACs), direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli, as well as transformation-competent artificial chromosome (TAC)-based acceptor vector, by exploiting the CreloxP recombination system and homing endonucleases."
            ],
            "exact_answer": [
                [
                    "Agrobacterium-mediated delivery"
                ],
                [
                    "direct delivery methods"
                ],
                [
                    "methods using plant artificial chromosomes"
                ],
                [
                    "site-directed plasmid mutagenesis"
                ],
                [
                    "combined use of Red/ET recombination and unique restriction site elimination"
                ],
                [
                    "Bacterial artificial chromosomes (BACs)"
                ],
                [
                    "direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli"
                ],
                [
                    "transformation-competent artificial chromosome (TAC)-based acceptor vector, by exploiting the CreloxP recombination system and homing endonucleases"
                ],
                [
                    "Microinjection"
                ],
                [
                    "electroporation"
                ],
                [
                    "viral vectors"
                ],
                [
                    "liposomes"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053672",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0009292",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008967",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008845",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039361",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018274",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055614",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015316",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014158",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005821",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D036281",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005823",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005822",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005820",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006579",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014162",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004247",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005826"
            ],
            "type": "list",
            "id": "52fa73e82059c6d71c000059",
            "snippets": [
                {
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 749,
                    "text": "For efficient genetic transformation, Agrobacterium-mediated as well as direct delivery methods have been used successfully. However, these methods suffer from many disadvantages especially in terms of transfer of large genes, gene complexes and gene silencing. To overcome these problems, recently, some efforts have been made to develop genetic transformation systems based on engineered plant chromosomes called minichromosomes or plant artificial chromosomes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249368",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 401,
                    "text": "Existing methods for site-directed plasmid mutagenesis are restrained by the small spectrum of modifications that can be introduced by mutagenic primers and the amplicon size limitations of in vitro DNA synthesis. As demonstrated here, the combined use of Red/ET recombination and unique restriction site elimination enables extensive manipulation regardless of plasmid size and DNA sequence elements.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19594452",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation of viral genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988631",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 790,
                    "text": "Here, we describe a novel method for cloning the genomes of large DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli. Determination of insertion sites and adjacent viral sequences identify the BAC clones for genetic manipulation and functional characterization.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988631",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 678,
                    "text": "Here, we describe a vector system for efficient multigene assembly and transformation. The system consists of a transformation-competent artificial chromosome (TAC)-based acceptor vector together with two donor vectors. By exploiting the CreloxP recombination system and homing endonucleases, multiple rounds of gene assembly cycling were carried out with alternate use of the donor vectors, and multiple genes were sequentially delivered into the TAC vector.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12719540",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List places in the body where somatostatin is produced.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25777539",
                "http://www.ncbi.nlm.nih.gov/pubmed/23370538",
                "http://www.ncbi.nlm.nih.gov/pubmed/24627166",
                "http://www.ncbi.nlm.nih.gov/pubmed/19819962",
                "http://www.ncbi.nlm.nih.gov/pubmed/23894587"
            ],
            "ideal_answer": [
                "Somatostatin is a cyclic peptide well known for its strong regulatory effects throughout the body. Also known by the name of growth hormone inhibiting hormone, it is produced in many locations, which include the olfactory bulb, hair follicles, pancreas, retina, and central nervous system (CNS)."
            ],
            "exact_answer": [
                [
                    "Hair follicles"
                ],
                [
                    "CNS"
                ],
                [
                    "pancreas"
                ],
                [
                    "olfactory bulb"
                ],
                [
                    "retina"
                ]
            ],
            "type": "list",
            "id": "5c97f579ecadf2e73f00002a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Somatostatin (SST) is a neuromodulator which is abundant throughout the central nervous system (CNS)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25777539",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Somatostatin (SST) is abundantly produced by the human retina, and the main source is the retinal pigment epithelium (RPE).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627166",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Somatostatin (Som), one of the most concentrated neuropeptides in the brain, is highly expressed in the olfactory bulb (OB)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894587",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "The production of somatostatin interneurons in the olfactory bulb is regulated by the transcription factor sp8",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894587",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Somatostatin expression in human hair follicles and its potential role in immune privilege",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23370538",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "The kinetics of insulin, glucagon and somatostatin release was studied in human pancreatic islets.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819962",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819962",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "What are the indications for treatment with anti-hepcidin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24159166",
                "http://www.ncbi.nlm.nih.gov/pubmed/24231125",
                "http://www.ncbi.nlm.nih.gov/pubmed/24175256"
            ],
            "ideal_answer": [
                "improving anemia control\nanemia management in hemodialysis\niron-restricted anemias"
            ],
            "exact_answer": [
                [
                    "iron-restricted anemias"
                ],
                [
                    "anemia of inflammation"
                ],
                [
                    "anemia of cancer"
                ],
                [
                    "anemia of chronic kidney disease"
                ],
                [
                    "anemia of chronic disease"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064451"
            ],
            "type": "list",
            "id": "535d59349a4572de6f000009",
            "snippets": [
                {
                    "offsetInBeginSection": 694,
                    "offsetInEndSection": 748,
                    "text": "anti-hepcidin strategies for improving anemia control.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231125",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1228,
                    "text": "anti-hepcidin therapies may improve anemia management in hemodialysis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24175256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "Anti-hepcidin therapy for iron-restricted anemias",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159166",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 73,
                    "offsetInEndSection": 219,
                    "text": "human anti-hepcidin antibody as a novel therapeutic for iron-restricted anemias such as anemia of inflammation, cancer, or chronic kidney disease ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159166",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List Mcl-1 inhibitors.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29580266",
                "http://www.ncbi.nlm.nih.gov/pubmed/30139826",
                "http://www.ncbi.nlm.nih.gov/pubmed/30017199",
                "http://www.ncbi.nlm.nih.gov/pubmed/30185782",
                "http://www.ncbi.nlm.nih.gov/pubmed/30185825"
            ],
            "ideal_answer": [
                "A-1210477\nS63845"
            ],
            "exact_answer": [
                [
                    "A-1210477"
                ],
                [
                    "S63845"
                ]
            ],
            "type": "list",
            "id": "5e6e8897c6a8763d23000003",
            "snippets": [
                {
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 363,
                    "text": "The recent description of S63845 as the first specific and potent MCL-1 inhibitor represents an important therapeutic advance",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185825",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 550,
                    "text": " We tested the efficacy of the BH3 mimetic combination of A-1210477 (an MCL-1 inhibitor)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185782",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 192,
                    "text": "a highly specific MCL-1 inhibitor, S63845,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30139826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 815,
                    "text": "Mcl-1 inhibitor S63845",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30017199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 702,
                    "text": "A-1210477, a selective MCL-1 inhibitor",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29580266",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "which are the risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23990187",
                "http://www.ncbi.nlm.nih.gov/pubmed/15929624",
                "http://www.ncbi.nlm.nih.gov/pubmed/18221594",
                "http://www.ncbi.nlm.nih.gov/pubmed/17652294",
                "http://www.ncbi.nlm.nih.gov/pubmed/19850699",
                "http://www.ncbi.nlm.nih.gov/pubmed/21475680",
                "http://www.ncbi.nlm.nih.gov/pubmed/9761089",
                "http://www.ncbi.nlm.nih.gov/pubmed/19791461",
                "http://www.ncbi.nlm.nih.gov/pubmed/23500286",
                "http://www.ncbi.nlm.nih.gov/pubmed/23867451",
                "http://www.ncbi.nlm.nih.gov/pubmed/17162272",
                "http://www.ncbi.nlm.nih.gov/pubmed/15856398",
                "http://www.ncbi.nlm.nih.gov/pubmed/7787270",
                "http://www.ncbi.nlm.nih.gov/pubmed/18033231",
                "http://www.ncbi.nlm.nih.gov/pubmed/2482379",
                "http://www.ncbi.nlm.nih.gov/pubmed/20118111",
                "http://www.ncbi.nlm.nih.gov/pubmed/20132378",
                "http://www.ncbi.nlm.nih.gov/pubmed/19419401",
                "http://www.ncbi.nlm.nih.gov/pubmed/22762717",
                "http://www.ncbi.nlm.nih.gov/pubmed/10957787",
                "http://www.ncbi.nlm.nih.gov/pubmed/19699347"
            ],
            "ideal_answer": [
                "The following risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy have been identified: 1) previous cardiac arrest; 2) sustained ventricular tachycardia; 3) family history of sudden cardiac death; 4) high-risk genetic mutations; 5) unexplained syncope; 6) non-sustained ventricular tachycardia; 7) hypotensive response to exercise; 8) marked left ventricular hypertrophy; 9) J-wave on ECG and 10) myocardial fibrosis using late gadolinium enhancement"
            ],
            "exact_answer": [
                [
                    "myocardial fibrosis using late gadolinium enhancement"
                ],
                [
                    "J-wave on ECG"
                ],
                [
                    "Extreme left ventricular hypertrophy (>30mm)"
                ],
                [
                    "Nonsustained ventricular tachycardia"
                ],
                [
                    "Sustained ventricular tachycardia"
                ],
                [
                    "previous cardiac arrest"
                ],
                [
                    "family history of sudden cardiac death"
                ],
                [
                    "unexplained syncope"
                ],
                [
                    "hypotensive response to exercise"
                ],
                [
                    "high-risk genetic mutations"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016757",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002312",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012307"
            ],
            "type": "list",
            "id": "531375a6e3eabad021000011",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 273,
                    "text": "Cardiac magnetic resonance (CMR) is used in the diagnosis and risk stratification of hypertrophic cardiomyopathy (HCM) and can detect myocardial replacement fibrosis (anindependent predictor of adverse cardiac outcomes) using late gadolinium enhancement (LGE). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990187",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "J wave is associated with increased risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23867451",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 962,
                    "offsetInEndSection": 1023,
                    "text": "The J wave may be a risk factor for SCA in patients with HCM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23867451",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1745,
                    "text": "Extreme left ventricular hypertrophy was the most common risk factor present (alone or in combination with other markers) in patients experiencing primary prevention interventions (17 of 26 [65%]).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23500286",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2024,
                    "offsetInEndSection": 2123,
                    "text": "Extreme left ventricular hypertrophy was most frequently associated with appropriate interventions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23500286",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 757,
                    "offsetInEndSection": 918,
                    "text": "In conclusion, it is demonstrated that LGE has incremental value in addition to clinical risk factors for risk stratification and management of patients with HC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762717",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1047,
                    "offsetInEndSection": 1196,
                    "text": "Fibrosis as detected by CMR should be evaluated as an additional risk factor to further delineate risk of SCD in carriers of an HCM causing mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21475680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 953,
                    "offsetInEndSection": 1119,
                    "text": "Nonsustained VT was the only predictive risk factor (RF) for an appropriate ICD intervention in the PP (positive predictive value 22%, negative predictive value 96%).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20132378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1541,
                    "offsetInEndSection": 1648,
                    "text": "Nonsustained ventricular tachycardia seems to be the most predictive RF for appropriate device discharges. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20132378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2427,
                    "offsetInEndSection": 2709,
                    "text": "However, LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent SCD and/or ICD discharge after controlling for other variables. If replicated, LGE may be considered an important risk factor for sudden death in patients with HCM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19850699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1272,
                    "offsetInEndSection": 1415,
                    "text": "In conclusion, our cohort study results do not support LVOTO as an independent risk factor for SD in patients with hypertrophic cardiomyopathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19699347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1157,
                    "offsetInEndSection": 1433,
                    "text": "The appearance of a \"hump\" at the ST segment during exercise testing appears to be a risk factor for SCD in patients with HCM. However, further studies are necessary to validate this finding in larger populations and to elucidate the mechanism of the appearance of the \"hump.\"",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19419401",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 667,
                    "text": "The ICD is definitely indicated for secondary prevention of sudden death in patients with HCM who have survived a cardiac arrest with documented ventricular fibrillation, or experienced one or more episodes of sustained ventricular tachycardia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18221594",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 1207,
                    "text": "A number of risk markers are used to assess the magnitude of risk, including family history of premature sudden death; extreme left ventricular (LV) hypertrophy (> 30 mm) in young patients; nonsustained ventricular tachycardia on Holter electrocardiographic recording; unexplained (not neurally mediated) syncope, particularly in young patients; and blood pressure decrease or inadequate increase during upright exercise.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18221594",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 755,
                    "offsetInEndSection": 962,
                    "text": "Measured risk factors for sudden death included family history of sudden death, massive left ventricular hypertrophy, nonsustained ventricular tachycardia on Holter monitoring, and unexplained prior syncope.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652294",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1311,
                    "text": "The following risk factors were analyzed: 1) previous cardiac arrest or sustained ventricular tachycardia; 2) family history of sudden cardiac death; 3) high-risk genetic mutations; 4) syncope; 5) non-sustained ventricular tachycardia; 6) hypotensive response to exercise; and 7) marked left ventricular hypertrophy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15929624",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1809,
                    "offsetInEndSection": 1989,
                    "text": "Family history of sudden death was associated with a positive predictive value of 25% for appropriate therapies, 40% for syncope and 50% for non-sustained ventricular tachycardia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15929624",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2592,
                    "offsetInEndSection": 2768,
                    "text": "In patients with an implantable cardioverter-defibrillator for primary prevention, non-sustained ventricular tachycardia was the risk factor with the highest predictive value. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15929624",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1231,
                    "offsetInEndSection": 1377,
                    "text": "It is concluded that there is an association of the mutation Arg719Trp in the beta-myosin heavy chain with sudden cardiac death in a young child. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10957787",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which drugs affect insulin resistance in obesity?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17482151",
                "http://www.ncbi.nlm.nih.gov/pubmed/9374813",
                "http://www.ncbi.nlm.nih.gov/pubmed/19236237",
                "http://www.ncbi.nlm.nih.gov/pubmed/21276223",
                "http://www.ncbi.nlm.nih.gov/pubmed/23619228",
                "http://www.ncbi.nlm.nih.gov/pubmed/17437648",
                "http://www.ncbi.nlm.nih.gov/pubmed/21270237",
                "http://www.ncbi.nlm.nih.gov/pubmed/22292446",
                "http://www.ncbi.nlm.nih.gov/pubmed/22247785",
                "http://www.ncbi.nlm.nih.gov/pubmed/23702383",
                "http://www.ncbi.nlm.nih.gov/pubmed/24090942",
                "http://www.ncbi.nlm.nih.gov/pubmed/22412882",
                "http://www.ncbi.nlm.nih.gov/pubmed/22983924",
                "http://www.ncbi.nlm.nih.gov/pubmed/23735317",
                "http://www.ncbi.nlm.nih.gov/pubmed/21440024",
                "http://www.ncbi.nlm.nih.gov/pubmed/22435392",
                "http://www.ncbi.nlm.nih.gov/pubmed/23144896",
                "http://www.ncbi.nlm.nih.gov/pubmed/18925326",
                "http://www.ncbi.nlm.nih.gov/pubmed/22275759",
                "http://www.ncbi.nlm.nih.gov/pubmed/24072084",
                "http://www.ncbi.nlm.nih.gov/pubmed/23176795",
                "http://www.ncbi.nlm.nih.gov/pubmed/23808738",
                "http://www.ncbi.nlm.nih.gov/pubmed/22878697",
                "http://www.ncbi.nlm.nih.gov/pubmed/23820981"
            ],
            "ideal_answer": [
                "Enistein treatment could help reduce insulin resistance\nACE inhibitor drugs may improve insulin resistance"
            ],
            "exact_answer": [
                [
                    "Enistein"
                ],
                [
                    "ACE inhibitors"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007333",
                "http://www.disease-ontology.org/api/metadata/DOID:14221",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009765",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061385",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007328",
                "http://www.disease-ontology.org/api/metadata/DOID:9970",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019440",
                "http://www.uniprot.org/uniprot/INS_CAIMO"
            ],
            "type": "list",
            "id": "52e7b7cb98d023950500001c",
            "snippets": [
                {
                    "offsetInBeginSection": 1481,
                    "offsetInEndSection": 1696,
                    "text": "enistein treatment could help reduce insulin resistance through the amelioration of OVX-induced metabolic dysfunction, and the GSEA approach may be useful in proposing putative targets related to insulin resistance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23176795",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1475,
                    "text": "he positive effects of ACE inhibitor drugs, particularly on hypertriglyceridemia and insulin resistance, might bring them forth as first-line drugs in the treatment of obese and hypertensive children. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072084",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8055935",
                "http://www.ncbi.nlm.nih.gov/pubmed/18239272",
                "http://www.ncbi.nlm.nih.gov/pubmed/15975091",
                "http://www.ncbi.nlm.nih.gov/pubmed/12925738",
                "http://www.ncbi.nlm.nih.gov/pubmed/11781102",
                "http://www.ncbi.nlm.nih.gov/pubmed/14710188",
                "http://www.ncbi.nlm.nih.gov/pubmed/18799313"
            ],
            "ideal_answer": [
                "The most common consensus motifs for CK1 are: pSer-Xaa-Xaa-Ser, K/R-X-K/R-X-X-S/T, SLS and acidic cluster motifs and SerP/ThrP-Xaa-Xaa-Ser/Thr."
            ],
            "exact_answer": [
                [
                    "pSer-Xaa-Xaa-Ser"
                ],
                [
                    "K/R-X-K/R-X-X-S/T"
                ],
                [
                    "SLS and acidic cluster motifs"
                ],
                [
                    "SerP/ThrP-Xaa-Xaa-Ser/Thr"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010766",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D047389",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016310",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042327",
                "http://www.uniprot.org/uniprot/KC1A_RAT",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D032921",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016384",
                "http://www.uniprot.org/uniprot/KC1_PLAF7",
                "http://www.uniprot.org/uniprot/KC1A_CAEEL",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042325",
                "http://www.uniprot.org/uniprot/KC1A_HUMAN",
                "http://www.uniprot.org/uniprot/KC1AL_HUMAN"
            ],
            "type": "list",
            "id": "52d832dd98d0239505000003",
            "snippets": [
                {
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 305,
                    "text": "Members of the protein kinase CK1 family usually phosphorylate residues of serine that are close to other phosphoserine in a consensus motif of pS-X-X-S,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 705,
                    "offsetInEndSection": 773,
                    "text": "a novel consensus phosphorylation motif (K/R-X-K/R-X-X-S/T) for CK1 ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18239272",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 299,
                    "text": "CK1 acts as a 'phosphate-directed' kinase whose targeting is primed by a single phosphorylated side chain at position n-3 or n-4 relative to serine/threonine",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15975091",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "The protein kinase CK1 phosphorylates serine residues that are located close to another phosphoserine in the consensus pSer-Xaa-Xaa-Ser.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14710188",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 911,
                    "offsetInEndSection": 1003,
                    "text": "The results demonstrate that SLS and acidic cluster motifs are crucial for CK1 recognition. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12925738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 750,
                    "text": "The common features include an SLS motif followed two to five residues downstream by a cluster of acidic residues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12925738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1686,
                    "offsetInEndSection": 1832,
                    "text": "These data provide the clear-cut demonstration that the consensus sequence with N-terminal prephosphorylated residue(s), SerP/ThrP-Xaa-Xaa-Ser/Thr",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8055935",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List 3 enterotoxins produced by Clostridium difficile.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28366569",
                "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
                "http://www.ncbi.nlm.nih.gov/pubmed/28232034",
                "http://www.ncbi.nlm.nih.gov/pubmed/12825250",
                "http://www.ncbi.nlm.nih.gov/pubmed/2115017"
            ],
            "ideal_answer": [
                "Toxin A (TcdA), toxin B (TcdB), and binary toxin (CDT) produced by Clostridium difficile (CD)"
            ],
            "exact_answer": [
                [
                    "binary toxin (CDT"
                ],
                [
                    "Toxin A (TcdA)"
                ],
                [
                    "Toxin B (TcdB)"
                ]
            ],
            "type": "list",
            "id": "5c851a8175a4a5d219000005",
            "snippets": [
                {
                    "offsetInBeginSection": 420,
                    "offsetInEndSection": 653,
                    "text": "The toxins produced by the C. diff. (toxin A, toxin B, and binary toxin) are the agents that cause injury and disease. Only toxin producing C. diff. Strains will cause disease. Binary toxin by itself is not thought to produce disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 745,
                    "text": "Binary toxin causes disease in humans when present with toxin A and B producing bacteria, ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 387,
                    "text": " The main virulence factor is related to the release of two major exotoxins, toxin A (TcdA) and toxin B (TcdB). Recent C. difficile-associated disease (CDAD) outbreaks have been caused by hypervirulent strains which secrete an additional binary toxin (CDTa/CDTb). V",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366569",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "text": "The exotoxins toxin A (TcdA) and toxin B (TcdB) are produced by the bacterial pathogen Clostridium difficile and are responsible for the pathology associated with C. difficile infection (CDI).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28232034",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 312,
                    "offsetInEndSection": 448,
                    "text": "The pathogenic organism, Clostridium difficile, produces two enterotoxins, toxin A and toxin B, that cause colonic mucosal inflammation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12825250",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine.The action of toxins A, B, and C from Clostridium difficile was studied in the small intestine and colon of rats. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2115017",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Which proteins are related to the loss of cell-cell adhesion during EMT (epithelial-mesenchymal transition)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19295128",
                "http://www.ncbi.nlm.nih.gov/pubmed/16080193",
                "http://www.ncbi.nlm.nih.gov/pubmed/19604397",
                "http://www.ncbi.nlm.nih.gov/pubmed/19029937",
                "http://www.ncbi.nlm.nih.gov/pubmed/20168079",
                "http://www.ncbi.nlm.nih.gov/pubmed/23880940",
                "http://www.ncbi.nlm.nih.gov/pubmed/18611248",
                "http://www.ncbi.nlm.nih.gov/pubmed/22249256"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#subClassOf",
                    "s": "http://purl.uniprot.org/go/0001837",
                    "o": "http://purl.uniprot.org/go/0014031"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/go/0014031",
                    "o": "http://www.geneontology.org/go#GO:0014031"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/go/0001837",
                    "o": "EMT"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/go/0001837",
                    "o": "epithelial-mesenchymal transition"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/go/0001837",
                    "o": "http://www.geneontology.org/go#GO:0001837"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/go/0014031",
                    "o": "mesenchymal cell development"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/go/0001837",
                    "o": "epithelial to mesenchymal transition"
                }
            ],
            "ideal_answer": [
                "Transcriptional and post-transcriptional regulatory mechanisms mediated by several inducers of EMT, in particular the ZEB and Snail factors, downregulate the expression and/or functional organization of core polarity complexes. Functional loss of the cell-cell adhesion molecule E-cadherin is an essential event for epithelial-mesenchymal transition (EMT), a process that allows cell migration during embryonic development and tumour invasion. Recently, we found that aPKC can also phosphorylate Par6 to drive EMT and increase the migratory potential of non-small cell lung cancer cells. We propose that the regulation of EMT by SIRT1 involves modulation of, and cooperation with, the EMT inducing transcription factor ZEB1. Knockdown of Numb by shRNA in MDCK cells led to a lateral to apical translocation of E-cadherin and beta-catenin, active F-actin polymerization, mis-localization of Par3 and aPKC, a decrease in cell-cell adhesion and an increase in cell migration and proliferation. Growth factors such as TGFb and EGF have also been shown to be related to EMT."
            ],
            "exact_answer": [
                [
                    "ZEB"
                ],
                [
                    "SNAIL"
                ],
                [
                    "SIRT1"
                ],
                [
                    "EGF"
                ],
                [
                    "TGFb"
                ],
                [
                    "aPKC"
                ],
                [
                    "Par6"
                ]
            ],
            "concepts": [
                "http://www.biosemantics.org/jochem#4269222",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001837",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011506",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002448",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007155",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058750"
            ],
            "type": "list",
            "id": "531b3ff3b166e2b80600003d",
            "snippets": [
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 82,
                    "text": "conserved polarity proteins Par6 and aPKC regulate cell polarization processes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 425,
                    "offsetInEndSection": 643,
                    "text": " In addition to signaling pathways that alter genetic programes that trigger the loss of cell-cell adhesion, alternative pathways can alter cell plasticity to regulate cell-cell cohesion and increase invasive potential",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 707,
                    "text": "One such pathway involves TGF\u03b2-induced phosphorylation of Par6",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1007,
                    "text": "Recently, we found that aPKC can also phosphorylate Par6 to drive EMT and increase the migratory potential of non-small cell lung cancer cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 493,
                    "text": "Here, we propose a novel mechanism through which the nicotinamide adenine dinucleotide-dependent histone deacetylase SIRT1 regulates EMT in prostate cancer cells through cooperation with the EMT inducing transcription factor ZEB1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 993,
                    "text": "In contrast, silencing SIRT1 in metastatic prostate tumor cells restores cell-cell adhesion and induces a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1123,
                    "text": "We also found that SIRT1 has a physiologically relevant role in endogenous EMT induced by EGF signaling in prostate cancer cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1125,
                    "offsetInEndSection": 1260,
                    "text": "We propose that the regulation of EMT by SIRT1 involves modulation of, and cooperation with, the EMT inducing transcription factor ZEB1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1523,
                    "offsetInEndSection": 1587,
                    "text": "We thus identify a necessary role for ZEB1 in SIRT1-mediated EMT",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 305,
                    "text": "Numb has been shown to play an important role in the proper functions of Par protein complex and in cell-cell junctions, both of which are associated with EMT",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20168079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 371,
                    "offsetInEndSection": 450,
                    "text": "Recently, we showed that Numb is capable of binding to both Par3 and E-cadherin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20168079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 873,
                    "text": "Knockdown of Numb by shRNA in MDCK cells led to a lateral to apical translocation of E-cadherin and beta-catenin, active F-actin polymerization, mis-localization of Par3 and aPKC, a decrease in cell-cell adhesion and an increase in cell migration and proliferation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20168079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 210,
                    "offsetInEndSection": 328,
                    "text": "This is coupled with the transcriptional repression of E-cadherin, often mediated by Snail1, Snail2 and Zeb1/deltaEF1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19604397",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 535,
                    "offsetInEndSection": 770,
                    "text": "EGF induces EMT in the breast cancer cell line PMC42-LA and the kinase inhibitor staurosporine (ST) induces EMT in embryonic neural epithelial cells, with F-actin de-bundling and disruption of cell-cell adhesion, via inhibition of aPKC",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19604397",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2071,
                    "offsetInEndSection": 2271,
                    "text": "ST in combination with EGF directed a greater EMT via actin depolymerisation and focal contact size reduction, resulting in a loosening of cell-ECM attachment along with Snail1-Zeb1/deltaEF1 induction",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19604397",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2273,
                    "offsetInEndSection": 2392,
                    "text": "This appeared fundamentally different to the EGF-induced EMT, highlighting the multiple pathways which can regulate EMT",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19604397",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 214,
                    "text": "unctional loss of the cell-cell adhesion molecule E-cadherin is an essential event for epithelial-mesenchymal transition (EMT), a process that allows cell migration during embryonic development and tumour invasion",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19295128",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 713,
                    "offsetInEndSection": 939,
                    "text": "Transcriptional and post-transcriptional regulatory mechanisms mediated by several inducers of EMT, in particular the ZEB and Snail factors, downregulate the expression and/or functional organization of core polarity complexes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029937",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 170,
                    "text": "TGFbeta has pleiotropic effects that range from regulation of proliferation and apoptosis to morphological changes and epithelial-mesenchymal transition (EMT)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18611248",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1194,
                    "offsetInEndSection": 1380,
                    "text": "Morphological changes were accompanied by decrease in E-cadherin and increased Snail expression but the mesenchymal markers (N-cadherin, SMAalpha and Vimentin) studied remained unchanged",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18611248",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 794,
                    "text": "Neutralising E-cadherin function promoted the invasion and inhibited the aggregation of endocrine-sensitive MCF7 cells, whilst having little effect on the behaviour of TamR cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080193",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which agents are included in the FLAMSA chemotherapy regimen?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18176613",
                "http://www.ncbi.nlm.nih.gov/pubmed/23728608",
                "http://www.ncbi.nlm.nih.gov/pubmed/21963618",
                "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
                "http://www.ncbi.nlm.nih.gov/pubmed/19430496",
                "http://www.ncbi.nlm.nih.gov/pubmed/23652585",
                "http://www.ncbi.nlm.nih.gov/pubmed/22983588"
            ],
            "ideal_answer": [
                "Fludarabine, cytarabine and amsacrine are included in the FLAMSA chemotherapy regimen."
            ],
            "exact_answer": [
                [
                    "fludarabine"
                ],
                [
                    "cytarabine"
                ],
                [
                    "amsacrine"
                ]
            ],
            "type": "list",
            "id": "54e071e11388e8454a00000d",
            "snippets": [
                {
                    "offsetInBeginSection": 560,
                    "offsetInEndSection": 770,
                    "text": "After 3 days of rest, RIC was carried out, consisting of 4 Gy total body irradiation, antithymocyte globulin (ATG-Fresenius), and cyclophosphamide (fludarabine, amsacrine, and cytarabine (FLAMSA)-RIC protocol).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 402,
                    "text": "We report a retrospective single center analysis of aplasia-inducing chemotherapy using fludarabine, cytarabine, and amsacrine (FLAMSA) followed by reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (HCT) in 62 consecutive primary refractory or relapsed AML patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652585",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 1041,
                    "text": "A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983588",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 661,
                    "text": "Between November 2003 and June 2010, 30 patients (20 high-risk MDS, 10 sAML) received fludarabine (4 \u00d7 30 mg/m(2)), amsacrine (4 \u00d7 100 mg/m(2)), and Ara-C (4 \u00d7 2 g/m(2), FLAMSA). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963618",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 457,
                    "text": "The preparative regimen consisted of fludarabine, Ara-C and amsacrine (FLAMSA) chemotherapy, followed by reduced intensity conditioning (RIC) 3 days later. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 250,
                    "offsetInEndSection": 605,
                    "text": "Fifteen patients received fludarabine 30 mg/m(2), cytarabine 2000 mg/m(2), amsacrine 100 mg/m(2) on days -10, -9, -8 and -7, anti-thymocyte globulin (ATG-Fresenius) 20 mg/kg body weight on days -6, -5 and -4 and fractionated total body irradiation 2 x 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) before allogeneic hematopoietic stem cell transplantation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19430496",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "text": "The goal of this analysis was to define the role of the moderate-intensity fludarabin Ara-C amsacrin (FLAMSA)-reduced intensity conditioning (RIC) regimen for patients with high-risk AML undergoing allogeneic SCT (alloSCT) in first CR1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18176613",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "text": "The goal of this analysis was to define the role of the moderate-intensity fludarabin Ara-C amsacrin (FLAMSA)-reduced intensity conditioning (RIC) regimen for patients with high-risk AML undergoing allogeneic SCT (alloSCT) in first CR1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18176613",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 454,
                    "text": "The preparative regimen consisted of fludarabine, Ara-C and amsacrine (FLAMSA) chemotherapy, followed by reduced intensity conditioning (RIC) 3 days later",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1039,
                    "text": "A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983588",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 1040,
                    "text": "A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983588",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 401,
                    "text": "We report a retrospective single center analysis of aplasia-inducing chemotherapy using fludarabine, cytarabine, and amsacrine (FLAMSA) followed by reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (HCT) in 62 consecutive primary refractory or relapsed AML patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652585",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 455,
                    "text": "The preparative regimen consisted of fludarabine, Ara-C and amsacrine (FLAMSA) chemotherapy, followed by reduced intensity conditioning (RIC) 3 days later",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "In which genomic positions is the histone variant macroH2A enriched?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16738309",
                "http://www.ncbi.nlm.nih.gov/pubmed/16213499",
                "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
                "http://www.ncbi.nlm.nih.gov/pubmed/14608463",
                "http://www.ncbi.nlm.nih.gov/pubmed/20937776",
                "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
                "http://www.ncbi.nlm.nih.gov/pubmed/17570398",
                "http://www.ncbi.nlm.nih.gov/pubmed/18195046",
                "http://www.ncbi.nlm.nih.gov/pubmed/18936163"
            ],
            "ideal_answer": [
                "macroH2A1 is enriched on the inactive X chromosome in female mammalian cells, where it functions to maintain gene silencing. The transcribed regions of most active genes are depleted of macroH2A, often in sharply localized domains that show depletion of 4-fold or more relative to bulk mouse liver chromatin. This repressor activity of marcroH2A is further supported by the substantial and relatively uniform macroH2A1 enrichment along the inactive X chromosome, which averages 4-fold. In addition to localizing to the MCB, macroH2A accumulates at a perinuclear structure centered at the centrosome"
            ],
            "exact_answer": [
                [
                    "Repressed regions"
                ],
                [
                    "Inactive X chromosome"
                ],
                [
                    "Centromeres"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657",
                "http://www.biosemantics.org/jochem#4278518",
                "http://www.uniprot.org/uniprot/H2AW_MOUSE"
            ],
            "type": "list",
            "id": "533c384dc45e133714000006",
            "snippets": [
                {
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 429,
                    "text": "Although macroH2A1 nucleosomes are widely distributed across the genome, their local concentration varies over a range of 100-fold or more",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20937776",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 431,
                    "offsetInEndSection": 614,
                    "text": "The transcribed regions of most active genes are depleted of macroH2A1, often in sharply localized domains that show depletion of 4-fold or more relative to bulk mouse liver chromatin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20937776",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 957,
                    "offsetInEndSection": 1119,
                    "text": "This repressor activity is further supported by the substantial and relatively uniform macroH2A1 enrichment along the inactive X chromosome, which averages 4-fold",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20937776",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1315,
                    "text": "mH2A1 consistently colocalizes with a heterochromatin marker (H3K27me2; histone H3 trimethylated at lysine 27) and mH2A2 with a euchromatin marker (H3K4me3; histone H3 trimethylated at lysine 4)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1317,
                    "offsetInEndSection": 1408,
                    "text": "Similar results were found for the L41gene, with enrichment of mH2A in the promoter region.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 117,
                    "offsetInEndSection": 358,
                    "text": "By using highly specific antibodies against mH2A1 and stable HEK 293 cell lines expressing either green fluorescent protein (GFP)-mH2A1 or GFP-H2A, we found that the Xi chromosome contains approximately 1.5-fold more mH2A1 than the autosomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18936163",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 693,
                    "offsetInEndSection": 775,
                    "text": "The data show that mH2A1 is uniformly distributed across the entire Xi chromosome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18936163",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 892,
                    "text": "Interestingly, a stronger mH2A1 enrichment along the pseudoautosomal X chromosome region was observed in both sexes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18936163",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 596,
                    "text": "macroH2A1 nucleosomes were enriched on endogenous MLVs, with the highest enrichment occurring on the 5' end of pro-pol",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18195046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 564,
                    "text": "macroH2A1 is enriched on the inactive X chromosome in female mammalian cells, where it functions to maintain gene silencing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17570398",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 269,
                    "text": "We found that macroH2A1 was depleted on the transcribed regions of active genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738309",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 402,
                    "offsetInEndSection": 528,
                    "text": "In contrast, macroH2A1 was concentrated on the inactive X chromosome, consistent with our previous immunofluorescence studies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738309",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 722,
                    "offsetInEndSection": 812,
                    "text": "These results support the hypothesis that macroH2As function as transcriptional repressors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738309",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 785,
                    "offsetInEndSection": 1198,
                    "text": "Taking into account the properties of macroH2A toward chromatin structure and dynamics and its role in gene repression our data suggest that the increased expression of macroH2A and the hypermethylation of DNA which occurs upon winter-acclimatization plays a major role for the reorganization of chromatin structure and the regulation of gene expression during the physiological adaptation to a colder environment",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16213499",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 380,
                    "text": "Inactivation is a multistep process that involves a large non-coding RNA termed XIST, a variety of epigenetic modifications of chromatin, and alterations in protein composition such as enrichment of the histone variant macroH2A",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14608463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "text": "One of several features acquired by chromatin of the inactive X chromosome (Xi) is enrichment for the core histone H2A variant macroH2A within a distinct nuclear structure referred to as a macrochromatin body (MCB)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 328,
                    "text": "In addition to localizing to the MCB, macroH2A accumulates at a perinuclear structure centered at the centrosome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1110,
                    "text": "The centrosomal pool of macroH2A1 accumulates in the presence of an inhibitor of the 20S proteasome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 650,
                    "offsetInEndSection": 849,
                    "text": "Although the MCB dissipates during late S phase and G2 before reforming in late G1, macroH2A1 remains associated during mitosis with specific regions of the Xi, including at the X inactivation center",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which drugs are included in TAS-102?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26557901",
                "http://www.ncbi.nlm.nih.gov/pubmed/26084259",
                "http://www.ncbi.nlm.nih.gov/pubmed/25776904",
                "http://www.ncbi.nlm.nih.gov/pubmed/25256052",
                "http://www.ncbi.nlm.nih.gov/pubmed/25230742",
                "http://www.ncbi.nlm.nih.gov/pubmed/25750295"
            ],
            "ideal_answer": [
                "TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5."
            ],
            "exact_answer": [
                [
                    "trifluridine"
                ],
                [
                    "tipiracil"
                ]
            ],
            "type": "list",
            "id": "56c1f000ef6e394741000037",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "PURPOSE: Trifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and tipiracil hydrochloride (thymidine phosphorylase inhibitor).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26084259",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 743,
                    "offsetInEndSection": 960,
                    "text": "TAS-102, a combination of trifluorothymidine and the thymidine phosphorylase inhibitor TPI in a 1:0.5 ratio, is a novel oral formulation, which is active in 5FU-resistant models, both in vitro and in xenograft models.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26557901",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25750295",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "PURPOSE: TAS-102 is an orally administered anticancer agent composed of \u03b1,\u03b1,\u03b1-trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25776904",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 1044,
                    "text": "Novel DNA synthesis inhibitors for the treatment of gastrointestinal malignancies include a combination of the antimetabolite TAS-102, which consists of trifluorothymidine with a thymidine phosphorylase inhibitor, and a novel micellar formulation of cisplatin NC-6004 that uses a nanotechnology-based drug delivery system. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256052",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230742",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230742",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which proteins are the different members of the NF-kappaB family of transcription factors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21122287",
                "http://www.ncbi.nlm.nih.gov/pubmed/22405852",
                "http://www.ncbi.nlm.nih.gov/pubmed/9129142",
                "http://www.ncbi.nlm.nih.gov/pubmed/9950430"
            ],
            "ideal_answer": [
                "Nuclear factor kappa B (NF\u03baB) is a dimeric transcription factor comprised of five family members RelA (p65), RelB, c-Rel, NF-kB1/p50 and NF-kB2/p52."
            ],
            "exact_answer": [
                [
                    "RelA",
                    "p65"
                ],
                [
                    "RelB"
                ],
                [
                    "c-Rel"
                ],
                [
                    "NF-kB1/p50"
                ],
                [
                    "NF-kB2/p52"
                ]
            ],
            "concepts": [
                "http://www.biosemantics.org/jochem#4263986",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016328"
            ],
            "type": "list",
            "id": "55192f20622b194345000014",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "The transcription factor NF-kappaB is composed of homodimeric and heterodimeric complexes of Rel/NF-kappaB-family polypeptides, which include Rel-A, c-Rel, Rel-B, NF-kappaB/p50 and NF-kappaB2/p52 .",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9950430",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Nuclear factor kappa B (NF\u03baB) is a dimeric transcription factor comprised of five family members RelA (p65), RelB, c-Rel, p50 and p52.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22405852",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 491,
                    "text": "In mammals, the genes rela, relb, crel, nfkappa\u03921, and nfkappaB encode the five NF-kB protein family members RelA (p65), RelB, c-Rel, p50, and p52, respectively, which form homo- and heterodimeric DNA-binding complexes capable of regulating target gene transcription of specific biological responses differentially.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21122287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 682,
                    "offsetInEndSection": 873,
                    "text": "These results suggest that the Rel-homology domain can act as an allosteric effector to promote transcription by p50/NFkappaB1 and that the configuration of p50 is important for its activity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9129142",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Please list 2 antitoxin antibodies approved by the FDA for reducing the recurrence of Clostridium difficile infection",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28232034",
                "http://www.ncbi.nlm.nih.gov/pubmed/27905086",
                "http://www.ncbi.nlm.nih.gov/pubmed/29760164",
                "http://www.ncbi.nlm.nih.gov/pubmed/28636484",
                "http://www.ncbi.nlm.nih.gov/pubmed/28480750",
                "http://www.ncbi.nlm.nih.gov/pubmed/28865041",
                "http://www.ncbi.nlm.nih.gov/pubmed/27757389",
                "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
                "http://www.ncbi.nlm.nih.gov/pubmed/28730660",
                "http://www.ncbi.nlm.nih.gov/pubmed/29234211"
            ],
            "ideal_answer": [
                "The antitoxin antibodies actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB, respectively. Bezlotoxumab was recently approved by the FDA for reducing the recurrence of CDI."
            ],
            "exact_answer": [
                [
                    "bezlotoxumab"
                ],
                [
                    "actoxumab"
                ]
            ],
            "type": "list",
            "id": "5c851c2675a4a5d219000006",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "The exotoxins toxin A (TcdA) and toxin B (TcdB) are produced by the bacterial pathogen Clostridium difficile and are responsible for the pathology associated with C. difficile infection (CDI). The antitoxin antibodies actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB, respectively. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28232034",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 378,
                    "text": "Bezlotoxumab was recently approved by the FDA for reducing the recurrence of CDI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28232034",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27757389",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 296,
                    "text": "The antitoxin antibodies actoxumab and bezlotoxumab bind to and neutralize TcdA and TcdB, respectively.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28232034",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636484",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905086",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "text": "Bezlotoxumab (Zinplava\u2122) is a fully human monoclonal antibody against Clostridium difficile toxin B indicated for the prevention of C. difficile infection (CDI) recurrence in patients with a high recurrence risk.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck &amp; Co.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905086",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which histone marks are deposited by Set7?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21963854",
                "http://www.ncbi.nlm.nih.gov/pubmed/15200950",
                "http://www.ncbi.nlm.nih.gov/pubmed/12086618",
                "http://www.ncbi.nlm.nih.gov/pubmed/12208845"
            ],
            "ideal_answer": [
                "Set7 is H4K20 monomethyltransferase. Upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation. Set7 (or some variant) has also been reported to perform mono-methylation on lysine-4 of H3."
            ],
            "exact_answer": [
                [
                    "H4K20 monomethylation"
                ],
                [
                    "H3K4 monomethylation"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011495",
                "http://www.uniprot.org/uniprot/SETD7_HALRO",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042393",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016571",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016570"
            ],
            "type": "list",
            "id": "5160412d298dcd4e5100003c",
            "snippets": [
                {
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 226,
                    "text": "the loss of H4 lysine 20 methylation",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 351,
                    "text": "Transcriptionally competent regions lack H4 lysine 20 methylation",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 17,
                    "offsetInEndSection": 102,
                    "text": "a human histone H4 lysine 20 methyltransferase and cloned the encoding gene, PR/SET07",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 433,
                    "text": "Localization of PR-Set7 to mitotic chromosomes and subsequent increase in H4 Lys 20 methylation",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208845",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 842,
                    "text": "the H4-K20 methyltransferase PR-Set7. Indeed, upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15200950",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Which are the available biomedical text mining tools for the detection of protein-protein interactions?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15719064",
                "http://www.ncbi.nlm.nih.gov/pubmed/23325628",
                "http://www.ncbi.nlm.nih.gov/pubmed/18834496",
                "http://www.ncbi.nlm.nih.gov/pubmed/22693219",
                "http://www.ncbi.nlm.nih.gov/pubmed/22595237",
                "http://www.ncbi.nlm.nih.gov/pubmed/19635172",
                "http://www.ncbi.nlm.nih.gov/pubmed/22513129",
                "http://www.ncbi.nlm.nih.gov/pubmed/21884822",
                "http://www.ncbi.nlm.nih.gov/pubmed/18204916",
                "http://www.ncbi.nlm.nih.gov/pubmed/18834498",
                "http://www.ncbi.nlm.nih.gov/pubmed/12689350",
                "http://www.ncbi.nlm.nih.gov/pubmed/18834492",
                "http://www.ncbi.nlm.nih.gov/pubmed/18508809",
                "http://www.ncbi.nlm.nih.gov/pubmed/18834495",
                "http://www.ncbi.nlm.nih.gov/pubmed/18712320",
                "http://www.ncbi.nlm.nih.gov/pubmed/18283029",
                "http://www.ncbi.nlm.nih.gov/pubmed/15998455",
                "http://www.ncbi.nlm.nih.gov/pubmed/19850753",
                "http://www.ncbi.nlm.nih.gov/pubmed/23221174",
                "http://www.ncbi.nlm.nih.gov/pubmed/18834500",
                "http://www.ncbi.nlm.nih.gov/pubmed/21106487",
                "http://www.ncbi.nlm.nih.gov/pubmed/21062765",
                "http://www.ncbi.nlm.nih.gov/pubmed/19828077",
                "http://www.ncbi.nlm.nih.gov/pubmed/18207462",
                "http://www.ncbi.nlm.nih.gov/pubmed/19234603",
                "http://www.ncbi.nlm.nih.gov/pubmed/20671319",
                "http://www.ncbi.nlm.nih.gov/pubmed/20617200",
                "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
                "http://www.ncbi.nlm.nih.gov/pubmed/18237434",
                "http://www.ncbi.nlm.nih.gov/pubmed/22711795",
                "http://www.ncbi.nlm.nih.gov/pubmed/22438567",
                "http://www.ncbi.nlm.nih.gov/pubmed/15941473",
                "http://www.ncbi.nlm.nih.gov/pubmed/19594875",
                "http://www.ncbi.nlm.nih.gov/pubmed/18487273"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7659857",
                    "o": "C18469"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0872079",
                    "o": "http://linkedlifedata.com/resource/umls/label/A1883605"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A1883605",
                    "o": "protein protein interaction"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0971869",
                    "o": "http://linkedlifedata.com/resource/umls/label/A2039412"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A2039412",
                    "o": "D025941"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A2039413",
                    "o": "Protein-Protein Interaction Maps"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A2039392",
                    "o": "D025941"
                },
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17004128",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17004128",
                    "o": "D057225"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17004128",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17004128",
                    "o": "Mining, Text"
                },
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7659857",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                }
            ],
            "ideal_answer": [
                "Protein-protein interactions (PPI) can be extracted from biomedical literature using text mining approaches. These approaches have been classified into two categories, the statistical calculation of the co-occurrence of proteins and the computational linguistic method. Moreover, bioinformatics methods based on sequence, structural, or evolutionary information have been developed to predict protein-protein interactions. The available state-of-the-art biomedical text mining tools are: eFIP (Extracting Functional Impact of Phosphorylation), a system for text mining of protein interaction networks of phosphorylated proteins; GeneView, a suite of state-of-the-art text-mining tools designed for the automated identification of protein\u2013protein interactions; PPI finder, a text mining tool for human protein-protein interactions based on computational linguistic methods. PPI Finder system consists of the Information Retrieval module and Information Extraction module; PreBIND and Textomy are two components of a biomedical literature-mining system optimized to discover protein-protein interactions using a support vector machine; BioMap system is optimized for the identification of protein-protein interactions from large biomedical literature datasets; Protopia searches for and integrates protein-protein interactions and the information about them contained in five different Protein Interaction Web Databases; STRING uses Natural Language Processing to extract a subset of semantically specified known and predicted protein-protein interactions.",
                "Several tools have been developed to detect protein-protein interactions (PPIs) by text mining the biomedical literature. Two main computational approaches used for this task are co-occurrence-based methods and Natural Language Processing methods. Biomedical text mining tools for PPI identification are the following (in alphabetical order): BioCreative Meta Server, BioMap, eFIP, Extracting Functional Impact of Phosphorylation, GeneView, HAPPI, Hidden Vector State model, iHop, LAITOR, OntoGene, OpenDMAP, PIE (Protein interaction information extraction system), PPI finder (Paired-PPI Finder), PPInterFinder, PPIs, PolySearch, PreBind and Textomy, Protopia, STRING, TafTalent."
            ],
            "exact_answer": [
                [
                    "BioCreative Meta Server"
                ],
                [
                    "Hidden Vector State model"
                ],
                [
                    "iHop"
                ],
                [
                    "LAITOR"
                ],
                [
                    "OntoGene"
                ],
                [
                    "PIE",
                    "Protein interaction information extraction system"
                ],
                [
                    "PPInterFinder"
                ],
                [
                    "PPIs"
                ],
                [
                    "TafTalent"
                ],
                [
                    "PolySearch"
                ],
                [
                    "OpenDMAP"
                ],
                [
                    "HAPPI"
                ],
                [
                    "GeneView"
                ],
                [
                    "PPI finder",
                    "Paired-PPI Finder"
                ],
                [
                    "PreBind",
                    "PreBIND",
                    "Textomy"
                ],
                [
                    "BioMap"
                ],
                [
                    "eFIP",
                    "Extracting Functional Impact of Phosphorylation"
                ],
                [
                    "Protopia"
                ],
                [
                    "STRING"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D060145",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057225"
            ],
            "type": "list",
            "id": "5149aafcd24251bc05000045",
            "snippets": [
                {
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 672,
                    "text": "In this study, we propose a novel algorithm for extracting PPIs from literature which consists of two phases. First, we automatically categorize the data into subsets based on its semantic properties and extract candidate PPI pairs from these subsets. Second, we apply support vector machines (SVMs) to classify candidate PPI pairs using features specific for each subset.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21062765",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1037,
                    "offsetInEndSection": 1161,
                    "text": "The source code and scripts used in this article are available for academic use at http://staff.science.uva.nl/~bui/PPIs.zip",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21062765",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "We describe a system for the detection of mentions of protein-protein interactions in the biomedical scientific literature. The original system was developed as a part of the OntoGene project",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20671319",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Extracting Protein-Protein Interactions from MEDLINE using the Hidden Vector State model",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283029",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 284,
                    "text": "We have constructed an information extraction system based on the Hidden Vector State (HVS) model for protein-protein interactions.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283029",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 571,
                    "text": "When applied in extracting protein-protein interactions, we found that it performed better than other established statistical methods",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283029",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1732,
                    "offsetInEndSection": 1855,
                    "text": "The developed BioMap system allows discovering implicit P-P interactions from large quantity of biomedical literature data.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204916",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 1077,
                    "text": "In this paper we examine if P-P interactions in regenerating tissues and cells of the anuran Xenopus laevis can be discovered from biomedical literature using computational and literature mining techniques. Using literature mining techniques, we have identified a set of implicitly interacting proteins in regenerating tissues and cells of Xenopus laevis that may interact with Cdc2 to control cell division.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204916",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1434,
                    "offsetInEndSection": 1560,
                    "text": "P-P interactions that are implicitly appearing in literature can be effectively discovered using literature mining techniques.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204916",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Which deiodinases are present in skeletal  muscle?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19293265",
                "http://www.ncbi.nlm.nih.gov/pubmed/17986277",
                "http://www.ncbi.nlm.nih.gov/pubmed/23396445",
                "http://www.ncbi.nlm.nih.gov/pubmed/16127464"
            ],
            "ideal_answer": [
                "Type 2 and Type 3 deiodinases are expressed in skeletal muscle and their expression is modulated by disease state and fasting."
            ],
            "exact_answer": [
                [
                    "Type 2 deiodinase"
                ],
                [
                    "Tipe 3 deiodinase"
                ]
            ],
            "type": "list",
            "id": "517a8bef8ed59a060a000041",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 335,
                    "text": "The iodothyronine deiodinases D1, D2, and D3 enable tissue-specific adaptation of thyroid hormone levels in response to various conditions, such as hypothyroidism or fasting. The possible expression of D2 mRNA in skeletal muscle is intriguing because this enzyme could play a role in systemic as well as local T3 production",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19293265",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1331,
                    "offsetInEndSection": 1435,
                    "text": "Human skeletal muscle D2 mRNA expression is modulated by fasting and insulin, but not by hypothyroidism.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19293265",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1414,
                    "text": "SM had very low D2 activity and again no differences were found between groups; D3 activity in SM was higher in NTIS than controls",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17986277",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 558,
                    "text": "Deiodinase activities were then assayed in cell sonicates. The ratio of T3 production in cell sonicates (catalytic efficiency) was multiplied by the tissue activities reported in human liver (D1) and skeletal muscle (D2)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16127464",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Which are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9803978",
                "http://www.ncbi.nlm.nih.gov/pubmed/11564050",
                "http://www.ncbi.nlm.nih.gov/pubmed/1290288",
                "http://www.ncbi.nlm.nih.gov/pubmed/7875632",
                "http://www.ncbi.nlm.nih.gov/pubmed/10810787"
            ],
            "ideal_answer": [
                "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV). Class I antiarrhythmic agents have as a common action, blockade of the sodium channels. Class II agents are antisympathetic drugs, particularly the beta-adrenoceptor blockers. Class-III antiarrhythmics have as a common action the potassium-channel blockade. Class IV antiarrhythmic drugs are calcium channel blockers."
            ],
            "exact_answer": [
                [
                    "Class I: sodium channel blockers"
                ],
                [
                    "ClassII: beta blockers"
                ],
                [
                    "Class III: potassium channel blockers"
                ],
                [
                    "Class IV: calcium channel blockers"
                ]
            ],
            "type": "list",
            "id": "54d4e03a3706e89528000001",
            "snippets": [
                {
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 577,
                    "text": "Class II agents are antisympathetic drugs, particularly the beta-adrenoceptor blockers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 709,
                    "text": "Class III antiarrhythmic agents include sotalol and amiodarone.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 835,
                    "offsetInEndSection": 923,
                    "text": "Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1111,
                    "text": "Other agents which do not fall neatly into the Vaughan Williams classification include digoxin and perhexiline.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 350,
                    "text": "Thus, the Vaughan Williams classification also coincides with the main myocardial targets of the antiarrhythmics, i.e., myocardial sodium-, potassium-, and calcium-channels or beta-adrenergic receptors. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 1079,
                    "text": "The sodium-channel blockade induced by class-I substances is enhanced with increasing heart rates. Thus, class-I antiarrhythmics can be subclassified as substances showing a more exponential, an approximately linear, or rather saturated block-frequency relation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1080,
                    "offsetInEndSection": 1270,
                    "text": "Class-III antiarrhythmics (potassium-channel blockade) can be further differentiated according to the component of the delayed rectifier potassium current (IK) which is inhibited by a drug. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1711,
                    "offsetInEndSection": 1863,
                    "text": "Class-III substances inhibiting the slowly activating IKs component are currently under investigation and are expected to show a direct rate dependence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "text": "Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 337,
                    "text": "The classification of antiarrhythmic agents according to Vaughan Williams is based on electrophysiological findings in isolated heart muscle and defines four classes of drug actions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1290288",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11564050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 575,
                    "text": "Class II agents are antisympathetic drugs, particularly the b-adrenoceptor blockers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11564050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 643,
                    "offsetInEndSection": 707,
                    "text": "Class III antiarrhythmic agents include sotalol and amiodarone. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11564050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 832,
                    "offsetInEndSection": 920,
                    "text": "Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11564050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 819,
                    "text": "These are classified according to their electrophysiological effects observed in isolated cardiac tissues in vitro (Vaughan Williams, 1989). Fast sodium channel blockers (class I) which reduce the upstroke velocity of the action potential are usually subclassified into three groups, class I A-C, according to their effect on the action potential duration. Beta-adrenergic antagonists (class II) exert their effects by antagonizing the electrophysiological effects of beta-adrenergic catecholamines. Class III antiarrhythmic agents (eg amiodarone) prolong the action potential and slow calcium channel blockers (class IV) suppress the calcium inward current and calcium-dependent action potentials. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7875632",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List four features of the WHIM syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24523241",
                "http://www.ncbi.nlm.nih.gov/pubmed/19956569",
                "http://www.ncbi.nlm.nih.gov/pubmed/12692554",
                "http://www.ncbi.nlm.nih.gov/pubmed/29715199",
                "http://www.ncbi.nlm.nih.gov/pubmed/28928741",
                "http://www.ncbi.nlm.nih.gov/pubmed/29057173",
                "http://www.ncbi.nlm.nih.gov/pubmed/29659363",
                "http://www.ncbi.nlm.nih.gov/pubmed/29066537",
                "http://www.ncbi.nlm.nih.gov/pubmed/28768817",
                "http://www.ncbi.nlm.nih.gov/pubmed/23009155",
                "http://www.ncbi.nlm.nih.gov/pubmed/21178277",
                "http://www.ncbi.nlm.nih.gov/pubmed/18274673",
                "http://www.ncbi.nlm.nih.gov/pubmed/21506920",
                "http://www.ncbi.nlm.nih.gov/pubmed/28512628",
                "http://www.ncbi.nlm.nih.gov/pubmed/22596258",
                "http://www.ncbi.nlm.nih.gov/pubmed/22748845",
                "http://www.ncbi.nlm.nih.gov/pubmed/16899028",
                "http://www.ncbi.nlm.nih.gov/pubmed/14612668"
            ],
            "ideal_answer": [
                "The Warts, Hypogammaglobulinemia, Infections, Myelokathexis (WHIM) syndrome is an immunodeficiency caused by mutations in chemokine receptor CXCR4."
            ],
            "exact_answer": [
                [
                    "Warts"
                ],
                [
                    "Hypogammaglobulinemia"
                ],
                [
                    "Infections"
                ],
                [
                    "Myelokathexis"
                ]
            ],
            "type": "list",
            "id": "5c55de1607647bbc4b00000a",
            "snippets": [
                {
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 565,
                    "text": "To test whether there may be an advantage of one approach over the other for WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome - a primary immunodeficiency disorder caused by gain-of-function autosomal dominant mutations in chemokine receptor CXCR4 - we performed competitive transplantation experiments using both lethally irradiated WT (Cxcr4+/+) and unconditioned WHIM (Cxcr4+/w) recipient mice. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29715199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "WHIM syndrome is a primary autosomal dominant immuno deficiency due to CXCR4 mutations characterized by mucocutaneous warts, hypogammaglobulinemia, recurrent bacterial infections and myelokathesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29659363",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "WHIM syndrome is a rare congenital immunodeficiency disease, named after its main clinical manifestations: warts, hypogammaglobulinemia, infections, and myelokathexis, which refers to abnormal accumulation of mature neutrophils in the bone marrow.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768817",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "The Warts, Hypogammaglobulinemia, Infections, Myelokathexis (WHIM) syndrome is an immunodeficiency caused by mutations in chemokine receptor CXCR4.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "WHIM syndrome is a condition in which affected persons have chronic peripheral neutropenia, lymphopenia, abnormal susceptibility to human papilloma virus infection, and myelokathexis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28512628",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 294,
                    "text": "Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a genetic disease characterized by neutropenia, lymphopenia, susceptibility to infections, and myelokathexis, which describes degenerative changes of mature neutrophils and hyperplasia of bone marrow myeloid cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29066537",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 278,
                    "text": "The WHIM syndrome features susceptibility to human Papillomavirus infection-induced warts and carcinomas, hypogammaglobulinemia, recurrent bacterial infections, B and T-cell lymphopenia, and neutropenia associated with retention of senescent neutrophils in the bone marrow (i.e.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21178277",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "text": "<b>PURPOSE OF REVIEW</b>: WHIM syndrome (the association of warts, hypogammaglobulinemia, recurrent bacterial infections, and 'myelokathexis') is a rare congenital form of neutropenia associated with an unusual immune disorder involving hypogammaglonulinemia and abnormal susceptibility to warts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14612668",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which disorders are caused by de novo mutations in ZSWIM6?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26706854",
                "http://www.ncbi.nlm.nih.gov/pubmed/29198722",
                "http://www.ncbi.nlm.nih.gov/pubmed/25105228"
            ],
            "ideal_answer": [
                "Mutations in the ZSWIM6 gene, which encodes the cellular iron exporter ZEB6, are the cause of de novo autosomal recessive acromelic frontonasal dysostosis and Leber's hereditary optic neuropathy and/or dystonia.",
                "A recurrent de novo nonsense variant in ZSWIM6 results in severe intellectual disability without frontonasal or limb malformations. Also, a recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 has previously been reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay, via a proposed gain-of-function effect.",
                "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal ZSWIM6 protein, are the cause of autosomal recessive acromelic frontonasal dysostosis and Leber's hereditary optic neuropathy and/or dystonia."
            ],
            "exact_answer": [
                [
                    "Severe intellectual disability without frontonasal or limb malformations"
                ],
                [
                    "Acromelic frontonasal dysostosis",
                    "AFND"
                ]
            ],
            "type": "list",
            "id": "5e2b0d167d50947c2f000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "A Recurrent De Novo Nonsense Variant in ZSWIM6 Results in Severe Intellectual Disability without Frontonasal or Limb Malformations.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29198722",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 321,
                    "text": "A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 was previously reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay, via a proposed gain-of-function effect. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29198722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 1199,
                    "text": "We show that the c.2737C>T variant does not trigger nonsense-mediated decay of the ZSWIM6 mRNA in affected individual-derived cells. This finding supports the existence of a truncated ZSWIM6 protein lacking the Sin3-like domain, which could have a dominant-negative effect. This study builds support for a key role for ZSWIM6 in neuronal development and function, in addition to its putative roles in limb and craniofacial development, and provides a striking example of different variants in the same gene leading to distinct phenotypes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29198722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Exome sequencing identifies a recurrent de novo ZSWIM6 mutation associated with acromelic frontonasal dysostosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105228",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1334,
                    "text": "Acromelic frontonasal dysostosis (AFND) is a rare disorder characterized by distinct craniofacial, brain, and limb malformations, including frontonasal dysplasia, interhemispheric lipoma, agenesis of the corpus callosum, tibial hemimelia, preaxial polydactyly of the feet, and intellectual disability. Exome sequencing of one trio and two unrelated probands revealed the same heterozygous variant (c.3487C>T [p. Arg1163Trp]) in a highly conserved protein domain of ZSWIM6; this variant has not been seen in the 1000 Genomes data, dbSNP, or the Exome Sequencing Project. Sanger validation of the three trios confirmed that the variant was de novo and was also present in a fourth isolated proband. In situ hybridization of early zebrafish embryos at 24 hr postfertilization (hpf) demonstrated telencephalic expression of zswim6 and onset of midbrain, hindbrain, and retinal expression at 48 hpf. Immunohistochemistry of later-stage mouse embryos demonstrated tissue-specific expression in the derivatives of all three germ layers. qRT-PCR expression analysis of osteoblast and fibroblast cell lines available from two probands was suggestive of Hedgehog pathway activation, indicating that the ZSWIM6 mutation associated with AFND may lead to the craniofacial, brain and limb malformations through the disruption of Hedgehog signaling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105228",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 320,
                    "text": "A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 was previously reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay, via a proposed gain-of-function effect.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29198722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 660,
                    "text": "We present detailed phenotypic information on seven unrelated individuals with a recurrent de novo nonsense variant (c.2737C>T [p.Arg913Ter]) in the penultimate exon of ZSWIM6 who have severe-profound intellectual disability and additional central and peripheral nervous system symptoms but an absence of frontonasal or limb malformations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29198722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Exome sequencing identifies a recurrent de novo ZSWIM6 mutation associated with acromelic frontonasal dysostosis .",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105228",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 321,
                    "text": "A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 was previously reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay, via a proposed gain-of-function effect.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29198722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 332,
                    "text": "A single recurrent heterozygous missense substitution in ZSWIM6, encoding a protein of unknown function, was previously shown to underlie this disorder in four unrelated cases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26706854",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the additions of the JASPAR 2016 open-access database of transcription factor binding profiles?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26531826"
            ],
            "ideal_answer": [
                "Compared to the JASPAR CORE collection, JASPAR 2016 has been expanded with 494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and 59 profiles (58 in vertebrates and 1 in fungi) have been updated. The introduced profiles represent an 83% expansion and 10% update when compared to the previous release. The structural annotation of the TF DNA binding domains (DBDs) has been updated following a published hierarchical structural classification. In addition, 130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites were introduced . The new JASPAR release is accompanied by a new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence. Moreover, users are provided with a Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles. JASPAR2016 R/Bioconductor data package is also provided with the data of this release."
            ],
            "exact_answer": [
                [
                    "494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and updated 59 profiles (58 in vertebrates and 1 in fungi)"
                ],
                [
                    "Updated structural annotation of the TF DNA binding domains (DBDs) following a published hierarchical structural classification"
                ],
                [
                    "130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites"
                ],
                [
                    "A new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence"
                ],
                [
                    "A Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles"
                ],
                [
                    "JASPAR2016 R/Bioconductor data package"
                ]
            ],
            "type": "list",
            "id": "587d2b7efe8a08052f000003",
            "snippets": [
                {
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 1301,
                    "text": "For this 2016 release, we expanded the JASPAR CORE collection with 494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and updated 59 profiles (58 in vertebrates and 1 in fungi). The introduced profiles represent an 83% expansion and 10% update when compared to the previous release. We updated the structural annotation of the TF DNA binding domains (DBDs) following a published hierarchical structural classification. In addition, we introduced 130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites. This new JASPAR release is accompanied by a new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence. Moreover, we provide the users with a Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles. Finally, we provide the JASPAR2016 R/Bioconductor data package with the data of this release",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26531826",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the triad symptoms of pheochromocytoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23513638",
                "http://www.ncbi.nlm.nih.gov/pubmed/8302154",
                "http://www.ncbi.nlm.nih.gov/pubmed/19497985",
                "http://www.ncbi.nlm.nih.gov/pubmed/27034920",
                "http://www.ncbi.nlm.nih.gov/pubmed/22980466",
                "http://www.ncbi.nlm.nih.gov/pubmed/1988766",
                "http://www.ncbi.nlm.nih.gov/pubmed/12584992",
                "http://www.ncbi.nlm.nih.gov/pubmed/12002199",
                "http://www.ncbi.nlm.nih.gov/pubmed/18206604",
                "http://www.ncbi.nlm.nih.gov/pubmed/12814824",
                "http://www.ncbi.nlm.nih.gov/pubmed/21125743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24382904",
                "http://www.ncbi.nlm.nih.gov/pubmed/24059371",
                "http://www.ncbi.nlm.nih.gov/pubmed/1867186",
                "http://www.ncbi.nlm.nih.gov/pubmed/20169139",
                "http://www.ncbi.nlm.nih.gov/pubmed/17102071",
                "http://www.ncbi.nlm.nih.gov/pubmed/22953071",
                "http://www.ncbi.nlm.nih.gov/pubmed/26998444",
                "http://www.ncbi.nlm.nih.gov/pubmed/21226896",
                "http://www.ncbi.nlm.nih.gov/pubmed/16789642"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0076994",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18632370"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18632370",
                    "o": "triad"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0076994",
                    "o": "triad"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0031511",
                    "o": "Pheochromocytoma"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0031511",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0486392"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0486392",
                    "o": "pheochromocytoma"
                }
            ],
            "ideal_answer": [
                "The classic triad of symptoms are episodic headache, excessive sweating (diaphoresis) and palpitation."
            ],
            "exact_answer": [
                [
                    "headache"
                ],
                [
                    "excessive sweating",
                    "diaphoresis"
                ],
                [
                    "palpitation"
                ]
            ],
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010673"
            ],
            "type": "list",
            "id": "58da5b588acda34529000015",
            "snippets": [
                {
                    "offsetInBeginSection": 2236,
                    "offsetInEndSection": 2403,
                    "text": "Diaphoresis (LR+ 2.2, LR- 0.45), Palpitation (LR+ 1.9, LR- 0.52) and headache (LR+ 1.6, LR- 0.24) were significant symptoms in clinical diagnosis of pheochromocytoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034920",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 723,
                    "offsetInEndSection": 931,
                    "text": "In the 52 cases analyzed, 40 of the patients had symptoms: 31 patients had hypertension; 10 had the triad of palpitations, diaphoresis, and headaches; and all had elevated urinary metanephrine concentrations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24059371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 322,
                    "text": " The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 543,
                    "text": "Among the presenting symptoms, episodes of palpitations, headaches, and profuse sweating are typical and constitute a classic triad.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22953071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 94,
                    "offsetInEndSection": 183,
                    "text": "The classic triad of symptoms are episodic headache, excessive sweating and palpitation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125743",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 320,
                    "text": "The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 830,
                    "offsetInEndSection": 1065,
                    "text": "Combinations of symptoms can be of value: 2 or more symptoms from the triad of headache, palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non-pheochromocytoma patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 320,
                    "text": "The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 67,
                    "offsetInEndSection": 411,
                    "text": "Pheochromocytoma in pregnancy is rare, and if unrecognized, can cause serious perinatal morbidity and mortality.A patient with severe hypertension, postpartum pulmonary edema, and a recognized pheochromocytoma is described.Abdominal palpation after vaginal childbirth reproduced the diagnostic triad of hypertension, headaches, and palpitations",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12002199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 836,
                    "offsetInEndSection": 1070,
                    "text": "Combinations of symptoms can be of value: 2 or more symptoms from the triad of headache, palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non-pheochromocytoma patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 457,
                    "text": "Although hypertension, headache, and diaphoresis are common symptoms in a dialyzed patient, pheochromocytoma has to be eliminated in the presence of this clinical triad",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1867186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 538,
                    "text": "Pheochromocytomas are catecholamine producing tumors that classically present with the triad of sweating, palpitations and headache.9-year-old boy whose only presenting complaints were polyuria and polydipsia for 2 years.Routine measurement of blood pressure detected mild hypertension, and subsequent investigations revealed bilateral pheochromocytoma.Surgical removal of the tumors resulted in complete resolution of polyuria and polydipsia.The case highlights the importance of measuring BP for children as part of physical examination",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24382904",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 321,
                    "text": "The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 458,
                    "text": "Although hypertension, headache, and diaphoresis are common symptoms in a dialyzed patient, pheochromocytoma has to be eliminated in the presence of this clinical triad.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1867186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 836,
                    "offsetInEndSection": 1071,
                    "text": "Combinations of symptoms can be of value: 2 or more symptoms from the triad of headache, palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non-pheochromocytoma patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 680,
                    "offsetInEndSection": 888,
                    "text": "In the 52 cases analyzed, 40 of the patients had symptoms: 31 patients had hypertension; 10 had the triad of palpitations, diaphoresis, and headaches; and all had elevated urinary metanephrine concentrations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24059371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 94,
                    "offsetInEndSection": 182,
                    "text": "The classic triad of symptoms are episodic headache, excessive sweating and palpitation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125743",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 857,
                    "offsetInEndSection": 1149,
                    "text": "The clinical symptoms of these tumors vary from isolated hypertension or hypertension accompanied by paroxysmal episodes -including the classical triad of headache, palpitations and diaphoresis-to potentially serious manifestations such as acute pulmonary edema, arrhythmias and sudden death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22980466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 841,
                    "text": "A very few symptoms were specific, like the triad \"headaches, sweating, palpitations\" whose onlyone third of patients was concerned by.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12814824",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 63,
                    "offsetInEndSection": 142,
                    "text": "Classically, a triad of symptoms includes sweating, palpitations, and headache.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17102071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 307,
                    "offsetInEndSection": 425,
                    "text": "The triad of diaphoresis, tachycardia, and headache in hypertensive patients is highly suggestive of pheochromocytoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8302154",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 708,
                    "offsetInEndSection": 843,
                    "text": "A very few symptoms were specific, like the triad \"headaches, sweating, palpitations\" whose onlyone third of patients was concerned by.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12814824",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 3501,
                    "offsetInEndSection": 3696,
                    "text": "We noticed, like others, when the triad of headache, sweating and palpitations is accompanied by hypertension, the diagnosis of pheochromocytoma can be made with specify and sensitivity over 93%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12584992",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List symptoms of the IFAP syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10398262",
                "http://www.ncbi.nlm.nih.gov/pubmed/1915513",
                "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
                "http://www.ncbi.nlm.nih.gov/pubmed/21886760",
                "http://www.ncbi.nlm.nih.gov/pubmed/14708109",
                "http://www.ncbi.nlm.nih.gov/pubmed/15370546",
                "http://www.ncbi.nlm.nih.gov/pubmed/25685152",
                "http://www.ncbi.nlm.nih.gov/pubmed/10694306",
                "http://www.ncbi.nlm.nih.gov/pubmed/16268889",
                "http://www.ncbi.nlm.nih.gov/pubmed/10326971",
                "http://www.ncbi.nlm.nih.gov/pubmed/21315478",
                "http://www.ncbi.nlm.nih.gov/pubmed/12004300",
                "http://www.ncbi.nlm.nih.gov/pubmed/1456297",
                "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                "http://www.ncbi.nlm.nih.gov/pubmed/24313295"
            ],
            "ideal_answer": [
                "The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia."
            ],
            "exact_answer": [
                [
                    "follicular ichthyosis"
                ],
                [
                    "atrichia"
                ],
                [
                    "photophobia"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816",
                "http://www.disease-ontology.org/api/metadata/DOID:225"
            ],
            "type": "list",
            "id": "56c1f038ef6e394741000051",
            "snippets": [
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 147,
                    "text": "The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685152",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 846,
                    "text": "Mutations in MBTPS2 have been reported to cause a broad phenotypic spectrum of X-linked genodermatoses, including IFAP (ichthyosis follicularis; atrichia and photophobia) syndrome (OMIM 308205) with or without BRESHECK (brain anomalies, retardation of mentality and growth, ectodermal dysplasia, skeletal malformations, Hirschsprung disease, ear deformity and deafness, eye hypoplasia, cleft palate, cryptorchidism, and kidney dysplasia/hypoplasia) syndrome, keratosis follicularis spinulosa decalvans (KFSD; OMIM 308800) and an X-linked form of Olmsted syndrome. We report a recurrent intronic mutation in MBTPS2 (c.671-9T>G) in a Chinese patient with the typical triad of IFAP syndrome (i.e. ichthyosis, atrichia and photophobia), along with pachyonychia, palmoplantar and periorificial keratoderma, which were reminiscent of Olmsted syndrome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313295",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "The ichthyosis follicular with atrichia and photophobia syndrome (IFAP) is a rare X-linked multiple congenital malformation syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 644,
                    "offsetInEndSection": 850,
                    "text": "This patient presented with a severe IFAP/BRESHECK phenotype including ichthyosis follicular, atrichia, photophobia, brain anomalies, global developmental delay, Hirschsprung disease and kidney hypoplasia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 787,
                    "text": "The clinical findings include all the features that dermotrichic and ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome have in common and in addition those that characterize IFAP syndrome (photophobia, recurrent respiratory infections, etc.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1456297",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "Photoletter to the editor: A new variant of ichthyosis follicularis with alopecia and photophobia (IFAP) syndrome with coexisting psoriasiform lesions and palmoplantar keratoderma. IFAP-PPK syndrome?",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21886760",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Ichthyosis follicularis, atrichia, and photophobia (IFAP) are typical features of a rare neuroichthyosis termed IFAP syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10326971",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Child with manifestations of dermotrichic syndrome and ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1456297",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 352,
                    "offsetInEndSection": 448,
                    "text": "These features correspond to the ichthyosis follicularis, alopecia, photophobia (IFAP) syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14708109",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Ichthyosis follicularis, atrichia, and photophobia (IFAP) syndrome is a rare congenital disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315478",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "Ichthyosis follicularis with atrichia and photophobia (IFAP) syndrome in two unrelated female patients.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12004300",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Linear lesions reflecting lyonization in women heterozygous for IFAP syndrome (ichthyosis follicularis with atrichia and photophobia).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10398262",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome due to mutation of the gene MBTPS2 in a large Australian kindred.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Ichthyosis follicularis, alopecia and photophobia (IFAP) syndrome treated with acitretin.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16268889",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation and inguinal hernia: a severe manifestation of IFAP syndrome?",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10694306",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Ocular findings in ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15370546",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "We describe an 18-month-old male infant suffering from the ichthyosis follicularis, atrichia, and photophobia (IFAP) syndrome and further delineate the clinical phenotype.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1915513",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 739,
                    "text": "The clinical findings include all the features that dermotrichic and ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome have in common and in addition those that characterize IFAP syndrome (photophobia, recurrent respiratory infections, etc.), those that are present only in dermotrichic syndrome (nail anomalies, hypohydrosis, megacolon, vertebral defects, etc.) and additional ones (enamel dysplasia, renal anomalies, inguinal hernia, etc.).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1456297",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 499,
                    "text": "The clinical findings include all the features that dermotrichic and ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome have in common and in addition those that characterize IFAP syndrome (photophobia,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1456297",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Ichthyosis follicularis, atrichia, and photophobia (IFAP) are typical features of a rare neuroichthyosis termed IFAP syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10326971",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 354,
                    "text": "These features correspond to the ichthyosis follicularis, alopecia, photophobia (IFAP) syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14708109",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Ichthyosis follicularis, atrichia, and photophobia (IFAP) syndrome is a rare congenital disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315478",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "The ichthyosis follicular with atrichia and photophobia syndrome (IFAP) is a rare X-linked multiple congenital malformation syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the major intramolecular phosphorylation sites of human Chk2 involved in cell cycle control?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18812180"
            ],
            "ideal_answer": [
                "The major phosphorylation sites of human Chk2 involved in cell cycle control are T68, S19, and S33/35."
            ],
            "exact_answer": [
                [
                    "T68"
                ],
                [
                    "S19"
                ],
                [
                    "S33/35"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010766",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064447",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016310",
                "http://www.uniprot.org/uniprot/CHK2_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006468",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042325",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001932"
            ],
            "type": "list",
            "id": "5357b9bcf1005d6b58000008",
            "snippets": [
                {
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 889,
                    "text": "Transfection of HEK293 cells with Chk2 wildtype and Chk2 mutants in the absence or presence of DNA damage showed significant T68 phosphorylation already in the absence of DNA damaging reagents",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 891,
                    "offsetInEndSection": 975,
                    "text": "Upon DNA damage, phosphorylation of additional Chk2 sites was observed (S19, S33/35)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 696,
                    "offsetInEndSection": 888,
                    "text": "Transfection of HEK293 cells with Chk2 wildtype and Chk2 mutants in the absence or presence of DNA damage showed significant T68 phosphorylation already in the absence of DNA damaging reagents",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 974,
                    "text": "Upon DNA damage, phosphorylation of additional Chk2 sites was observed (S19, S33/35)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 500,
                    "text": "Despite distinct time-dependent autophosphorylation kinetics by monitoring the phosphorylation of amino acid residues T68, S19, S33/35, T432, in Chk2 wildtype and Chk2 mutants (T68A, T68D and Q69E) they gave identical specific activities",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812180",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the typical symptoms of M\u00e9ni\u00e8re's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12806289",
                "http://www.ncbi.nlm.nih.gov/pubmed/3631415",
                "http://www.ncbi.nlm.nih.gov/pubmed/15198043",
                "http://www.ncbi.nlm.nih.gov/pubmed/22705835",
                "http://www.ncbi.nlm.nih.gov/pubmed/1896679",
                "http://www.ncbi.nlm.nih.gov/pubmed/1896669",
                "http://www.ncbi.nlm.nih.gov/pubmed/18046258",
                "http://www.ncbi.nlm.nih.gov/pubmed/23418296",
                "http://www.ncbi.nlm.nih.gov/pubmed/16640061",
                "http://www.ncbi.nlm.nih.gov/pubmed/18229792",
                "http://www.ncbi.nlm.nih.gov/pubmed/21851581",
                "http://www.ncbi.nlm.nih.gov/pubmed/11074796",
                "http://www.ncbi.nlm.nih.gov/pubmed/3968944",
                "http://www.ncbi.nlm.nih.gov/pubmed/12160282",
                "http://www.ncbi.nlm.nih.gov/pubmed/2610793",
                "http://www.ncbi.nlm.nih.gov/pubmed/11936909",
                "http://www.ncbi.nlm.nih.gov/pubmed/22801040",
                "http://www.ncbi.nlm.nih.gov/pubmed/11583396"
            ],
            "ideal_answer": [
                "The typical symptoms of M\u00e9ni\u00e8re's disease are:\n1) sensorineural hearing loss, \n2) vertigo and \n3) tinnitus."
            ],
            "exact_answer": [
                [
                    "sensorineural hearing loss",
                    "hypoacusia"
                ],
                [
                    "vertigo",
                    "dizziness"
                ],
                [
                    "tinnitus"
                ]
            ],
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008575",
                "http://www.disease-ontology.org/api/metadata/DOID:9849"
            ],
            "type": "list",
            "id": "58c6a6c502b8c60953000027",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 156,
                    "text": "To evaluate the onset of vertigo, hearing loss and tinnitus in M\u00e9ni\u00e8re's disease and the associated endolymphatic hydrops (EH) of the inner ear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1554,
                    "offsetInEndSection": 1783,
                    "text": "We suggest that a 3T MRI measurement should be carried out in patients with sensory-neural hearing loss, vertigo and tinnitus, 4 h after the intravenous injection of a gadolinium-contrast agent to verify the inner ear pathology. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 819,
                    "text": "Eleven of the 17425 veterans appeared to have typical M\u00e9ni\u00e8re's Disease. Their symptoms included attacks of vertigo, lasting between half an hour and a few hours and no more than 24 hours; the sensation of aural fullness; and tinnitus accompanied by a fluctuating or permanent low-tone hearing loss. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12806289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Diagnosis of Meni\u00e8re's Disease is based upon the wellknown labyrinthic syndrome (hypoacusia, tinnitus and dizziness) which manifests with the typical abscessual, recurrent and unforeseeable course. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15198043",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 814,
                    "text": "Typical clinical manifestations of M\u00e9ni\u00e8re's disease (vertigo, sensorineural hearing loss and tinnitus) were found in 6/11 patients (54.5%) in the Lyme disease group.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11936909",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 428,
                    "text": "Among 93 patients presenting the typical symptoms of a M\u00e9ni\u00e8re's disease associating an unilateral fluctuating hearing loss of sensorineural type, tinnitus and vertiginous attacks lasting minutes to hours, 40 patients (43%) presented in their personal history a particular otologic insult in the ear which later on developed into the full M\u00e9ni\u00e8re's symptomatology, or a particular systemic disease with otologic manifestations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896669",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "Fourteen children (aged 14 years or younger) with typical M\u00e9ni\u00e8re's triad with cochlear sensorineural hearing loss, tinnitus, and intermittent vertigo attacks lasting from minutes to hours were investigated in four different neuro-otologic centers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631415",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 427,
                    "text": "Among 93 patients presenting the typical symptoms of a M\u00e9ni\u00e8re's disease associating an unilateral fluctuating hearing loss of sensorineural type, tinnitus and vertiginous attacks lasting minutes to hours, 40 patients (43%) presented in their personal history a particular otologic insult in the ear which later on developed into the full M\u00e9ni\u00e8re's symptomatology, or a particular systemic disease with otologic manifestations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896669",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 355,
                    "text": "To evaluate the onset of vertigo, hearing loss and tinnitus in M\u00e9ni\u00e8res disease and the associated endolymphatic hydrops (EH) of the inner ear.Multicentre evaluation of three patient groups.Disease-specific symptoms were reviewed among referred patients in a tertiary referral hospital in Finland and in members of a Finnish M\u00e9ni\u00e8re Association in Finland",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1441,
                    "text": "In monosymptomatic patients with vertigo, tinnitus or hearing loss; EH was demonstrated in 55-90% of the patients either in the cochlea and/or the vestibulum of the symptomatic ear.M\u00e9ni\u00e8res disease often shows bilateral EH and comprises a continuum from a monosymptomatic disease to the typical symptom complex of the disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 815,
                    "text": "Typical clinical manifestations of M\u00e9ni\u00e8re's disease (vertigo, sensorineural hearing loss and tinnitus) were found in 6/11 patients (54.5%) in the Lyme disease group. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11936909",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 401,
                    "text": "Nine children, labeled as having \"idiopathic M\u00e9ni\u00e8re's disease,\" developed the auditory and vestibular symptoms without any detectable causative factor.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631415",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 357,
                    "text": "To evaluate the onset of vertigo, hearing loss and tinnitus in M\u00e9ni\u00e8re's disease and the associated endolymphatic hydrops (EH) of the inner ear.Multicentre evaluation of three patient groups.Disease-specific symptoms were reviewed among referred patients in a tertiary referral hospital in Finland and in members of a Finnish M\u00e9ni\u00e8re Association in Finland.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1202,
                    "offsetInEndSection": 1658,
                    "text": "In each twin pair, one twin had migraine and M\u00e9ni\u00e8re's disease, whereas the other experienced migraine and episodic vertigo without auditory symptoms.The frequent association of episodic vertigo, migraine, and M\u00e9ni\u00e8re's disease in closely related individuals, including identical twins supports the heritability of a migraine-M\u00e9ni\u00e8re's syndrome, with variable expression of the individual features of hearing loss, episodic vertigo, and migraine headaches.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18046258",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 400,
                    "text": "There has been literature, beginning with M\u00e9ni\u00e8re himself, suggesting a relationship between M\u00e9ni\u00e8re's disease and migraine-associated dizziness.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16640061",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 254,
                    "text": "In the characterizations of the migraine-associated dizziness, the signs and symptoms show overlap with those characterizing Meniere's disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16640061",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which web-based pedigree editors are available?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29095980",
                "http://www.ncbi.nlm.nih.gov/pubmed/17488757"
            ],
            "ideal_answer": [
                "Pedigreejs and Madeline 2.0 Pedigree Drawing Engine (PDE)"
            ],
            "exact_answer": [
                [
                    "Pedigreejs"
                ],
                [
                    "Madeline 2.0 Pedigree Drawing Engine (PDE)"
                ]
            ],
            "type": "list",
            "id": "5c6d6b377c78d69471000039",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 50,
                    "text": "pedigreejs: a web-based graphical pedigree editor.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29095980",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 1092,
                    "text": "Several standalone graphical pedigree editors and drawing applications exist but there are no freely available lightweight graphical pedigree editors that can be easily configured and incorporated into web applications.Results: We developed 'pedigreejs', an interactive graphical pedigree editor written in JavaScript, which uses standard pedigree nomenclature. Pedigreejs provides an easily configurable, extensible and lightweight pedigree editor. It makes use of an open-source Javascript library to define a hierarchical layout and to produce images in scalable vector graphics (SVG) format that can be viewed and edited in web browsers.Availability and implementation: The software is freely available under GPL licence (https://ccge-boadicea.github.io/pedigreejs/).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29095980",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 73,
                    "text": "Madeline 2.0 PDE: a new program for local and web-based pedigree drawing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17488757",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 962,
                    "text": "The Madeline 2.0 Pedigree Drawing Engine (PDE) is a pedigree drawing program for use in linkage and family-based association studies. The program is designed to handle large and complex pedigrees with an emphasis on readability and aesthetics. For complex pedigrees, we use a hybrid algorithm in which consanguinous loops are drawn as cyclic graphs whenever possible, but we resort to acyclic graphs when matings can no longer be connected without line crossings. A similar hybrid approach is used to avoid line crossings for matings between distant descendants of different founding groups. Written in object-oriented C++ and released under the GNU General Public License (GPL), Madeline 2.0 PDE reads input files specified on the command line and generates pedigree drawings without user interaction. Pedigree output in scalable vector graphics (SVG) format can be viewed in browsers with native SVG rendering support or in vector graphics editors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17488757",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Madeline 2.0 PDE: a new program for local and web-based pedigree drawing.http://kellogg.umich.edu/madeline.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17488757",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "pedigreejs: a web-based graphical pedigree editor.Supplementary data are available at Bioinformatics online.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29095980",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "List non-surgical treatment modalities that are included in the Stupp protocol.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24111708",
                "http://www.ncbi.nlm.nih.gov/pubmed/23453151",
                "http://www.ncbi.nlm.nih.gov/pubmed/25201633",
                "http://www.ncbi.nlm.nih.gov/pubmed/23254891",
                "http://www.ncbi.nlm.nih.gov/pubmed/24600235",
                "http://www.ncbi.nlm.nih.gov/pubmed/22464950",
                "http://www.ncbi.nlm.nih.gov/pubmed/24287680",
                "http://www.ncbi.nlm.nih.gov/pubmed/22141608",
                "http://www.ncbi.nlm.nih.gov/pubmed/21156036",
                "http://www.ncbi.nlm.nih.gov/pubmed/23588276",
                "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
                "http://www.ncbi.nlm.nih.gov/pubmed/23535992",
                "http://www.ncbi.nlm.nih.gov/pubmed/21344976",
                "http://www.ncbi.nlm.nih.gov/pubmed/18808066",
                "http://www.ncbi.nlm.nih.gov/pubmed/25434389",
                "http://www.ncbi.nlm.nih.gov/pubmed/24518393",
                "http://www.ncbi.nlm.nih.gov/pubmed/20045159",
                "http://www.ncbi.nlm.nih.gov/pubmed/20870254",
                "http://www.ncbi.nlm.nih.gov/pubmed/22359215"
            ],
            "ideal_answer": [
                "Radiotherapy and chemotherapy are non-surgical treatment modalities that are included in the Stupp protocol. This protocol is widely used for treatment of glioblastoma."
            ],
            "exact_answer": [
                [
                    "radiotherapy"
                ],
                [
                    "chemotherapy"
                ]
            ],
            "type": "list",
            "id": "54df6ed91388e8454a000007",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 283,
                    "text": "OBJECTIVE: It is now accepted that the concomitant administration of temozolomide with radiotherapy (Stupp regime), in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), significantly improves survival and this practice has been adopted locally since 2004.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24111708",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "BACKGROUND: The introduction of ALA-Fluorescence-guided surgery (FGS) followed by concomitant radiochemotherapy according to the Stupp-protocol is representative of the major changes in glioblastoma therapy in the past years.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23588276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1485,
                    "offsetInEndSection": 1641,
                    "text": "CONCLUSIONS: FGS and radiochemotherapy according to the Stupp protocol have induced an impressive improvement in overall survival in glioblastoma patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23588276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 330,
                    "text": "Current treatment strategies in patients with newly-diagnosed glioblastoma include surgical resection with post-operative radiotherapy and concomitant/adjuvant temozolomide (the \"Stupp protocol\") or resection with implantation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers in the surgical cavity followed by radiotherapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23535992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 345,
                    "text": "The standard treatment today is maximal surgical resection followed by concomitant chemo-radiation therapy followed by adjuvant TMZ according to Stupp protocol. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453151",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 508,
                    "text": "PATIENTS AND METHODS: A total of 191 patients with primary GBM were postoperatively treated with either radiation and concomitant TMZ, followed by adjuvant TMZ (Stupp protocol) (n = 154), or radiation followed by adjuvant TMZ (n = 37).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23254891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 843,
                    "offsetInEndSection": 935,
                    "text": "Afterward, patients received concomitant radiochemotherapy according to the Stupp protocol. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434389",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 228,
                    "text": "The treatment of glioblastoma includes surgery followed by chemoradiation with the protocol of Stupp et al. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25201633",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 595,
                    "offsetInEndSection": 1043,
                    "text": "Since the publication of a study by Stupp et al in 2005, which used a protocol of conventional fractionated irradiation with concomitant TMZ followed by standard TMZ for six cycles, many clinical studies in the People's Republic of China have demonstrated that such a treatment strategy has significantly improved efficacy with limited side effects for newly diagnosed glioblastoma after surgery as compared with strategies that do not contain TMZ.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600235",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 739,
                    "text": "Standard chemoradiotherapy as per the Stupp protocol, together with multimodal rehabilitation, resulted in substantial functional improvement within 6 weeks of initiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24518393",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "BACKGROUND: Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24287680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 244,
                    "text": "This is followed by concurrent radio-chemotherapy with temozolomide (TMZ) according to the Stupp protocol. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22464950",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1718,
                    "offsetInEndSection": 2045,
                    "text": "CONCLUSIONS: MGMT promoter methylation status and low MGMT expression both were identified as positive prognosticators in patients with newly diagnosed glioblastoma who underwent surgical resection and received Gliadel wafer implants followed by adjuvant radiotherapy and concomitant oral TMZ chemotherapy (the Stupp protocol).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22359215",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 345,
                    "text": "INTRODUCTION: To evaluate the incidence and impact of early post-chemoradiation (cRT) 'pseudoprogression' (PsPD) amongst glioblastoma multiforme (GBM) patients treated with the current standard of care - 60 Gy conformal radiotherapy with concurrent low-dose temozolomide, followed by six cycles of high-dose temozolomide (the 'Stupp protocol'). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22141608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 280,
                    "text": "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol'). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 727,
                    "text": "We also screened for associations between the level of methylation of CpG sites and overall survival in a cohort of 50 patients uniformly treated by surgery, radiotherapy and chemotherapy with concomitant and adjuvant temozolomide (STUPP protocol). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21156036",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 777,
                    "text": "Surprisingly, less than half the patients having surgery received concomitant radiochemotherapy according to the Stupp protocol. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870254",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 365,
                    "offsetInEndSection": 578,
                    "text": "We analyzed MGMT methylation by methylation-specific PCR in 90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy combined with concomitant and adjuvant temozolomide (Stupp protocol).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 296,
                    "text": "The current care standards for newly diagnosed glioblastoma consist, when feasible, in surgical resection, radiotherapy, and chemotherapy, as described in the Stupp protocol. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20045159",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 400,
                    "text": "Moreover, there are no data concerning the effect of concomitant radiochemotherapy according to the STUPP protocol on the course ofMS in patients with coexisting glioblastoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18808066",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 327,
                    "text": "Current treatment strategies in patients with newly-diagnosed glioblastoma include surgical resection with post-operative radiotherapy and concomitant/adjuvant temozolomide (the \"Stupp protocol\") or resection with implantation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers in the surgical cavity followed by radiotherapy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23535992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 328,
                    "text": "Current treatment strategies in patients with newly-diagnosed glioblastoma include surgical resection with post-operative radiotherapy and concomitant/adjuvant temozolomide (the \"Stupp protocol\") or resection with implantation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers in the surgical cavity followed by radiotherapy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23535992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 331,
                    "text": "The standard treatment today is maximal surgical resection followed by concomitant chemo-radiation therapy followed by adjuvant TMZ according to Stupp protocol",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453151",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which genes does thyroid hormone receptor alpha1 regulate in the heart?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19171649",
                "http://www.ncbi.nlm.nih.gov/pubmed/15808842",
                "http://www.ncbi.nlm.nih.gov/pubmed/15831522",
                "http://www.ncbi.nlm.nih.gov/pubmed/23532677",
                "http://www.ncbi.nlm.nih.gov/pubmed/17317766",
                "http://www.ncbi.nlm.nih.gov/pubmed/11577024",
                "http://www.ncbi.nlm.nih.gov/pubmed/18622044",
                "http://www.ncbi.nlm.nih.gov/pubmed/20228172",
                "http://www.ncbi.nlm.nih.gov/pubmed/19832729",
                "http://www.ncbi.nlm.nih.gov/pubmed/19629520",
                "http://www.ncbi.nlm.nih.gov/pubmed/16155104",
                "http://www.ncbi.nlm.nih.gov/pubmed/15687816",
                "http://www.ncbi.nlm.nih.gov/pubmed/14704232"
            ],
            "ideal_answer": [
                "\u03b2-myosin heavy chain, alpha-myosin heavy chain, SR(Ca)ATPase, phospholamban, nucleotide-gated potassium channel 2, KCNE1, HCN2, HCN4, KCND2, KCND3, KCNA4"
            ],
            "exact_answer": [
                [
                    "\u03b2-myosin heavy chain"
                ],
                [
                    "alpha-myosin heavy chain"
                ],
                [
                    "SR(Ca)ATPase"
                ],
                [
                    "phospholamban"
                ],
                [
                    "nucleotide-gated potassium channel 2"
                ],
                [
                    "KCNE1"
                ],
                [
                    "HCN2"
                ],
                [
                    "HCN4"
                ],
                [
                    "KCND2"
                ],
                [
                    "KCND3"
                ],
                [
                    "KCNA4"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966",
                "http://www.uniprot.org/uniprot/THAA_XENLA",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021",
                "http://www.uniprot.org/uniprot/THA_PYGAD",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887",
                "http://www.uniprot.org/uniprot/THA_LITCT",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.uniprot.org/uniprot/THA_NECMA",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861"
            ],
            "type": "list",
            "id": "515c4f05298dcd4e51000006",
            "snippets": [
                {
                    "offsetInBeginSection": 547,
                    "offsetInEndSection": 643,
                    "text": "A group of mice was treated with debutyl-dronedarone (DBD), a selective TR\u03b11 inhibitor (AMI-DBD)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532677",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1223,
                    "offsetInEndSection": 1435,
                    "text": "Furthermore, AMI resulted in \u03b2-myosin heavy chain overexpression and reduction in the ratio of SR(Ca)ATPase to phospholamban (PLB). The latter further declined in AMI-DBD mainly due to increased expression of PLB",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532677",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 774,
                    "text": "We identified that mice expressing the mutant TRalpha1R384C (TRalpha1+m mice) displayed a mild bradycardia, which becomes more pronounced during night activity or on stress and is accompanied by a reduced expression of nucleotide-gated potassium channel 2 mRNA in the heart",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20228172",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 794,
                    "offsetInEndSection": 863,
                    "text": "KCNE1 was four to 10-fold overexpressed in mice deficient in TRalpha1",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19832729",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1361,
                    "offsetInEndSection": 1542,
                    "text": "The bradycardia and prolonged QT(end) time in hypothyroid states can be explained by altered K(+) channel function due to decreased TRalpha1-dependent repression of KCNE1 expression",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19832729",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 965,
                    "offsetInEndSection": 1107,
                    "text": "Consistently, TR alpha 1-infected myocytes exhibited larger I(f) current densities along with increased HCN2 and HCN4 mRNA and protein levels.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19629520",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 530,
                    "offsetInEndSection": 649,
                    "text": "T3 stimulation enhanced KCND2 and KCND3 expression and decreased KCNA4 transcription, while KCNIP2 remained unaffected.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 824,
                    "offsetInEndSection": 1010,
                    "text": "TRalpha1 increased I(to), while TRbeta1 significantly reduced I(to) in size, which was associated with TRalpha1-mediated increase and TRbeta1-mediated reduction of KCND2/3 transcription.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1474,
                    "text": "While the TRalpha1 aporeceptor enhanced KCND3 transcription, the TRbeta1 aporeceptor suppressed KCND3 expression, with both effects exhibiting ligand-dependent amplification upon T3 stimulation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 791,
                    "offsetInEndSection": 1097,
                    "text": "PE, in the absence of T3, resulted in 5.0 fold increase in TRalpha1 expression in nucleus and 2.0 fold decrease in TRalpha1 expression in cytosol, P<0.05. As a result, a fetal pattern of myosin isoform expression with marked expression of beta-MHC was observed in PE treated vs the untreated cells, P<0.05.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18622044",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1597,
                    "offsetInEndSection": 2002,
                    "text": "PKC alpha overexpression in cardiomyocytes caused marked repression of triiodothyronine (T3)-responsive genes, alpha-myosin heavy chain, and the sarcoplasmic reticulum calcium-activated adenosinetriphosphatase SERCA2. Treatment with T3 for 4 h resulted in significant reductions of PKC alpha in nuclear and cytosolic compartments, and decreased TR alpha1 mRNA and protein, with normalization of phenotype.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155104",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 618,
                    "text": "The mechanism of TH and TRalpha1-specific hypertrophy is novel for a nuclear hormone receptor and involves the transforming growth factor beta-activated kinase (TAK1) and p38",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831522",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1301,
                    "offsetInEndSection": 1383,
                    "text": "Excised TRalpha(1)+/m hearts showed an increased expression of phospholamban (PLB)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15808842",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 290,
                    "text": "administration of dronedarone, an amiodarone-like compound that has been shown to preferentially antagonize thyroid hormone binding to thyroid hormone receptor alpha1 (TRalpha1),",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 976,
                    "text": "lpha-Myosin heavy chain (alpha-MHC) decreased in DRON while beta-myosin heavy chain (beta-MHC) and sarcoplasmic reticulum Ca2+ adenosine triphosphatase (ATPase) expression (SERCA) was similar to CONT.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1094,
                    "offsetInEndSection": 1424,
                    "text": "The activity of TR DNA binding to the transcriptional regulatory region in the alpha-MHC and SR Ca(2+)-ATPase genes and the mRNA and protein expression of alpha-MHC and SR Ca(2+)-ATPase in the heart and plasma 3,3'-triiodothyronine and thyroxine levels were altered in association with changes in the myocardial TR protein levels.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704232",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1173,
                    "offsetInEndSection": 1441,
                    "text": "addition, TR cotransfection and treatment with the TRbeta1-selective agonist GC-1 suggested different functional coupling of the TR isoforms, TRbeta1 to transcription of beta-MyHC, SERCA, and TRbeta1, and TRalpha1 to alpha-MyHC transcription and increased myocyte size",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11577024",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "text": "OBJECTIVE: The reduced heart rate and prolonged QT(end) duration in mice deficient in thyroid hormone receptor (TR) alpha1 may involve aberrant expression of the K(+) channel alpha-subunit KCNQ1 and its regulatory beta-subunit KCNE1.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19832729",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16339652",
                "http://www.ncbi.nlm.nih.gov/pubmed/15920471",
                "http://www.ncbi.nlm.nih.gov/pubmed/16888367",
                "http://www.ncbi.nlm.nih.gov/pubmed/19196479"
            ],
            "ideal_answer": [
                "Our work describes, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes",
                "Using a biotinylation tagging/proteomics approach in erythroid cells, we describe distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes  ",
                "The biotinylation tagging approach revealed, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes."
            ],
            "exact_answer": [
                [
                    "Gfi-1b"
                ],
                [
                    "MeCP1 complex"
                ],
                [
                    "ACF/WCRF complex"
                ],
                [
                    "fog-1"
                ],
                [
                    "tal-1"
                ]
            ],
            "type": "list",
            "id": "553a7a59f321868558000002",
            "snippets": [
                {
                    "offsetInBeginSection": 752,
                    "offsetInEndSection": 1010,
                    "text": "Our work describes, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339652",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1302,
                    "text": "We also provide evidence that distinct GATA-1 complexes are associated with specific GATA-1 functions in erythroid differentiation, for example, GATA-1/Gfi-1b with the suppression of cell proliferation and GATA-1/FOG-1/MeCP1 with the repression of other hematopoietic transcription programs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339652",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1517,
                    "text": "We next applied the biotinylation tag to Ldb-1, a known partner of GATA-1, and characterized a number of novel interaction partners that are essential in erythroid development, in particular, Eto-2, Lmo4, and CdK9",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339652",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 365,
                    "offsetInEndSection": 664,
                    "text": "Using a biotinylation tagging/proteomics approach in erythroid cells, we describe distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15920471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 1015,
                    "text": " Importantly, we show that FOG-1 mediates GATA-1 interactions with the MeCP1 complex, thus providing an explanation for the overlapping functions of these two factors in erythropoiesis. We also show that subsets of GATA-1 gene targets are bound in vivo by distinct complexes, thus linking specific GATA-1 partners to distinct aspects of its functions",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15920471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 663,
                    "text": "Using a biotinylation tagging/proteomics approach in erythroid cells, we describe distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15920471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 365,
                    "offsetInEndSection": 665,
                    "text": "Using a biotinylation tagging/proteomics approach in erythroid cells, we describe distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15920471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1303,
                    "text": "We also provide evidence that distinct GATA-1 complexes are associated with specific GATA-1 functions in erythroid differentiation, for example, GATA-1/Gfi-1b with the suppression of cell proliferation and GATA-1/FOG-1/MeCP1 with the repression of other hematopoietic transcription programs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339652",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 752,
                    "offsetInEndSection": 1011,
                    "text": "Our work describes, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339652",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Name two inhalable insulin products.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25485886"
            ],
            "ideal_answer": [
                "Despite discontinuation of the first inhalable insulin, Exubera(r), due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of Afrezza(r)."
            ],
            "exact_answer": [
                [
                    "Exubera"
                ],
                [
                    "Afrezza"
                ]
            ],
            "type": "list",
            "id": "5e7768f9835f4e477700000b",
            "snippets": [
                {
                    "offsetInBeginSection": 196,
                    "offsetInEndSection": 446,
                    "text": "Despite discontinuation of the first inhalable insulin, Exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of Afrezza\u00ae and several others awaiting approval.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25485886",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List proteins of lipids droplets",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23204327",
                "http://www.ncbi.nlm.nih.gov/pubmed/18202123",
                "http://www.ncbi.nlm.nih.gov/pubmed/21420243",
                "http://www.ncbi.nlm.nih.gov/pubmed/24036367",
                "http://www.ncbi.nlm.nih.gov/pubmed/19717842",
                "http://www.ncbi.nlm.nih.gov/pubmed/19748893",
                "http://www.ncbi.nlm.nih.gov/pubmed/15731108",
                "http://www.ncbi.nlm.nih.gov/pubmed/20870251"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/mnemonic",
                    "s": "http://purl.uniprot.org/uniprot/O60240",
                    "o": "PLIN1_HUMAN"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/O60240",
                    "o": "http://linkedlifedata.com/resource/#_4F363032343000B"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/O60240",
                    "o": "http://linkedlifedata.com/resource/#_4F363032343000C"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_4F363032343000B",
                    "o": "Perilipin-1"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_4F363032343000C",
                    "o": "Lipid droplet-associated protein"
                },
                {
                    "p": "http://purl.uniprot.org/core/mnemonic",
                    "s": "http://purl.uniprot.org/uniprot/P43884",
                    "o": "PLIN_RAT"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P43884",
                    "o": "http://linkedlifedata.com/resource/#_503433383834009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503433383834009",
                    "o": "Lipid droplet-associated protein"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503433383834008",
                    "o": "Perilipin-1"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P43884",
                    "o": "http://linkedlifedata.com/resource/#_503433383834008"
                },
                {
                    "p": "http://purl.uniprot.org/core/mnemonic",
                    "s": "http://purl.uniprot.org/uniprot/P43884",
                    "o": "PERL_RAT"
                }
            ],
            "ideal_answer": [
                "perilipins\nadipose differentiation-related protein\nlipid storage droplet protein 5 \ntail-interacting protein of 47 kilodaltons \nS3-12"
            ],
            "exact_answer": [
                [
                    "perilipins"
                ],
                [
                    "adipose differentiation-related protein",
                    "ADFP"
                ],
                [
                    "LSDP5",
                    "lipid storage droplet protein 5"
                ],
                [
                    "tail-interacting protein of 47 kilodaltons",
                    "TIP47"
                ],
                [
                    "S3-12"
                ]
            ],
            "type": "list",
            "id": "56b3a3ce8525abca1e000005",
            "snippets": [
                {
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 690,
                    "text": "The perilipins are a multi-protein family that targets lipid droplet surfaces and regulates lipid storage and hydrolysis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24036367",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1264,
                    "offsetInEndSection": 1364,
                    "text": "or the abundance of the lipid droplet coat proteins (perilipins 2, 3, 4, and 5) between treatments. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870251",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "This study investigated the lipid droplet coat proteins perilipin 1 (PLIN1) and perilipin 2 (PLIN2) localization in pig skeletal muscle and their relationship with intramuscular fat (IMF) content.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21420243",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 587,
                    "text": "Lipid droplets of mammalian cells are coated with one or more members of the PAT protein family, which serve important functions in regulating lipolysis. In this study, we investigate the mechanisms by which PAT family members, perilipin A, adipose differentiation-related protein (ADFP), and LSDP5, control lipolysis catalyzed by hormone-sensitive lipase (HSL), a major lipase in adipocytes and several non-adipose cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19717842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 640,
                    "text": "The coordination of lipid storage and utilization is regulated by the perilipin family of lipid droplet coat proteins [perilipin, adipophilin/adipocyte differentiation-related protein (ADRP), S3-12, tail-interacting protein of 47 kilodaltons (TIP47), and myocardial lipid droplet protein (MLDP)/oxidative tissues-enriched PAT protein (OXPAT)/lipid storage droplet protein 5 (LSDP5)].",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18202123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 337,
                    "offsetInEndSection": 523,
                    "text": " Perilipin is a member of the evolutionarily related family of PAT proteins (Perilipin, Adipophilin, TIP47), which is defined by sequence similarity and association with lipid droplets. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15731108",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List 3 NK3R antagonists.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28977601",
                "http://www.ncbi.nlm.nih.gov/pubmed/26653113",
                "http://www.ncbi.nlm.nih.gov/pubmed/28380486",
                "http://www.ncbi.nlm.nih.gov/pubmed/27636018"
            ],
            "ideal_answer": [
                "NK3 receptor antagonists include MLE4901 (also known as AZD4901), SB222200 and ESN364."
            ],
            "exact_answer": [
                [
                    "MLE4901",
                    "AZD4901"
                ],
                [
                    "SB222200"
                ],
                [
                    "ESN364"
                ]
            ],
            "type": "list",
            "id": "5e55046fb761aafe09000004",
            "snippets": [
                {
                    "offsetInBeginSection": 344,
                    "offsetInEndSection": 457,
                    "text": "Eleven postmenopausal women were administered the NK3R antagonist MLE4901 at 40 mg twice daily orally for 7 days.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28380486",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 678,
                    "offsetInEndSection": 1225,
                    "text": "Results indicate that (1) similar to those previously reported for GnRH stimulation by the KISS1R agonist (i.e., human kisspeptin-10), the NK3R agonist senktide stimulated GnRH release in a dose-responsive manner in both prepubertal and pubertal monkeys; (2) the senktide-induced GnRH release was blocked in the presence of the KISS1R antagonist peptide 234 in pubertal but not prepubertal monkeys; and (3) the kisspeptin-induced GnRH release was blocked in the presence of the NK3R antagonist SB222200 in the pubertal but not prepubertal monkeys.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28977601",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 738,
                    "text": "NK3R antagonist AZD4901 40 mg twice daily orally was taken from cycle day 4-6 for 6 days (n = 10, with 10 no treatment controls). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27636018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1797,
                    "offsetInEndSection": 2043,
                    "text": " Oral administration of the NK3R antagonist, ESN364, suppressed the hypothalamic-pituitary-gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653113",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the main manifestations of Ohdo syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10706355",
                "http://www.ncbi.nlm.nih.gov/pubmed/27500536",
                "http://www.ncbi.nlm.nih.gov/pubmed/27312080",
                "http://www.ncbi.nlm.nih.gov/pubmed/15127758"
            ],
            "ideal_answer": [
                "Severe ID, absent or deficient language, skeletal manifestations including bilateral patella dislocations."
            ],
            "exact_answer": [
                [
                    "intellectual disability",
                    "ID"
                ],
                [
                    "deficient language"
                ],
                [
                    "bilateral patella dislocations"
                ],
                [
                    "skeletal manifestations"
                ]
            ],
            "type": "list",
            "id": "58f8a08370f9fc6f0f00001b",
            "snippets": [
                {
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 1072,
                    "text": " This finding together with the phenotypic analogies shared with the carriers of c.5898dupC mutation suggests the existence of a fourth MED12-related disorder, characterized by severe ID, absent or deficient language and, milder, clinical manifestation in heterozygotes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312080",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Skeletal manifestations in Ohdo syndrome: a case with bilateral patella dislocations.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "text": "We report a new case of Ohdo syndrome with bilateral patella dislocations where surgical intervention has been indicated. A review of the skeletal manifestations reported in the literature on Ohdo syndrome reveals that joint laxity and skeletal deformities are important aspects of the phenotype.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 482,
                    "text": "We confirm the existence of this condition that, although similar to Ohdo syndrome, seems to be an independent clinical entity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10706355",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "We report a new case of Ohdo syndrome with bilateral patella dislocations where surgical intervention has been indicated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Skeletal manifestations in Ohdo syndrome: a case with bilateral patella dislocations.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 1072,
                    "text": "This finding together with the phenotypic analogies shared with the carriers of c.5898dupC mutation suggests the existence of a fourth MED12-related disorder, characterized by severe ID, absent or deficient language and, milder, clinical manifestation in heterozygotes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312080",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which curated databases exist for spider-venom toxins?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21036864",
                "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
                "http://www.ncbi.nlm.nih.gov/pubmed/29069336"
            ],
            "ideal_answer": [
                "ArachnoServer and its updated version ArachnoServer 2.0 are manually curated databases providing information on the sequence, structure and biological activity of protein toxins from spider venoms."
            ],
            "exact_answer": [
                [
                    "ArachnoServer"
                ],
                [
                    "ArachnoServer 2.0"
                ]
            ],
            "type": "list",
            "id": "5c6d783e7c78d6947100003a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 57,
                    "text": "ArachnoServer: a database of protein toxins from spiders.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 1703,
                    "text": "We have developed ArachnoServer, a manually curated database that provides detailed information about proteinaceous toxins from spiders. Key features of ArachnoServer include a new molecular target ontology designed especially for venom toxins, the most up-to-date taxonomic information available, and a powerful advanced search interface. Toxin information can be browsed through dynamic trees, and each toxin has a dedicated page summarising all available information about its sequence, structure, and biological activity. ArachnoServer currently manages 567 protein sequences, 334 nucleic acid sequences, and 51 protein structures.CONCLUSION: ArachnoServer provides a single source of high-quality information about proteinaceous spider toxins that will be an invaluable resource for pharmacologists, neuroscientists, toxinologists, medicinal chemists, ion channel scientists, clinicians, and structural biologists. ArachnoServer is available online at http://www.arachnoserver.org.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "ArachnoServer 2.0, an updated online resource for spider toxin sequences and structures.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21036864",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1423,
                    "text": "ArachnoServer (www.arachnoserver.org) is a manually curated database providing information on the sequence, structure and biological activity of protein toxins from spider venoms. These proteins are of interest to a wide range of biologists due to their diverse applications in medicine, neuroscience, pharmacology, drug discovery and agriculture. ArachnoServer currently manages 1078 protein sequences, 759 nucleic acid sequences and 56 protein structures. Key features of ArachnoServer include a molecular target ontology designed specifically for venom toxins, current and historic taxonomic information and a powerful advanced search interface. The following significant improvements have been implemented in version 2.0: (i) the average and monoisotopic molecular masses of both the reduced and oxidized form of each mature toxin are provided; (ii) the advanced search feature now enables searches on the basis of toxin mass, external database accession numbers and publication date in ArachnoServer; (iii) toxins can now be browsed on the basis of their phyletic specificity; (iv) rapid BLAST searches based on the mature toxin sequence can be performed directly from the toxin card; (v) private silos can be requested from research groups engaged in venoms-based research, enabling them to easily manage and securely store data during the process of toxin discovery; and (vi) a detailed user manual is now available.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21036864",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Summary\nArachnoServer is a manually curated database that consolidates information on the sequence, structure, function and pharmacology of spider-venom toxins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069336",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "ArachnoServer is a manually curated database that consolidates information on the sequence, structure, function and pharmacology of spider-venom toxins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069336",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Please list 3 diseases treated with Valtrex(valacyclovir)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25749332",
                "http://www.ncbi.nlm.nih.gov/pubmed/8593015",
                "http://www.ncbi.nlm.nih.gov/pubmed/22670895",
                "http://www.ncbi.nlm.nih.gov/pubmed/15482124",
                "http://www.ncbi.nlm.nih.gov/pubmed/16771614",
                "http://www.ncbi.nlm.nih.gov/pubmed/14505192",
                "http://www.ncbi.nlm.nih.gov/pubmed/15550990",
                "http://www.ncbi.nlm.nih.gov/pubmed/15989601",
                "http://www.ncbi.nlm.nih.gov/pubmed/11772333",
                "http://www.ncbi.nlm.nih.gov/pubmed/12556212"
            ],
            "ideal_answer": [
                "Valtrex (valacyclovir) is an antiviral medication used to treat infections with: herpes zoster (shingles), herpes simplex genitalis (genital herpes),\nand herpes labialis (cold sores)."
            ],
            "exact_answer": [
                [
                    "Herpes zoster or Shingles"
                ],
                [
                    "Herpes genitalis, or genital herpes"
                ],
                [
                    "Herpes labialis or cold sores"
                ]
            ],
            "concepts": [
                "http://www.biosemantics.org/jochem#4273236",
                "http://www.biosemantics.org/jochem#4265772"
            ],
            "type": "list",
            "id": "5abcf755fcf4565872000028",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "Valaciclovir (Valtrex, Zelitrex), the L-valine ester of aciclovir, increases aciclovir bioavailability by 3- to 5-fold over that achievable with oral aciclovir. It addresses many unmet needs of currently available anti-herpesvirus therapie",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15989601",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1355,
                    "offsetInEndSection": 1550,
                    "text": "In controlled clinical trials in herpes zoster, valaciclovir (1000 mg three times daily) is superior to aciclovir in speeding the resolution of zoster-associated pain and post-herpetic neuralgia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15989601",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1169,
                    "offsetInEndSection": 1403,
                    "text": "alacyclovir is the only antiviral drug approved for a once-daily dose of suppressive therapy for genital herpes, as well as the only antiviral drug US FDA approved for a 3-day regimen of episodic treatment of recurrent genital herpes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16771614",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1417,
                    "offsetInEndSection": 1568,
                    "text": "valacyclovir is also indicated in the reduction of the sexual transmission of herpes simplex virus infection and for the treatment of herpes labialis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16771614",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1569,
                    "offsetInEndSection": 1784,
                    "text": "n herpes zoster, valacyclovir is more effective than acyclovir or placebo (and as equally effective as famciclovir) in shortening the length and severity of herpes zoster-associated pain and postherpetic neuralgia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16771614",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 823,
                    "text": "valacyclovir and famciclovir are efficacious and safe for the treatment of the first episode and recurrent genital herpes and are useful as suppressive therapy for individuals with frequent genital herpes recurrences.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482124",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 867,
                    "offsetInEndSection": 1073,
                    "text": "valacyclovir and famciclovir have been shown to speed the healing of herpes zoster, and data suggests that these agents also decrease associated acute and chronic pain in people of 50 years of age or older.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482124",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "Valaciclovir (Valtrex), the L-valyl ester of acyclovir, is undergoing clinical development for the treatment and suppression of herpesviral diseases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8593015",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "Valacyclovir is frequently prescribed to the elderly to treat diseases such as herpes zoster.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25749332",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "The study group comprised 86 immunocompetent adult patients suffering from herpes zoster, who were treated with either famciclovir or valacyclovir for 7 days.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22670895",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 702,
                    "text": "Over the past two decades, the treatment of these conditions has been transformed by guanosine nucleoside antivirals such as valacyclovir (Valtrex, a highly bioavailable prodrug of acyclovir (Zovirax, and famciclovir (Famvir), a highly bioavailable prodrug of penciclovir (Denavir).<br><b>OBJECTIVE</b>: We describe the pharmacology, pharmacokinetics, and clinical efficacy of valacyclovir for the treatment of herpes simplex, herpes zoster, and other viral infections.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14505192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1228,
                    "text": "In herpes zoster, valacyclovir is as effective as famciclovir and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster-associated pain and post-herpetic neuralgia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11772333",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 685,
                    "text": "OBJECTIVE: We describe the pharmacology, pharmacokinetics, and clinical efficacy of valacyclovir for the treatment of herpes simplex, herpes zoster, and other viral infections.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14505192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1229,
                    "offsetInEndSection": 1536,
                    "text": "Valacyclovir is well tolerated, with convenient dosing frequencies for the treatment of genital herpes or herpes zoster, it also has the option for use as a short course therapy in the episodic treatment of recurrent genital herpes, all of which are important benefits in the management of these conditions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11772333",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 620,
                    "text": "Acyclovir (Zoviraxr, GlaxoSmithKline), valacyclovir (Valtrex, GlaxoSmithKline) or famciclovir (Famvir, Novartis) can be used to treat herpes zoster, and all three have been shown to reduce the duration of the herpetic rash and zoster-associated pain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15550990",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List common symptoms of patients with the DOORS syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24291220"
            ],
            "ideal_answer": [
                "DOORS syndrome is a constellation of deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures. It is a rare autosomal recessive disorder of unknown cause."
            ],
            "exact_answer": [
                [
                    "deafness"
                ],
                [
                    "onychodystrophy"
                ],
                [
                    "osteodystrophy"
                ],
                [
                    "mental retardation"
                ],
                [
                    "seizures"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013568",
                "http://www.disease-ontology.org/api/metadata/DOID:225",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"
            ],
            "type": "list",
            "id": "530e1c985937551c09000004",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 162,
                    "text": "Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome is a rare autosomal recessive disorder of unknown cause. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 577,
                    "text": "Through a search of available case studies and communication with collaborators, we identified families that included at least one individual with at least three of the five main features of the DOORS syndrome: deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291220",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which kinases are inhibited by Pyrotinib?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28498781",
                "http://www.ncbi.nlm.nih.gov/pubmed/30382184",
                "http://www.ncbi.nlm.nih.gov/pubmed/28115222",
                "http://www.ncbi.nlm.nih.gov/pubmed/27541626",
                "http://www.ncbi.nlm.nih.gov/pubmed/30341682"
            ],
            "ideal_answer": [
                "Pyrotinib is a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor that is used to treat HER2-positive breast cancer."
            ],
            "exact_answer": [
                [
                    "EGFR"
                ],
                [
                    "HER2"
                ]
            ],
            "type": "list",
            "id": "5e44baaa48dab47f2600001a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Pyrotinib is a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor that is used to treat HER2-positive breast cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30382184",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341682",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "The discovery and development of a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor SHR1258 (pyrotinib) for the treatment of HER2-postive breast cancer is presented. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28115222",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 276,
                    "text": "Purpose This phase I study assessed the safety, tolerability, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28498781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Pyrotinib is a novel irreversible tyrosine kinase inhibitor developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27541626",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Pyrotinib is a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor that is used to treat HER2-positive breast cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30382184",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28115222",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "The discovery and development of a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor SHR1258 (pyrotinib) for the treatment of HER2-postive breast cancer is presented.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28115222",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 619,
                    "offsetInEndSection": 924,
                    "text": "Overall, the potent and selective EGFR/HER2 dual inhibitor, pyrotinib, displayed robust anti-tumor effects on HER2-overexpressing xenograft models and sufficiently safety windows in animals as well as favorable pharmacokinetic properties in human, which substantially ensures current clinical development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28115222",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which drugs are included in the Lonsurf pill?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
                "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
                "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
                "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
                "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
                "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
                "http://www.ncbi.nlm.nih.gov/pubmed/30350179",
                "http://www.ncbi.nlm.nih.gov/pubmed/27568360"
            ],
            "ideal_answer": [
                "Lunsurf pill includes trifluridine and tipiracil. It is a novel form of chemotherapy for metastatic colorectal cancer."
            ],
            "exact_answer": [
                [
                    "trifluridine"
                ],
                [
                    "tipiracil"
                ]
            ],
            "type": "list",
            "id": "5c72a9147c78d6947100006e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 323,
                    "text": "The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf\u00ae), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cancer (third-line or later). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "text": "PURPOSE: Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf\u00ae), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350179",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 372,
                    "text": "BACKGROUND: Trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 370,
                    "text": "These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies.\u2029",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 763,
                    "text": "Trifluridine/tipiracil has recently been approved for the treatment of adult patients with metastatic colorectal cancer (mCRC) who are refractory to or are not considered candidates for, current standard chemotherapy and biological therapy in the EU and USA and in unresectable advanced or recurrent CRC in Japan. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 352,
                    "text": "TAS-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 283,
                    "text": "Evolocumab (Repatha) for patients with hypercholesterolemia whose condition has not been controlled by statins and other therapies; trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer; and blood coagulation factor VIII (Nuwiq) for adults and children with hemophilia A.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf\u00ae tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "Initial Evaluation of the Efficacy and Safety of Tablets Containing Trifluridine and Tipiracil Hydrochloride--Safety Measures Devised by a Multidisciplinary Team Including a Pharmaceutical Outpatient Clinic.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Which genes are associated with Epidermolysis Bullosa Simplex?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19797037",
                "http://www.ncbi.nlm.nih.gov/pubmed/7539246",
                "http://www.ncbi.nlm.nih.gov/pubmed/9036937",
                "http://www.ncbi.nlm.nih.gov/pubmed/10494094",
                "http://www.ncbi.nlm.nih.gov/pubmed/7561171",
                "http://www.ncbi.nlm.nih.gov/pubmed/21375516",
                "http://www.ncbi.nlm.nih.gov/pubmed/11159198",
                "http://www.ncbi.nlm.nih.gov/pubmed/1720261",
                "http://www.ncbi.nlm.nih.gov/pubmed/9804355",
                "http://www.ncbi.nlm.nih.gov/pubmed/22639907",
                "http://www.ncbi.nlm.nih.gov/pubmed/26929861",
                "http://www.ncbi.nlm.nih.gov/pubmed/20199538",
                "http://www.ncbi.nlm.nih.gov/pubmed/11407988",
                "http://www.ncbi.nlm.nih.gov/pubmed/8894687",
                "http://www.ncbi.nlm.nih.gov/pubmed/20030639",
                "http://www.ncbi.nlm.nih.gov/pubmed/8941634",
                "http://www.ncbi.nlm.nih.gov/pubmed/1381443",
                "http://www.ncbi.nlm.nih.gov/pubmed/12655565",
                "http://www.ncbi.nlm.nih.gov/pubmed/28777847"
            ],
            "ideal_answer": [
                "In one family studied, inheritance of EBS is linked to the gene encoding keratin 14",
                "Epidermolysis bullosa simplex (EBS) is mainly caused by mutations in the KRT5 and KRT14 genes.  A compound heterozygous one amino-acid insertion/nonsense mutation in the plectin gene causes epidermolysis bullosa simplex with plectin deficiency.",
                "In one family studied, inheritance of EBS is linked to the gene encoding keratin 14 Homozygous deletion mutations in the plectin gene (PLEC1) in patients with epidermolysis bullosa simplex associated with late-onset muscular dystrophy. Epidermolysis bullosa simplex (EBS) is a rare genodermatosis resulting from multiple gene mutations, including KRT5 and KRT14.",
                "Epidermolysis bullosa simplex (EBS) is a rare genodermatosis resulting from multiple gene mutations, including KRT5 and KRT14.",
                "Keratin 5 and keratin 14 are known to be essential for the basal keratinocyte cytoskeleton and are defective in several forms of epidermolysis bullosa simplex. Homozygous deletion mutations in the plectin gene in patients with epidermolysis bullosa simplex associated with late-onset muscular dystrophy. The KRT5 and KRT14 genes encode the proteins keratin 5 and 14, respectively, which are the primary structural components of the 10-nm intermediate filaments of the mitotic epidermal basal cells. Epidermolysis bullosa simplex is mainly caused by mutations in the KRT5 and KRT14 genes. Verrucous carcinoma in epidermolysis bullosa simplex is possibly associated with a novel mutation in the keratin 5 gene. This is the first report of EBS-generalized intermediate in a newborn with de novo KRT5 gene mutation and KRT14 gene polymorphism, and no familial history of epidermolysis. Study of a family with epidermolysis bullosa simplex resulting from a novel mutation of KRT14 gene. We have systematically scanned genomic sequences of one of these keratins, keratin 14, for mutations in patients from 49 apparently independent kindreds using single-strand conformation polymorphism analysis. ",
                "Homozygous deletion mutations in the plectin gene (PLEC1) in patients with epidermolysis bullosa simplex associated with late-onset muscular dystrophy. Epidermolysis bullosa simplex (EBS) is mainly caused by mutations in the KRT5 and KRT14 genes. Verrucous carcinoma in epidermolysis bullosa simplex is possibly associated with a novel mutation in the keratin 5 gene.",
                "Recent advances in molecular biology have enabled the association of epidermolysis bullosa simplex (EBS) with point mutations of keratin 14 and/or keratin 5 genes to be established. ",
                "Keratin 14 gene mutations in patients with epidermolysis bullosa simplex. Mutant keratins 5 or 14 are implicated in the etiology of epidermolysis bullosa simplex (EBS).  Keratin 14 gene point mutation in the K\u00f6bner and Dowling-Meara types of epidermolysis bullosa simplex as detected by the PASA method."
            ],
            "exact_answer": [
                [
                    "Keratin 14",
                    "KRT14"
                ],
                [
                    "Keratin 5",
                    "KRT5"
                ],
                [
                    "Plectin",
                    "PLEC1"
                ]
            ],
            "type": "list",
            "id": "5ace34eb0340b9f058000010",
            "snippets": [
                {
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 192,
                    "text": "In one family studied, inheritance of EBS is linked to the gene encoding keratin 14",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1720261",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 778,
                    "text": "In the first family, linkage was found to chromosome 17 markers flanking the keratin 14 gene (D17S74: Zmax = +2.45, theta = 0.10; COL1A1: Zmax = +0.97, theta = 0.00) and markers near the keratin 5 gene on chromosome 12 were excluded (D12S17: Z less than -2.0, theta = 0.08; COL2A1: Z less than -2.0, theta = 0.13). In contrast, the second family showed linkage to the region containing the keratin 5 gene (D12S17: Zmax = +1.37, theta = 0.08; COL2A1: Zmax = +0.33, theta = 0.15) and was not linked to the keratin 14 gene (D17S74: Z less than -2.0, theta = 0.14). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1381443",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 73,
                    "text": "Keratin 14 gene mutations in patients with epidermolysis bullosa simplex.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7561171",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 411,
                    "text": "We have systematically scanned genomic sequences of one of these keratins, keratin 14, for mutations in patients from 49 apparently independent kindreds using single-strand conformation polymorphism analysis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7561171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Keratin 14 gene point mutation in the K\u00f6bner and Dowling-Meara types of epidermolysis bullosa simplex as detected by the PASA method.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7539246",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "Recent advances in molecular biology have enabled the association of epidermolysis bullosa simplex (EBS) with point mutations of keratin 14 and/or keratin 5 genes to be established. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7539246",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Homozygous deletion mutations in the plectin gene (PLEC1) in patients with epidermolysis bullosa simplex associated with late-onset muscular dystrophy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8894687",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 566,
                    "text": " In this study, we report two patients with EB-MD, each with a homozygous deletion mutation in the plectin gene, PLEC1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8894687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "A homozygous nonsense mutation in the PLEC1 gene in patients with epidermolysis bullosa simplex with muscular dystrophy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8941634",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "A compound heterozygous one amino-acid insertion/nonsense mutation in the plectin gene causes epidermolysis bullosa simplex with plectin deficiency.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11159198",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "The KRT5 and KRT14 genes encode the proteins keratin 5 and 14, respectively, which are the primary structural components of the 10-nm intermediate filaments of the mitotic epidermal basal cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9036937",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 447,
                    "text": "Keratin 5 and keratin 14 are known to be essential for the basal keratinocyte cytoskeleton and are defective in several forms of epidermolysis bullosa simplex.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10494094",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Severe palmo-plantar hyperkeratosis in Dowling-Meara epidermolysis bullosa simplex caused by a mutation in the keratin 14 gene (KRT14).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804355",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Mutant keratins 5 or 14 are implicated in the etiology of epidermolysis bullosa simplex (EBS). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804355",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Epidermolysis bullosa simplex (EBS) is mainly caused by mutations in the KRT5 and KRT14 genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639907",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Verrucous carcinoma in epidermolysis bullosa simplex is possibly associated with a novel mutation in the keratin 5 gene.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639907",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 137,
                    "text": "Epidermolysis bullosa simplex (EBS) is a rare genodermatosis resulting from multiple gene mutations, including KRT5 and KRT14.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26929861",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 99,
                    "text": "Study of a family with epidermolysis bullosa simplex resulting from a novel mutation of KRT14 gene",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28777847",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 977,
                    "offsetInEndSection": 1150,
                    "text": "This is the first report of EBS-generalized intermediate in a newborn with de novo KRT5 gene mutation and KRT14 gene polymorphism, and no familial history of epidermolysis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26929861",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 461,
                    "text": "Epidermolysis bullosa simplex (EBS) is an inherited skin disorder caused by mutations in the keratin 5 (KRT5) and keratin 14 (KRT14) genes, with fragility of basal keratinocytes leading to epidermal cytolysis and blistering.In this study, we characterized mutations in KRT5 and KRT14 genes in patients with EBS and investigated their possible structure-function correlations.Mutations were characterized using polymerase chain reaction (PCR) and DNA sequencing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20030639",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Epidermolysis bullosa simplex (EBS) is a mechanobullous genodermatosis that may be caused by mutations in the genes KRT5 and KRT14 encoding the basal epidermal keratins 5 (K5) and 14 (K14).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Basal epidermolysis bullosa simplex (EBS) is a hereditary skin blistering disorder resulting in most cases from missense mutations in the keratin 5 (KRT5) or keratin 14 (KRT14) genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20199538",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Epidermolysis bullosa simplex is a hereditary skin blistering disorder caused by mutations in the KRT5 or KRT14 genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11407988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "BACKGROUND Basal epidermolysis bullosa simplex (EBS) is a hereditary skin blistering disorder resulting in most cases from missense mutations in the keratin 5 (KRT5) or keratin 14 (KRT14) genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20199538",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Epidermolysis bullosa simplex is a group of blistering skin disorders caused by defects in one of the keratin genes, KRT5 and KRT14.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655565",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "Epidermolysis bullosa simplex is an autosomal dominant inherited skin blistering disorder caused by mutations in the genes KRT5 or KRT14 coding for the basal epidermal keratins 5 and 14, respectively.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19797037",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "What are the symptoms of Rotor syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17464171",
                "http://www.ncbi.nlm.nih.gov/pubmed/22232210",
                "http://www.ncbi.nlm.nih.gov/pubmed/20955959",
                "http://www.ncbi.nlm.nih.gov/pubmed/6807787",
                "http://www.ncbi.nlm.nih.gov/pubmed/11972401",
                "http://www.ncbi.nlm.nih.gov/pubmed/22982575"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0067659",
                    "o": "D006933"
                }
            ],
            "ideal_answer": [
                "Rotor syndrome is characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics."
            ],
            "exact_answer": [
                [
                    "conjugated hyperbilirubinemia"
                ],
                [
                    "coproporphyrinuria"
                ],
                [
                    "near-absent hepatic uptake of anionic diagnostics"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006932",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006933"
            ],
            "type": "list",
            "id": "571e417bbb137a4b0c00000a",
            "snippets": [
                {
                    "offsetInBeginSection": 210,
                    "offsetInEndSection": 518,
                    "text": "The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 58,
                    "text": "[A case with Rotor syndrome in hyperbilirubinemic family].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17464171",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome)",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20955959",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "Rotor syndrome is a rare, benign familial disorder characterized by chronic fluctuating, nonhemolytic and predominantly conjugated hyperbilirubinemia with normal hepatic histology",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17464171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 324,
                    "text": "Jaundice is often the first and sometimes the only symptom of liver disease. Besides in parenchymal liver disease jaundice is also observed in chronic non-haemolytic hyperbilirubinemias (Crigler-Najjar type I and II, Gilbert's syndrome) and in hereditary conjugated hyperbilirubinaemias (Dubin-Johnson- and Rotor-syndrome).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6807787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 270,
                    "text": " Rotor syndrome is a rare, benign familial disorder characterized by chronic fluctuating, nonhemolytic and predominantly conjugated hyperbilirubinemia with normal hepatic histology. In contrast to Dubin-Johnson syndrome, there is no liver pigmentation in Rotor syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17464171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 742,
                    "text": "The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 742,
                    "text": "The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20955959",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20955959",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "text": "[A case with Rotor syndrome in hyperbilirubinemic family].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17464171",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "The MMR vaccine protects against what 3 viruses?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7686463",
                "http://www.ncbi.nlm.nih.gov/pubmed/26265115"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0065828",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18558018"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18558018",
                    "o": "mmr vaccine"
                }
            ],
            "ideal_answer": [
                "The MMR vaccine provides immunity to measles, mumps and rubella.",
                " measles, mumps and rubella (mmr) vaccine ."
            ],
            "exact_answer": [
                [
                    "Measles"
                ],
                [
                    "Mumps"
                ],
                [
                    "Rubella"
                ]
            ],
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012411",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012412",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008458",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D022542",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009109",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009108",
                "http://www.disease-ontology.org/api/metadata/DOID:934"
            ],
            "type": "list",
            "id": "58f4b73b70f9fc6f0f000014",
            "snippets": [
                {
                    "offsetInBeginSection": 29,
                    "offsetInEndSection": 71,
                    "text": " measles, mumps and rubella (MMR) vaccine ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26265115",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Measles, mumps, rubella (MMR) vaccine is a live vaccine preparation containing attenuated strains of all 3 viruses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7686463",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List clinical features of the IMAGe syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25517553",
                "http://www.ncbi.nlm.nih.gov/pubmed/25861374",
                "http://www.ncbi.nlm.nih.gov/pubmed/16835919",
                "http://www.ncbi.nlm.nih.gov/pubmed/25258553",
                "http://www.ncbi.nlm.nih.gov/pubmed/22634751",
                "http://www.ncbi.nlm.nih.gov/pubmed/25541901",
                "http://www.ncbi.nlm.nih.gov/pubmed/24313804",
                "http://www.ncbi.nlm.nih.gov/pubmed/24617583",
                "http://www.ncbi.nlm.nih.gov/pubmed/14760276",
                "http://www.ncbi.nlm.nih.gov/pubmed/21108398"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0683325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18567231"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0683325",
                    "o": "clinical aspects"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0683325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18697112"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18697112",
                    "o": "clinical aspects"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0683325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A1810832"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A1810832",
                    "o": "clinical aspects"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0683325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18585749"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18585749",
                    "o": "aspects clinical"
                }
            ],
            "ideal_answer": [
                "Clinical features of IMAGe syndrome include intra-uterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and genital abnormalities. It is s caused by gain-of-function mutations of maternally expressed gene CDKN1C on chromosome 11p15.5."
            ],
            "exact_answer": [
                [
                    "intra-uterine growth restriction"
                ],
                [
                    "metaphyseal dysplasia"
                ],
                [
                    "adrenal hypoplasia congenita"
                ],
                [
                    "genital abnormalities"
                ]
            ],
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:0050885"
            ],
            "type": "list",
            "id": "5895e4637d9090f353000012",
            "snippets": [
                {
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 461,
                    "text": "Recently, our group described gain-of-function mutations in the PCNA-binding site of CDKN1C that result in an undergrowth syndrome called IMAGe Syndrome (Intrauterine Growth Restriction, Metaphyseal dysplasia, Adrenal hypoplasia, and Genital anomalies), with life-threatening consequences. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25861374",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "text": "IMAGe syndrome is an exceedingly rare condition first described in 1999. Components of the syndrome are intrauterine growth retardation (IUGR), metaphyseal dysplasia, congenital adrenal hypoplasia and genital anomalies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25541901",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 280,
                    "text": "OBJECTIVE: Arboleda et al. have recently shown that IMAGe (intra-uterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and genital abnormalities) syndrome is caused by gain-of-function mutations of maternally expressed gene CDKN1C on chromosome 11p15.5. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313804",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 493,
                    "text": "Intriguing is that CDKN1C gain-of-function variations were recently found in patients with IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, congenital adrenal hypoplasia, and genital anomalies). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25258553",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List the 5 different human immunoglobulin heavy chains.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
                "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
                "http://www.ncbi.nlm.nih.gov/pubmed/16148123"
            ],
            "ideal_answer": [
                "The 5 human immunoglobulin heavy chains are Alpha, Delta Epsilon, Gamma and Mu",
                "using heavy chain specific gamma, alpha, mu, delta and epsilon"
            ],
            "exact_answer": [
                [
                    "alpha"
                ],
                [
                    "delta"
                ],
                [
                    "epsilon"
                ],
                [
                    "gamma"
                ],
                [
                    "mu"
                ]
            ],
            "type": "list",
            "id": "5e4f0a4f6d0a277941000031",
            "snippets": [
                {
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 433,
                    "text": ". Despite this, Ag-specific single H chain Ig repertoires, using mu-, gamma-, epsilon-, or alpha-H chain",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16148123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 219,
                    "text": "he neoplastic proliferation of single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma, alpha, mu, delta or epsilon chain ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 437,
                    "offsetInEndSection": 499,
                    "text": "using heavy chain specific gamma, alpha, mu, delta and epsilon",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which genes/proteins have been found to inhibit cyclin dependent kinase 4 (CDK4)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7630635",
                "http://www.ncbi.nlm.nih.gov/pubmed/9031081",
                "http://www.ncbi.nlm.nih.gov/pubmed/9042862",
                "http://www.ncbi.nlm.nih.gov/pubmed/10454538",
                "http://www.ncbi.nlm.nih.gov/pubmed/17881001",
                "http://www.ncbi.nlm.nih.gov/pubmed/7630199",
                "http://www.ncbi.nlm.nih.gov/pubmed/9827724",
                "http://www.ncbi.nlm.nih.gov/pubmed/19147556",
                "http://www.ncbi.nlm.nih.gov/pubmed/9973200",
                "http://www.ncbi.nlm.nih.gov/pubmed/9194486",
                "http://www.ncbi.nlm.nih.gov/pubmed/7652577",
                "http://www.ncbi.nlm.nih.gov/pubmed/7936665",
                "http://www.ncbi.nlm.nih.gov/pubmed/9325318",
                "http://www.ncbi.nlm.nih.gov/pubmed/11790141"
            ],
            "ideal_answer": [
                "The p15(ink4b) and p16(ink4a) CDK4 inhibitor genes map within the chromosome band 9p21 region deleted frequently in various cancers.The Cdk4 inhibitor p18(Ink4c) is a tumor suppressor. Recent studies of Cyclin D1/Cdk4 have proposed that p21(Waf1/Cip1/Sdi1) plays a key role as a potent Cdk4 inhibitor. p27KIP1 is also a cdk4 ihibitor."
            ],
            "exact_answer": [
                [
                    "p16",
                    "p16INK4",
                    "p16INK4a",
                    "MTS1",
                    "CDKN2"
                ],
                [
                    "p15",
                    "p15INK4B"
                ],
                [
                    "p18(Ink4c)"
                ],
                [
                    "p21(Waf1/Cip1/Sdi1)"
                ],
                [
                    "p27KIP1"
                ]
            ],
            "concepts": [
                "http://www.uniprot.org/uniprot/CDK4_BOVIN",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050756",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045736",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051358"
            ],
            "type": "list",
            "id": "552435602c8b63434a000009",
            "snippets": [
                {
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1289,
                    "text": "Interestingly, the Cdk inhibitor p18(Ink4c) was induced in the transgenic pineal glands independently of p53, and transgenic mice that lacked Ink4c developed invasive PNET, although at an older age than those lacking p53.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19147556",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1446,
                    "offsetInEndSection": 1713,
                    "text": "Our finding that the Cdk4 inhibitor p18(Ink4c) is a tumor suppressor in cyclin D1-driven PNET suggests that pharmacologic interventions to inhibit Cdk4 activity may be a useful chemoprevention or therapeutic strategy in cancer driven by primary RB pathway disruption.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19147556",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 704,
                    "text": "Our previous studies showed that while both specific CDK4 inhibitor p16INK4A (P16) and gankyrin bind to cyclin-dependent kinase 4 (CDK4) in similar fashion, only P16 inhibits the kinase activity of CDK4.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17881001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 316,
                    "text": "Recent biological studies of Cyclin D1/Cdk4 have proposed that p21 C-terminal domain (p21(CT)) plays a key role as a potent Cdk4 inhibitor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790141",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 1107,
                    "text": "Especially, our data suggests that the D(149)FYHSKRR(156) region of p21 is critical for Cdk4 binding, indicating that the major driving force for complex originates from hydrophobic interaction between p21 and Cdk4.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790141",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 466,
                    "offsetInEndSection": 592,
                    "text": "We show that c-Myc prevents induction of the cdk4 inhibitor p15(Ink4b) and the subsequent inhibition of G(1) cdks by TGF-beta.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10454538",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 430,
                    "text": "CDK activity is modulated by inhibitors such as p15INK4b and p16INK4a. Loss of function of p15INK4b and p16INK4a (multiple tumor suppressor-I and CDK4 inhibitor) determines impairment in the control of the cell cycle and contributes to the transformation of several cell types. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9827724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 151,
                    "text": "D-type cyclins, in association with the cyclin-dependent kinases CDK4 and CDK6, promote progression through the G1 phase of the cell cycle.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9827724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "text": "In the present study, we analyzed human ovarian carcinoma cell lines for abnormalities in the tumor suppressor gene Rb (retinoblastoma) and in cyclin-dependent kinase 4 (CDK4) inhibitor genes (p16INK4 and p15INK4B) using molecular biology techniques.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9194486",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1607,
                    "offsetInEndSection": 1744,
                    "text": "These data suggest that abnormalities of Rb and CDK4 inhibitor genes (p16INK4, p15INK4B) may be involved in human ovarian carcinogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9194486",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 513,
                    "text": "The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16INK4a, but not of p21 or of p27KIP1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7652577",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "The p15 and p16 CDK4 inhibitor genes map within the chromosome band 9p21 region deleted frequently in malignant mesothelioma and other cancers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7630635",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 257,
                    "text": "The cyclin-dependent kinase 4 (cdk4) inhibitor (p16INK4/MTS1/CDKN2) gene has been recently identified as a putative tumor suppressor gene because of the high frequency of homozygous deletion observed in numerous human tumor cell lines, including leukemias. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7630199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 369,
                    "text": "The identification of a cdk4 inhibitor, p16INK4, as a target for mutations in cultured tumor lines and primary tumors suggested that RB activity may be affected in these cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7936665",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1180,
                    "text": "Roles of cyclin A-Cdk2 as a p27 target and cyclin D2-Cdk4 as a p27 reservoir may result from the differential ability of bound p27 to inhibit the kinase subunit in these complexes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9325318",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9031081",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9973200",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 364,
                    "text": "One of the INK4 molecules, p16, is also known as multiple tumor suppressor and has been found to be mutated or deleted in various tumors and cell lines. We have previously identified p18 as a member of the INK4 family.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9973200",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "Members of the INK4 family of cyclin-dependent kinase (CDK) inhibitors specifically bind and inhibit the G1-specific CDK molecules CDK4 and CDK6.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9973200",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9042862",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "What is SCENAR therapy used for?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20396722",
                "http://www.ncbi.nlm.nih.gov/pubmed/20879466",
                "http://www.ncbi.nlm.nih.gov/pubmed/16924799",
                "http://www.ncbi.nlm.nih.gov/pubmed/8779182"
            ],
            "ideal_answer": [
                "all patients experienced substantial relief of pain from the first treatment. an electronic biofeedback device (scenar) may be successfully utilized in the management of post-herpetic neuralgia. scenar) as effective in the treatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis. post-herpetic neuralgia using a bioelectronical device (scenar). addition of scenar therapy to the complex conventional pharmacotherapy fastened ulcer healing, increased the effectiveness of helicobacter pylori eradication, and improved the condition of the gastroduodenal mucosa. scenar therapy to patients with localized suppurative peritonitis in the postoperative period. a new technique of low-frequency modulated electric current therapy, scenar therapy, was used in treatment of 103 patients with duodenal ulcer (du). ",
                "localized suppurative peritonitis in the postoperative period\nmanagement of post-herpetic neuralgia\ntreatment of 103 patients with duodenal ulcer\ntreatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis"
            ],
            "exact_answer": [
                [
                    "peritonitis postoperative"
                ],
                [
                    "pain in postherpetic neuralgia"
                ],
                [
                    "duodenal ulcer"
                ],
                [
                    "nocturnal enuresis"
                ]
            ],
            "type": "list",
            "id": "535d69177d100faa09000003",
            "snippets": [
                {
                    "offsetInBeginSection": 48,
                    "offsetInEndSection": 141,
                    "text": "SCENAR therapy to patients with localized suppurative peritonitis in the postoperative period",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20396722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 94,
                    "offsetInEndSection": 157,
                    "text": "post-herpetic neuralgia using a bioelectronical device (SCENAR)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 474,
                    "text": "All patients experienced substantial relief of pain from the first treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 715,
                    "offsetInEndSection": 831,
                    "text": "An electronic biofeedback device (SCENAR) may be successfully utilized in the management of post-herpetic neuralgia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "A new technique of low-frequency modulated electric current therapy, SCENAR therapy, was used in treatment of 103 patients with duodenal ulcer (DU).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16924799",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 648,
                    "text": "Addition of SCENAR therapy to the complex conventional pharmacotherapy fastened ulcer healing, increased the effectiveness of Helicobacter pylori eradication, and improved the condition of the gastroduodenal mucosa.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16924799",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 68,
                    "offsetInEndSection": 184,
                    "text": "SCENAR) as effective in the treatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8779182",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which markers are screened with the triple test for the detection of syndromes in fetus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21699408",
                "http://www.ncbi.nlm.nih.gov/pubmed/10585342",
                "http://www.ncbi.nlm.nih.gov/pubmed/8624312",
                "http://www.ncbi.nlm.nih.gov/pubmed/7544745",
                "http://www.ncbi.nlm.nih.gov/pubmed/15512289",
                "http://www.ncbi.nlm.nih.gov/pubmed/11084551",
                "http://www.ncbi.nlm.nih.gov/pubmed/8630836",
                "http://www.ncbi.nlm.nih.gov/pubmed/10521756",
                "http://www.ncbi.nlm.nih.gov/pubmed/16378329",
                "http://www.ncbi.nlm.nih.gov/pubmed/7485343",
                "http://www.ncbi.nlm.nih.gov/pubmed/9166168",
                "http://www.ncbi.nlm.nih.gov/pubmed/25330176",
                "http://www.ncbi.nlm.nih.gov/pubmed/8650125",
                "http://www.ncbi.nlm.nih.gov/pubmed/18306921",
                "http://www.ncbi.nlm.nih.gov/pubmed/14669430",
                "http://www.ncbi.nlm.nih.gov/pubmed/18839465"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0015965",
                    "o": "Fetus"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0015965",
                    "o": "http://linkedlifedata.com/resource/umls/label/A1392741"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A1392741",
                    "o": "fetus"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0554819",
                    "o": "triple test"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0554819",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18640308"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18640308",
                    "o": "triple test"
                }
            ],
            "ideal_answer": [
                "The markers that are screened with the triple test for the detection of syndromes in fetus are:\n1) alpha-fetoprotein (AFP), \n2) beta-chorionic gonadotrophin (beta-CG) and \n3) unconjugated oestriol (uE3)."
            ],
            "exact_answer": [
                [
                    "alpha-fetoprotein",
                    "AFP",
                    "\u03b1-fetoprotein"
                ],
                [
                    "beta-chorionic gonadotrophin",
                    "beta-CG"
                ],
                [
                    "unconjugated oestriol",
                    "uE3"
                ]
            ],
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005333",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062145",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011258",
                "http://amigo.geneontology.org/amigo/term/GO:0007565"
            ],
            "type": "list",
            "id": "58da2a348acda34529000014",
            "snippets": [
                {
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 515,
                    "text": "Our study aimed at calculation and validation of the triple marker medians used in screening Egyptian females as well as to recommend programme conventions to unify screening in this country.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25330176",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 619,
                    "offsetInEndSection": 743,
                    "text": "Chorionic gonadotropin (CG), \u03b1-fetoprotein (AFP) and unconjugated oestriol (uE3) were measured on Siemens Immulite analyzer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25330176",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68,
                    "text": "Triple test screening for Down syndrome: an Egyptian-tailored study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25330176",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 5,
                    "offsetInEndSection": 272,
                    "text": "The purpose of this article was to evaluate the reliability of maternal serum triple marker screening of alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities in Turkish pregnant women.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699408",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1174,
                    "offsetInEndSection": 1285,
                    "text": "Second trimester triple test is an effective screening tool for detecting fetal Down syndrome in Turkish women.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699408",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 252,
                    "text": "The aim of this prospective study was to compare triple test screening (alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome in women of 35 years of age or more. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15512289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 251,
                    "text": "The aim of this prospective study was to compare triple test screening (alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome in women of 35 years of age or more.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15512289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1559,
                    "offsetInEndSection": 1953,
                    "text": "None of the other five markers added more than 2% detection for the same false-positive rate.The performance of screening using maternal age and serum-free beta-hCG and PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein and hCG with maternal age) and similar to the triple test (alpha-fetoprotein, unconjugated oestriol and hCG with maternal age) at 15-22 weeks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8624312",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 612,
                    "text": "To make recommendations to physicians providing prenatal care on (1) whether prenatal screening for and diagnosis of Down syndrome (DS) is advisable and (2) alternative screening and diagnosis manoeuvres.\"Triple-marker\" screening of maternal serum levels of alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol; fetal ultrasonographic examination; amniocentesis; and chorionic villus sampling (CVS).Accuracy of detection of DS in fetuses, and risks to the mother, including psychologic distress, and to the fetus from the screening and diagnostic interventions.A MEDLINE search for relevant a",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8630836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 507,
                    "text": "A decision analytic model was designed for women at increased risk for a DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP) screening test, also known as a triple screen (+triple) test.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16378329",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 569,
                    "text": "These tests have a limited detection rate for Down syndrome: approximately 40% for hCG or free beta-subunit alone, approximately 60% for the triple screen test, and approximately 70% for the quadruple marker test, all at 5%, or a relatively high, false-positive rate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585342",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 301,
                    "text": "Serum human chorionic gonadotropin (hCG) and hCG free beta-subunit tests are used in combination with unconjugated estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome in the second trimester of pregnancy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585342",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 242,
                    "offsetInEndSection": 452,
                    "text": "Initial and revised screen-positive rates and detection rates were reviewed for women undergoing triple-marker testing (maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9166168",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List fluorescent reporter proteins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23741385",
                "http://www.ncbi.nlm.nih.gov/pubmed/18501461",
                "http://www.ncbi.nlm.nih.gov/pubmed/18566430",
                "http://www.ncbi.nlm.nih.gov/pubmed/20471991",
                "http://www.ncbi.nlm.nih.gov/pubmed/15258449",
                "http://www.ncbi.nlm.nih.gov/pubmed/16468989",
                "http://www.ncbi.nlm.nih.gov/pubmed/18556507",
                "http://www.ncbi.nlm.nih.gov/pubmed/17407539",
                "http://www.ncbi.nlm.nih.gov/pubmed/18473954",
                "http://www.ncbi.nlm.nih.gov/pubmed/23822504",
                "http://www.ncbi.nlm.nih.gov/pubmed/20532610",
                "http://www.ncbi.nlm.nih.gov/pubmed/14579736",
                "http://www.ncbi.nlm.nih.gov/pubmed/12771211",
                "http://www.ncbi.nlm.nih.gov/pubmed/17646710",
                "http://www.ncbi.nlm.nih.gov/pubmed/20601526",
                "http://www.ncbi.nlm.nih.gov/pubmed/23347004",
                "http://www.ncbi.nlm.nih.gov/pubmed/24128932",
                "http://www.ncbi.nlm.nih.gov/pubmed/18592415",
                "http://www.ncbi.nlm.nih.gov/pubmed/20429918",
                "http://www.ncbi.nlm.nih.gov/pubmed/17553146"
            ],
            "ideal_answer": [
                "Fluorescent and luminescent reporter genes have become popular tools for the real-time monitoring of gene expression in living cells:\ngreen fluorescent protein\nTimer\nred fluorescent protein\nyellow fluorescent protein\nbeta-phycoerythrin\ncoral fluorescent reporter protein\nenhanced green fluorescent reporter protein\nmCherry"
            ],
            "exact_answer": [
                [
                    "green fluorescent protein",
                    "Gfp"
                ],
                [
                    "Timer",
                    "DsRed1-E5"
                ],
                [
                    "red fluorescent protein",
                    "dsRed"
                ],
                [
                    "yellow fluorescent protein"
                ],
                [
                    "beta-phycoerythrin"
                ],
                [
                    "coral fluorescent reporter protein"
                ],
                [
                    "enhanced green fluorescent reporter protein"
                ],
                [
                    "mCherry"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017930",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061848",
                "http://www.uniprot.org/uniprot/GFP_AEQVI",
                "http://www.uniprot.org/uniprot/LUXY_VIBFI",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005453",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D049452",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005455",
                "http://www.uniprot.org/uniprot/BFP_VIBFI"
            ],
            "type": "list",
            "id": "5523e47f7b523f2123000004",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Fluorescent Timer, or DsRed1-E5, is a mutant of the red fluorescent protein, dsRed, in which fluorescence shifts over time from green to red as the protein matures.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24128932",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 807,
                    "text": "green fluorescent protein (Gfp)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23822504",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Characterization of flavin-based fluorescent proteins: an emerging class of fluorescent reporters.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741385",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 256,
                    "text": "Flavin-based fluorescent proteins (FbFPs)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741385",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 329,
                    "text": "mCherry was employed as a reporter protein ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23347004",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 723,
                    "offsetInEndSection": 749,
                    "text": "yellow fluorescent protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601526",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 295,
                    "text": "red cytoplasmic fluorescent reporter protein. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532610",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 510,
                    "text": "red fluorescent reporter protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532610",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 623,
                    "offsetInEndSection": 667,
                    "text": " enhanced green fluorescent reporter protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20471991",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 146,
                    "text": "Fluorescent and luminescent reporter genes have become popular tools for the real-time monitoring of gene expression in living cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20429918",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 715,
                    "text": " fluorescent reporter protein [green fluorescent protein (GFP) and DsRed2]",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18592415",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 222,
                    "text": "coral fluorescent reporter protein ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18566430",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 402,
                    "offsetInEndSection": 487,
                    "text": "driving a cassette for the enhanced green \"live\" fluorescent reporter protein (eGFP) ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18556507",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 290,
                    "text": "GFP as a fluorescent reporter protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18501461",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 154,
                    "text": " protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18473954",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 311,
                    "offsetInEndSection": 356,
                    "text": "red fluorescent reporter protein (RFP) gene. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17646710",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 35,
                    "text": "The red fluorescent protein eqFP611",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553146",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 748,
                    "offsetInEndSection": 792,
                    "text": "the green fluorescent reporter protein gene ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17407539",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 447,
                    "text": " red fluorescent reporter protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16468989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 603,
                    "text": "beta-phycoerythrin, a fluorescent reporter protein derived from algae",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15258449",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 504,
                    "text": " live-cell fluorescent reporter protein, Timer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14579736",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1204,
                    "text": "red fluorescent reporter protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12771211",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which are the enzymes involved in the addition of 7-methylguanosine in mRNA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24200467",
                "http://www.ncbi.nlm.nih.gov/pubmed/7831320",
                "http://www.ncbi.nlm.nih.gov/pubmed/24552703",
                "http://www.ncbi.nlm.nih.gov/pubmed/21170289",
                "http://www.ncbi.nlm.nih.gov/pubmed/23863084",
                "http://www.ncbi.nlm.nih.gov/pubmed/729595",
                "http://www.ncbi.nlm.nih.gov/pubmed/24273643",
                "http://www.ncbi.nlm.nih.gov/pubmed/6478055",
                "http://www.ncbi.nlm.nih.gov/pubmed/956186",
                "http://www.ncbi.nlm.nih.gov/pubmed/11879179",
                "http://www.ncbi.nlm.nih.gov/pubmed/21118133",
                "http://www.ncbi.nlm.nih.gov/pubmed/22817748",
                "http://www.ncbi.nlm.nih.gov/pubmed/2072458",
                "http://www.ncbi.nlm.nih.gov/pubmed/9707557",
                "http://www.ncbi.nlm.nih.gov/pubmed/9725672",
                "http://www.ncbi.nlm.nih.gov/pubmed/1002690",
                "http://www.ncbi.nlm.nih.gov/pubmed/6649413",
                "http://www.ncbi.nlm.nih.gov/pubmed/20713356",
                "http://www.ncbi.nlm.nih.gov/pubmed/22985415",
                "http://www.ncbi.nlm.nih.gov/pubmed/10662770"
            ],
            "ideal_answer": [
                "The 7-methylguanosine cap added to the 5\u2032 end of mRNA is essential for efficient gene expression and cell viability. Methylation of the guanosine cap is necessary for the translation of most cellular mRNAs in all eukaryotic organisms in which it has been investigated. In some experimental systems, cap methylation has also been demonstrated to promote transcription, splicing, polyadenylation and nuclear export of mRNA. In the addition of 7-methylguanosine in mRNA involved the RNA polymerase II, RNA guanylyltransferase and RNA guanine-7 methyltransferase enzymes.",
                "The enzymes involved in the addition of 7-methylguanosine in mRNA are RNA guanylyltransferase and 5'-phosphatase (RNGTT), RNA guanine-7 methyltransferase (RNMT or hMTr1), RNMT-activating mini-protein (RAM), RNA polymerase II, S-adenosylhomocysteine hydrolase (SAHH), and Myc."
            ],
            "exact_answer": [
                [
                    "RNA guanylyltransferase and 5'-phosphatase (RNGTT)",
                    "RNA guanylyltransferase and 5'-phosphatase",
                    "RNGTT"
                ],
                [
                    "RNA guanine-7 methyltransferase",
                    "RNA guanine-7 methyltransferase (RNMT or hMTr1)",
                    "RNMT",
                    "hMTr1"
                ],
                [
                    "RNMT-activating mini-protein",
                    "RNMT-activating mini-protein (RAM)",
                    "RAM"
                ],
                [
                    "RNA polymerase II"
                ],
                [
                    "S-adenosylhomocysteine hydrolase",
                    "S-adenosylhomocysteine hydrolase (SAHH)",
                    "SAHH"
                ],
                [
                    "Myc"
                ]
            ],
            "concepts": [
                "http://www.uniprot.org/uniprot/MCE1_MOUSE",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0009452",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008618",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006370",
                "http://www.biosemantics.org/jochem#4270220",
                "http://www.uniprot.org/uniprot/RSMG_OENOB",
                "http://www.uniprot.org/uniprot/MCE1_CAEEL",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004484",
                "http://www.biosemantics.org/jochem#4270249",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798",
                "http://www.uniprot.org/uniprot/MCE_ASFP4",
                "http://www.uniprot.org/uniprot/MCE1_DANRE",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045762",
                "http://www.biosemantics.org/jochem#4211619",
                "http://www.uniprot.org/uniprot/MCE_ASFB7",
                "http://www.biosemantics.org/jochem#4270250",
                "http://www.uniprot.org/uniprot/MCE_PBCV1",
                "http://www.uniprot.org/uniprot/MCE1_HUMAN",
                "http://www.biosemantics.org/jochem#4269944",
                "http://www.uniprot.org/uniprot/MCE_ASFK5",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0046118",
                "http://www.uniprot.org/uniprot/MCE_ASFM2",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000340",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004789",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020536",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031533",
                "http://www.biosemantics.org/jochem#4195237",
                "http://www.uniprot.org/uniprot/MCE_MIMIV"
            ],
            "type": "list",
            "id": "52f112bb2059c6d71c000002",
            "snippets": [
                {
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 975,
                    "text": "In mammals, cap synthesis is catalysed by the sequential action of RNGTT (RNA guanylyltransferase and 5'-phosphatase) and RNMT (RNA guanine-7 methyltransferase), enzymes recruited to RNA pol II (polymerase II) during the early stages of transcription. We recently discovered that the mammalian cap methyltransferase is a heterodimer consisting of RNMT and the RNMT-activating subunit RAM (RNMT-activating mini-protein). RAM activates and stabilizes RNMT and thus is critical for cellular cap methylation and cell viability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24200467",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 447,
                    "text": "Synthesis of the methyl cap initiates with the addition of 7-methylguanosine to the initiating nucleotide of RNA pol II (polymerase II) transcripts, which occurs predominantly during transcription and in mammals is catalysed by RNGTT (RNA guanylyltransferase and 5' phosphatase) and RNMT (RNA guanine-7 methyltransferase).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23863084",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 1006,
                    "text": "The RNMT-activating subunit, RAM (RNMT-activating miniprotein), is also recruited to transcription initiation sites via an interaction with RNMT.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23863084",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 902,
                    "text": "Phosphorylation of the CTD recruits RNGTT and RNMT, the enzymes involved in mRNA capping, to the nascent transcript.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21170289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 931,
                    "text": "Myc induces methyl cap formation by promoting RNA polymerase II phosphorylation which recruits the capping enzymes to RNA, and by up-regulating the enzyme SAHH (S-adenosylhomocysteine hydrolase), which neutralizes the inhibitory by-product of methylation reactions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21118133",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 535,
                    "offsetInEndSection": 691,
                    "text": "In the present study, we identify the methyltransferase responsible for cap1 formation in human cells, which we call hMTr1 (also known as FTSJD2 and ISG95).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20713356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 329,
                    "text": "The guanylyltransferase (GTP:mRNA guanylyltransferase, EC 2.7.7.50) reaction responsible for cap formation usually proceeds via a covalent enzyme-GMP intermediate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7831320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 363,
                    "text": "The methylation of the 5' terminal guanosine residue of the cap structure of Semliki Forest virus (SFV) mRNAs has been shown to occur in vitro concomitantly with their synthesis (R. K. Cross and P. J. Gomatos, Virology, 114, 542-554, 1981). The enzyme responsible for this methylation, a guanine-7-methyltransferase, is associated with the SFV replication complex",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6649413",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 303,
                    "text": "An RNA (guanine-7-)-methyltransferase that specifically methylates the 5'-terminal guanosine residue of RNAs ending in the dinucleoside triphosphate G(5')pppN- has been purified from the cytoplasm of HeLa cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/956186",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "By which methods can we evaluate the reliability of a phylogenetic tree?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19423664",
                "http://www.ncbi.nlm.nih.gov/pubmed/19748458",
                "http://www.ncbi.nlm.nih.gov/pubmed/21940641",
                "http://www.ncbi.nlm.nih.gov/pubmed/20207713",
                "http://www.ncbi.nlm.nih.gov/pubmed/21851592",
                "http://www.ncbi.nlm.nih.gov/pubmed/12857639",
                "http://www.ncbi.nlm.nih.gov/pubmed/15008414",
                "http://www.ncbi.nlm.nih.gov/pubmed/22940609",
                "http://www.ncbi.nlm.nih.gov/pubmed/11411692",
                "http://www.ncbi.nlm.nih.gov/pubmed/7544864",
                "http://www.ncbi.nlm.nih.gov/pubmed/22289866",
                "http://www.ncbi.nlm.nih.gov/pubmed/21899420",
                "http://www.ncbi.nlm.nih.gov/pubmed/23060619"
            ],
            "ideal_answer": [
                "The methods for assessing the robustness/reliability of the topology of the inferred phylogenetic trees are: the widely used bootstrap method and the jackknife method.",
                "In contrast to other similar software, the program FreeTree (available at http://www.natur.cuni.cz/~flegr/programs/freetree or http://ijs.sgmjournals.org/content/vol51/issue3/) can also assess the robustness of the tree topology by bootstrap, jackknife or operational taxonomic unit-jackknife analysis. (PMID: 11411692)"
            ],
            "exact_answer": [
                [
                    "bootstrap"
                ],
                [
                    "jackknife"
                ]
            ],
            "type": "list",
            "id": "516ec97f298dcd4e51000087",
            "snippets": [
                {
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 473,
                    "text": "For robustness evaluation, we apply bootstrap and jackknife techniques to input data.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22940609",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "An alignment confidence score capturing robustness to guide tree uncertainty.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207713",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 817,
                    "text": "We build on the widely used bootstrap method for perturbing the phylogenetic tree.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207713",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "SuperTRI: A new approach based on branch support analyses of multiple independent data sets for assessing reliability of phylogenetic inferences.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19748458",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 1076,
                    "text": "To overcome these limitations, we propose a new approach, called SuperTRI, which is based on the branch support analyses of the independent data sets, and where the reliability of the nodes is assessed using three measures: the supertree Bootstrap percentage and two other values calculated from the separate analyses: the mean branch support (mean Bootstrap percentage or mean posterior probability) and the reproducibility index.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19748458",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 517,
                    "text": "In contrast to other similar software, the program FreeTree (available at http://www.natur.cuni.cz/~flegr/programs/freetree or http://ijs.sgmjournals.org/content/vol51/issue3/) can also assess the robustness of the tree topology by bootstrap, jackknife or operational taxonomic unit-jackknife analysis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11411692",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 665,
                    "text": "Unlike any previous tool for inferring phylogenies from rearrangement data, TIBA uses novel methods of robustness estimation to provide support values for the edges in the inferred tree.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23060619",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Fast and accurate phylogenetic reconstruction from high-resolution whole-genome data and a novel robustness estimator.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21899420",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 767,
                    "text": "Moreover, whereas phylogenetic analyses from sequence data are deemed incomplete unless bootstrapping scores (a measure of confidence) are given for each tree edge, no equivalent to bootstrapping exists for rearrangement-based phylogenetic analysis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21899420",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 920,
                    "offsetInEndSection": 1087,
                    "text": "We also describe a novel approach to estimate the robustness of results-an equivalent to the bootstrapping analysis used in sequence-based phylogenetic reconstruction.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21899420",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1431,
                    "offsetInEndSection": 1510,
                    "text": "The standard deviation also suggests the reliability level of the branch order.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15008414",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Assessment of the reliability of a given phylogenetic hypothesis is an important step in phylogenetic analysis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12857639",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 936,
                    "text": "The reliability of the phylogenetic trees was probed with the bootstrapping of 100 replicates of the original sequence alignments.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7544864",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Which X chromosome abnormalities present lupus-like symptoms?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18606711"
            ],
            "ideal_answer": [
                "Lupus-like symptoms of systemic lupus erythematosus (SLE) are caused by X-linked mutations in the genes Tlr7 and Y.",
                "Yaa-mediated acceleration of SLE as well as various Yaa-linked cellular traits cannot be explained by the Tlr7 gene duplication alone, and suggest additional contributions from other duplicated genes in the translocated X chromosome.",
                "genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration).",
                "Tlr7 and Y chromosome abnormalities present lupus-like symptoms with considerable phenotypic overlap.",
                "X-chromosome abnormalities (Tlr7 and Y) present lupus-like symptoms.",
                "the accelerated development of systemic lupus erythematosus (sle) in male bxsb mice is associated with the genetic abnormality in its y chromosome",
                "Yaa-mediated acceleration of SLE as well as various Yaa-linked cellular traits cannot be explained by the Tlr7 gene duplication alone, and suggest additional contributions from other duplicated genes in the translocated X chromosome. The accelerated development of systemic lupus erythematosus (SLE) in male BXSB mice is associated with the genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration).",
                "The accelerated development of systemic lupus erythematosus (SLE) in male BXSB mice is associated with the genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration) but additional contributions from other duplicated genes in the translocated X chromosome also exist",
                "The accelerated development of systemic lupus erythematosus (SLE) in male BXSB mice is associated with the genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration).",
                "X-chromosomal abnormalities in patients with SLE present lupus-like symptoms. X-chromatin abnormality on X chromosome 14q11.2, which encodes X-linked leiomyosarcoma, is the most common chromosomal abnormality in SLE. There is also a publication that links X- chromosome abnormalities to lupUS disease with synostosis.",
                "The accelerated development of systemic lupus erythematosus (SLE) in male BXSB mice is associated with the genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration). Yaa-mediated acceleration of SLE as well as various Yaa-linked cellular traits cannot be explained by the Tlr7 gene duplication alone, and suggest additional contributions from other duplicated genes in the translocated X chromosome.",
                "yaa",
                "Lupus-like symptoms are present due to X-chromosomal abnormalities such as X-linked leiomyosarcoma, polycystic kidney disease, myelodysplastic syndrome (MDS), and X- linked hypogonadotropic hypomyelitis."
            ],
            "exact_answer": [
                [
                    "Y-linked autoimmune acceleration",
                    "Yaa"
                ],
                [
                    "X-linked translocations"
                ]
            ],
            "type": "list",
            "id": "5d38790da1e159510500000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "The accelerated development of systemic lupus erythematosus (SLE) in male BXSB mice is associated with the genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18606711",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1340,
                    "offsetInEndSection": 1573,
                    "text": "Yaa-mediated acceleration of SLE as well as various Yaa-linked cellular traits cannot be explained by the Tlr7 gene duplication alone, and suggest additional contributions from other duplicated genes in the translocated X chromosome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18606711",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List lymphocytes that are analyzed by a flow cytometer.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29516957",
                "http://www.ncbi.nlm.nih.gov/pubmed/29935030",
                "http://www.ncbi.nlm.nih.gov/pubmed/29466232"
            ],
            "ideal_answer": [
                "Quantitation of lymphocyte subsets (B cells, T cells, CD4 and CD8 T cells and NK cells) classically relies on quantitation of lymphocytes and immunophenotyping by flow cytometry."
            ],
            "exact_answer": [
                [
                    "B cells"
                ],
                [
                    "T cells"
                ],
                [
                    "CD4 and CD8 T cells"
                ],
                [
                    "NK cells"
                ]
            ],
            "type": "list",
            "id": "5c5f0f581a4c55d80b000012",
            "snippets": [
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 191,
                    "text": " Quantitation of lymphocyte subsets (B cells, T cells, CD4 and CD8 T cells and NK cells) classically relies on quantitation of lymphocytes and immunophenotyping by flow cytometry. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466232",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 653,
                    "text": "The distributions of Th17 cells, regulatory Treg-cells, CD4+ T-cells, CD8+ T-cells, and CD3+ T-cells were determined by flow cytometer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29516957",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 37,
                    "offsetInEndSection": 80,
                    "text": " main lymphocyte subsets (T, B and NK cell ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29935030",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which gene mutations are predictive of response to anti-TNF therapy in Rheumatoid Arthritis patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26440629",
                "http://www.ncbi.nlm.nih.gov/pubmed/22044414",
                "http://www.ncbi.nlm.nih.gov/pubmed/25848939"
            ],
            "ideal_answer": [
                "\u039cutations in TLR5 and TLR1 genes contribute to differential response to anti-TNF treatment in RA. Variation at FCGR2A and functionally related genes such as DHX32 and RGS12 is also associated with the response to anti-TNF therapy in rheumatoid arthritis."
            ],
            "exact_answer": [
                [
                    "TLR5"
                ],
                [
                    "TLR1"
                ],
                [
                    "FCGR2A"
                ],
                [
                    "DHX32"
                ],
                [
                    "RGS12"
                ]
            ],
            "type": "list",
            "id": "58e7a1393e8b6dc87c00000b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440629",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 877,
                    "offsetInEndSection": 1682,
                    "text": "Six of twenty successfully genotyped polymorphisms were nominally associated with EULAR treatment response. Three of these were in weak to moderate linkage disequilibrium with polymorphisms previously reported associated with anti-TNF treatment response. TLR5(rs5744174) variant allele carriers (odds ratio(OR) = 1.7(1.1-2.5),p = 0.010,q = 0.46) and TLR1(rs4833095) homozygous variant carriers (OR = 2.8(1.1-7.4),p = 0.037,q = 0.46) had higher odds for a positive treatment response. NLRP3(rs10754558) variant allele carriers (odds ratio(OR) = 0.6(0.4-1.0),p = 0.045,q = 0.46) were more likely to have a negative treatment response. The association in TLR5(rs5744174) remained significant after correction for multiple comparisons among patients negative for RF (OR = 6.2(2.4-16.3),p = 0.0002,q = 0.024). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440629",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 306,
                    "offsetInEndSection": 511,
                    "text": "We aimed to validate this genetic association in a patient cohort from the Spanish population, and also to identify new genes functionally related to FCGR2A that are also associated with anti-TNF response.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 642,
                    "text": "A total of 348 RA patients treated with an anti-TNF therapy were included and genotyped for FCGR2A polymorphism rs1081274.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 812,
                    "offsetInEndSection": 969,
                    "text": " Using gene expression profiles from macrophages obtained from synovial fluid of RA patients, we searched for genes highly correlated with FCGR2A expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1459,
                    "text": "We found a significant association between FCGR2A and the response to adalimumab (P=0.022). Analyzing the subset of anti-CCP positive RA patients (78%), we also found a significant association between FCGR2A and the response to infliximab (P=0.035). DHX32 and RGS12 were the most consistently correlated genes with FCGR2A expression in RA synovial fluid macrophages (P<0.001).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1460,
                    "offsetInEndSection": 1684,
                    "text": "We found a significant association between the genetic variation at DHX32 (rs12356233, corrected P=0.019) and a nominally significant association between RGS12 and the response to adalimumab (rs4690093, uncorrected P=0.040).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1685,
                    "offsetInEndSection": 1857,
                    "text": "In the anti-CCP positive group of patients, we also found a nominally significant association between RGS12 and the response to infliximab (rs2857859, uncorrected P=0.042).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which diseases can be treated with Afamelanotide?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23277150",
                "http://www.ncbi.nlm.nih.gov/pubmed/19656325",
                "http://www.ncbi.nlm.nih.gov/pubmed/21073357",
                "http://www.ncbi.nlm.nih.gov/pubmed/22845050",
                "http://www.ncbi.nlm.nih.gov/pubmed/24256215",
                "http://www.ncbi.nlm.nih.gov/pubmed/20545686",
                "http://www.ncbi.nlm.nih.gov/pubmed/25402764",
                "http://www.ncbi.nlm.nih.gov/pubmed/23884489",
                "http://www.ncbi.nlm.nih.gov/pubmed/20565969",
                "http://www.ncbi.nlm.nih.gov/pubmed/25230094",
                "http://www.ncbi.nlm.nih.gov/pubmed/25470471",
                "http://www.ncbi.nlm.nih.gov/pubmed/20725548",
                "http://www.ncbi.nlm.nih.gov/pubmed/26132941",
                "http://www.ncbi.nlm.nih.gov/pubmed/23407924"
            ],
            "ideal_answer": [
                "Afamelanotide was ivestigated for treatment of erythropoietic protoporphyria, vitiligo, Hailey-Hailey disease,  acne vulgaris, polymorphic light eruption, prevention of actinic keratoses in organ transplant recipients and nonmelanoma skin cancer."
            ],
            "exact_answer": [
                [
                    "erythropoietic protoporphyria"
                ],
                [
                    "vitiligo"
                ],
                [
                    "Hailey-Hailey disease"
                ],
                [
                    "acne vulgaris"
                ],
                [
                    "polymorphic light eruption"
                ],
                [
                    "ctinic keratoses"
                ],
                [
                    "nonmelanoma skin cancer"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194"
            ],
            "type": "list",
            "id": "56c08702ef6e394741000024",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 48,
                    "text": "Afamelanotide for Erythropoietic Protoporphyria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26132941",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1848,
                    "offsetInEndSection": 2082,
                    "text": "CONCLUSIONS: Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26132941",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230094",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2195,
                    "offsetInEndSection": 2414,
                    "text": "CONCLUSIONS AND RELEVANCE: A combination of afamelanotide implant and NB-UV-B phototherapy resulted in clinically apparent, statistically significant superior and faster repigmentation compared with NB-UV-B monotherapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230094",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "UNLABELLED: Afamelanotide is an \u03b1-melanocyte-stimulating hormone (\u03b1-MSH) agonist with proven efficacy in photodermatoses such as erythropoietic protoporphyria (EPP). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402764",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "text": "Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470471",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1728,
                    "offsetInEndSection": 1809,
                    "text": "CONCLUSIONS: Afamelanotide is effective for the treatment of skin lesions in HHD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256215",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1415,
                    "offsetInEndSection": 1532,
                    "text": "CONCLUSIONS: Afamelanotide appears to have anti-inflammatory effects in patients with mild-to-moderate acne vulgaris.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 529,
                    "text": "In a recent trial, afamelanotide administered as controlled release implants protected erythropoietic protoporphyria (EPP) patients from sunlight induced phototoxic skin reactions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23277150",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1058,
                    "offsetInEndSection": 1169,
                    "text": "CONCLUSIONS: We propose that afamelanotide represents a novel and potentially effective treatment for vitiligo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407924",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 375,
                    "text": "Afamelanotide is currently undergoing phase II and III trials in Europe and the US for skin diseases including vitiligo, erythropoietic protoporphyria, polymorphic light eruption and prevention of actinic keratoses in organ transplant recipients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23884489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 542,
                    "offsetInEndSection": 666,
                    "text": "Currently, afamelanotide is already on the market in Italy and Switzerland for patients with erythropoietic protoporphyria. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23884489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1460,
                    "offsetInEndSection": 1921,
                    "text": "Agents that are showing promising results in early phases of clinical trials include betulinic acid; hedgehog signaling pathway inhibitors, such as cyclopamine and GDC-0449; alpha-melanocyte-stimulating hormone analogs, such as afamelanotide; epidermal growth factor receptor inhibitors, such as gefitinib and erlotinib; anti-epidermal growth factor receptor monoclonal antibodies, such as cetuximab and panitumumab; and the 5-fluorouracil prodrug capecitabine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20725548",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 917,
                    "offsetInEndSection": 1214,
                    "text": "Meanwhile, the regulated \u03b1-MSH analogue afamelanotide (Clinuvel Pharmaceuticals Ltd, Melbourne, Australia) is showing promise for its photoprotective potential, and is undergoing phase II and III clinical trials in people with photosensitivity disorders and those prone to nonmelanoma skin cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545686",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1240,
                    "offsetInEndSection": 1467,
                    "text": "CONCLUSIONS: Among the six models proposed to assess the effectiveness of therapeutic interventions in PP the ETFP model demonstrates the highest sensitivity using the existing data from a clinical trial of afamelanotide in PP.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20565969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Afamelanotide, an agonistic analog of \u03b1-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073357",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 241,
                    "text": "IMPORTANCE OF THE FIELD: Afamelanotide, an \u03b1-melanocyte stimulating hormone (MSH) agonistic analog is a first-in-class therapeutic. Its application to protoporphyria (PP), a disease associated with absolute sunlight-intolerance is discussed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1089,
                    "offsetInEndSection": 1242,
                    "text": "TAKE HOME MESSAGE: Although early, results of the first trials of afamelanotide for PP are promising and the risk-safety profile appears favorable today.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 483,
                    "offsetInEndSection": 577,
                    "text": "This study examines the efficacy of afamelanotide in preventing symptoms in patients with EPP.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656325",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1364,
                    "text": "The findings demonstrate beneficial effects of afamelanotide in patients with EPP.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656325",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 619,
                    "text": "Afamelanotide is currently undergoing phase II and III trials in Europe and the US for skin diseases including vitiligo, erythropoietic protoporphyria, polymorphic light eruption and prevention of actinic keratoses in organ transplant recipients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23884489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "The application of afamelanotide, an \u03b1-melanocyte stimulating hormone agonistic analogue to protoporphyria, a disease with absolute sunlight-intolerance is discussed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 269,
                    "text": "UNLABELLED: Afamelanotide is an \ufffd-melanocyte-stimulating hormone (\ufffd-MSH) agonist with proven efficacy in photodermatoses such as erythropoietic protoporphyria (EPP). This peptide drug, repeatedly administered over prolonged time, may induce anti-drug antibodies (ADA). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402764",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1743,
                    "offsetInEndSection": 2189,
                    "text": "Adverse events were mostly mild; serious adverse events were not thought to be related to the study drug.CONCLUSIONS: Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria. (Funded by Clinuvel Pharmaceuticals and others; ClinicalTrials.gov numbers, NCT01605136 and NCT00979745.).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26132941",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which micro-RNAs have been associated in the pathogenesis of Rheumatoid Arthritis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20840794",
                "http://www.ncbi.nlm.nih.gov/pubmed/18383392",
                "http://www.ncbi.nlm.nih.gov/pubmed/21611196",
                "http://www.ncbi.nlm.nih.gov/pubmed/23649045",
                "http://www.ncbi.nlm.nih.gov/pubmed/21600203",
                "http://www.ncbi.nlm.nih.gov/pubmed/18759964",
                "http://www.ncbi.nlm.nih.gov/pubmed/22161761",
                "http://www.ncbi.nlm.nih.gov/pubmed/22903258",
                "http://www.ncbi.nlm.nih.gov/pubmed/21339228",
                "http://www.ncbi.nlm.nih.gov/pubmed/22823586",
                "http://www.ncbi.nlm.nih.gov/pubmed/21339227",
                "http://www.ncbi.nlm.nih.gov/pubmed/19404929",
                "http://www.ncbi.nlm.nih.gov/pubmed/20459811",
                "http://www.ncbi.nlm.nih.gov/pubmed/24283221",
                "http://www.ncbi.nlm.nih.gov/pubmed/21279994",
                "http://www.ncbi.nlm.nih.gov/pubmed/19931339",
                "http://www.ncbi.nlm.nih.gov/pubmed/24120842",
                "http://www.ncbi.nlm.nih.gov/pubmed/23318734",
                "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
                "http://www.ncbi.nlm.nih.gov/pubmed/18438844",
                "http://www.ncbi.nlm.nih.gov/pubmed/22100329",
                "http://www.ncbi.nlm.nih.gov/pubmed/23280137",
                "http://www.ncbi.nlm.nih.gov/pubmed/23385088",
                "http://www.ncbi.nlm.nih.gov/pubmed/20223711",
                "http://www.ncbi.nlm.nih.gov/pubmed/20870441",
                "http://www.ncbi.nlm.nih.gov/pubmed/20864373",
                "http://www.ncbi.nlm.nih.gov/pubmed/21354921",
                "http://www.ncbi.nlm.nih.gov/pubmed/22494429",
                "http://www.ncbi.nlm.nih.gov/pubmed/23138379",
                "http://www.ncbi.nlm.nih.gov/pubmed/22562984"
            ],
            "ideal_answer": [
                "Different expression patterns of mir-146a, miRNA-155, miRNA-124a, mir-203, mir-223, mir-346, mir-132, mir-363, mir-498, mir-15a, and mir-16 were documented in several tissue sample types of RA patients."
            ],
            "exact_answer": [
                [
                    "miR-155"
                ],
                [
                    "miR-146a"
                ],
                [
                    "miR-124a"
                ],
                [
                    "miR-222"
                ],
                [
                    "miR-223"
                ],
                [
                    "miR-203"
                ],
                [
                    "miR-346"
                ],
                [
                    "miR-132"
                ],
                [
                    "miR-363"
                ],
                [
                    "miR-498"
                ],
                [
                    "miR-15a"
                ],
                [
                    "miR-16"
                ],
                [
                    "miR-18a"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001172",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0009405",
                "http://www.disease-ontology.org/api/metadata/DOID:7148",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"
            ],
            "type": "list",
            "id": "533c3533c45e133714000004",
            "snippets": [
                {
                    "offsetInBeginSection": 1447,
                    "offsetInEndSection": 1548,
                    "text": "This study provides the first description of increased expression of miRNA miR-155 and miR-146a in RA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18383392",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 275,
                    "text": "In this study we investigated the expression, regulation, and function of miR-155 and miR-146a in rheumatoid arthritis (RA) synovial fibroblasts (RASFs) and RA synovial tissue",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18383392",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 355,
                    "text": "The objective of this study was to identify the expression pattern of microRNA-146 (miR-146) in synovial tissue from patients with rheumatoid arthritis (RA)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18438844",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1478,
                    "offsetInEndSection": 1619,
                    "text": "This study shows that miR-146 is expressed in RA synovial tissue and that its expression is induced by stimulation with TNFalpha and IL-1beta",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18438844",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 104,
                    "text": "pregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 707,
                    "text": "Total RNA was isolated from peripheral blood mononuclear cells obtained from patients with rheumatoid arthritis, and healthy and disease control individuals, and the expression of miR-146a, miR-155, miR-132, miR-16, and microRNA let-7a was analyzed using quantitative real-time PCR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 977,
                    "text": "Rheumatoid arthritis peripheral blood mononuclear cells exhibited between 1.8-fold and 2.6-fold increases in miR-146a, miR-155, miR-132, and miR-16 expression, whereas let-7a expression was not significantly different compared with healthy control individuals",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2106,
                    "offsetInEndSection": 2371,
                    "text": "Our data also suggest a possible mechanism contributing to rheumatoid arthritis pathogenesis, whereby miR-146a expression is increased but unable to properly function, leading to prolonged tumor necrosis factor-alpha production in patients with rheumatoid arthritis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1299,
                    "offsetInEndSection": 1540,
                    "text": "Repression of TRAF6 and/or IRAK-1 in THP-1 cells resulted in up to an 86% reduction in tumor necrosis factor-alpha production, implicating that normal miR-146a function is critical for the regulation of tumor necrosis factor-alpha production",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 170,
                    "text": "icroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1051,
                    "offsetInEndSection": 1156,
                    "text": "We found that miR-124a levels significantly decreased in RA synoviocytes as compared with OA synoviocytes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1485,
                    "offsetInEndSection": 1597,
                    "text": "Induction of miR-124a in RA synoviocytes significantly suppressed the production of the CDK-2 and MCP-1 proteins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1774,
                    "offsetInEndSection": 1903,
                    "text": "he results of this study suggest that miR-124a is a key miRNA in the posttranscriptional regulatory mechanisms of RA synoviocytes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 87,
                    "text": "iR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931339",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 627,
                    "text": "Although a multifactorial pathogenesis has been hypothesized, the precise mechanisms leading to the disease are still poorly understood at the molecular level. miRNA expression profile analysis highlighted that miR-223 is the only miRNA that is strikingly deregulated in peripheral T-lymphocytes from RA patients compared with healthy donors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931339",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1055,
                    "offsetInEndSection": 1275,
                    "text": "In summary, our data provide a first characterization of the miRNA expression profiles of peripheral T-lymphocytes of RA patients, identifying miR-223 as overexpressed in CD4(+) naive T-lymphocytes from these individuals",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931339",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459811",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 692,
                    "text": "The role of miR-146a overexpression in regulating T cell apoptosis was evaluated by flow cytometry",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1483,
                    "offsetInEndSection": 1763,
                    "text": "We have detected increased miR-146a in CD4+ T cells of RA patients and its close correlation with TNF-alpha levels. Our findings that miR-146a overexpression suppresses T cell apoptosis indicate a role of miR-146a in RA pathogenesis and provide potential novel therapeutic targets",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 92,
                    "text": "icroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20840794",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1059,
                    "text": "Six miRNAs, let-7a, miR-26, miR-146a/b, miR-150, and miR-155 were significantly up regulated in the IL-17 producing T cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20840794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1487,
                    "offsetInEndSection": 1601,
                    "text": "These results indicated that miR-146a was associated with IL-17 expression in the PBMC and synovium in RA patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20840794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2,
                    "offsetInEndSection": 163,
                    "text": "polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870441",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 374,
                    "text": "MicroRNA-146a was found to be increased in synovial fibroblasts, synovial tissue and PBMC from patients with RA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1011,
                    "offsetInEndSection": 1134,
                    "text": "This is the first study that addresses association of a variant in a target of miR-146a, IRAK1 gene, with RA susceptibility",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870441",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 117,
                    "text": "ltered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 335,
                    "text": "Previously, we described increased expression of miR-155 and miR-146a in rheumatoid arthritis (RA) and showed a repressive effect of miR-155 on matrix metalloproteinase (MMP) expression in RA synovial fibroblasts (RASFs)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1575,
                    "offsetInEndSection": 1670,
                    "text": "The current results demonstrate methylation-dependent regulation of miR-203 expression in RASFs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1671,
                    "offsetInEndSection": 1879,
                    "text": " Importantly, they also show that elevated levels of miR-203 lead to increased secretion of MMP-1 and IL-6 via the NF-\u03baB pathway and thereby contribute to the activated phenotype of synovial fibroblasts in RA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 120,
                    "text": "iR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339227",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 498,
                    "text": "Transfection of miR-124a into RA synoviocytes significantly suppressed their proliferation and arrested the cell cycle at the G1 phase",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339227",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 911,
                    "text": "It is proposed that miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339227",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 156,
                    "text": "Expression of miR-146a and miR-16 in peripheral blood mononuclear cells of patients with rheumatoid arthritis and their correlation to the disease activity",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21354921",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 960,
                    "offsetInEndSection": 1128,
                    "text": "The elevated expression levels of miR-146a and miR-16 are correlated to RA disease activity, suggesting their value in assessment of the clinical disease activity of RA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21354921",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 125,
                    "text": "iR-346 controls release of TNF-\u03b1 protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21611196",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 650,
                    "text": "Using a microarray, we found two miRNAs, miR-125b and miR-939 predicted to target the 3'-UTR of TNF-\u03b1 mRNA, to be up-regulated in RA FLS in response to LPS, but their repression did not restore mature TNF-\u03b1 expression in FLS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21611196",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 781,
                    "text": "We showed previously that miR-346, which is upregulated in LPS-activated FLS, inhibited Btk expression that stabilized TNF-\u03b1 mRNA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21611196",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 555,
                    "text": "Different expression patterns of mir-146a, miRNA-155, miRNA-124a, mir-203, mir-223, mir-346, mir-132, mir-363, mir-498, mir-15a, and mir-16 were documented in several tissue sample types of RA patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100329",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 107,
                    "text": "own-regulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161761",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 848,
                    "offsetInEndSection": 1055,
                    "text": "Basal expression levels of miR-34a* were found to be reduced in synovial fibroblasts from RA patients compared to osteoarthritis patients, whereas levels of miR-34a, miR-34b/b*, and miR-34c/c* did not differ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161761",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1623,
                    "offsetInEndSection": 1724,
                    "text": "Our data provide evidence of a methylation-specific down-regulation of proapoptotic miR-34a* in RASFs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161761",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 170,
                    "text": "dentification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 720,
                    "offsetInEndSection": 867,
                    "text": "miR-seq demonstrated that TghuTNF-SF exhibit a distinct pathogenic profile with 22 significantly upregulated and 30 significantly downregulated miR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 869,
                    "offsetInEndSection": 1063,
                    "text": "Validation assays confirmed the dysregulation of miR-223, miR-146a and miR-155 previously associated with human rheumatoid arthritis (RA) pathology, as well as that of miR-221/222 and miR-323-3p",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1594,
                    "offsetInEndSection": 1678,
                    "text": "the authors identified miR-221/222 and miR-323-3p as novel dysregulated miR in RA SF",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1495,
                    "offsetInEndSection": 1633,
                    "text": "Further association studies may contribute to determining the role of miR-146a single-nucleotide polymorphisms in immune-mediated diseases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22823586",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 144,
                    "text": "iR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22823586",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 99,
                    "text": "verexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 80,
                    "offsetInEndSection": 159,
                    "text": "MicroRNA-223 (miR-223) is reported to play critical roles in osteoclastogenesis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 1589,
                    "text": "MiR-223 is intensely expressed in RA synovium, and overexpression of miR-223 suppresses osteoclastogenesis in vitro",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1591,
                    "offsetInEndSection": 1700,
                    "text": "This study demonstrates the possibility of gene therapy with miR-223 to treat bone destruction in RA patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 931,
                    "offsetInEndSection": 1085,
                    "text": "MiR-223 was more highly expressed in RA synovium than in osteoarthritis (OA) synovium due to the increased number of miR-223-positive cells in RA synovium",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 124,
                    "text": "ssociation of pre-miRNA-146a rs2910164 and pre\u2011miRNA-499 rs3746444 polymorphisms and susceptibility to rheumatoid arthritis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23138379",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1263,
                    "offsetInEndSection": 1439,
                    "text": "Our findings demonstrated that the hsa-mir-499 rs3746444, but not mir-146a rs2910164, polymorphism is associated with an increased RA risk in a sample of the Iranian population",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23138379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 139,
                    "text": "umor necrosis factor \u03b1-induced microRNA-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-\u03baB signaling",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 161,
                    "text": "To elucidate whether the microRNA (miRNA) cluster miR-17-92 contributes to the activated phenotype of rheumatoid arthritis synovial fibroblasts (RASFs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 895,
                    "text": "We found that TNF\u03b1 induces the expression of miR-17-92 in RASFs in an NF-\u03baB-dependent manner",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1151,
                    "offsetInEndSection": 1270,
                    "text": "Using reporter gene assays, we identified the NF-\u03baB pathway inhibitor TNF\u03b1-induced protein 3 as a new target of miR-18a",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1431,
                    "offsetInEndSection": 1708,
                    "text": "Our data suggest that the miR-17-92-derived miR-18a contributes to cartilage destruction and chronic inflammation in the joint through a positive feedback loop in NF-\u03baB signaling, with concomitant up-regulation of matrix-degrading enzymes and mediators of inflammation in RASFs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 774,
                    "text": "As inflammation and joint damage are the main hallmarks of RA, we focused on the three miRNAs, miR-146a, miR-155 and miR-223, whose functions have been studied in both the processes and the pathogenic role investigated in the experimental models",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318734",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 785,
                    "offsetInEndSection": 979,
                    "text": "Focusing on the role of miR-146a, miR-155 and miR-223 in RA pathogenesis emphasizes the intertwined relationships between bone homeostasis and immunity, and the prominent role of monocytes in RA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318734",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 619,
                    "text": "In a final perspective section we discuss the potential impact of therapeutic miR-155 modulation in RA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649045",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 15,
                    "offsetInEndSection": 151,
                    "text": "correlation between whole blood and PBMC expression levels of miR-155 and miR-146a in healthy controls and rheumatoid arthritis patients",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120842",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 654,
                    "offsetInEndSection": 821,
                    "text": "We demonstrated a highly significant linear correlation between miR-146a and miR-155 expression in PBMC and whole blood, from both healthy individuals and RA patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 183,
                    "text": "expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 106,
                    "text": "icroRNA-323-3p with clinical potential in rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283221",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 491,
                    "text": "It has been shown that miR-323-3p associates with the pathogenesis of several diseases, such as rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283221",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List genes that have been found mutated in CMT1A (Charcot-Marie-Tooth disease type 1 A).",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25522693",
                "http://www.ncbi.nlm.nih.gov/pubmed/25430934",
                "http://www.ncbi.nlm.nih.gov/pubmed/24819634",
                "http://www.ncbi.nlm.nih.gov/pubmed/25500726",
                "http://www.ncbi.nlm.nih.gov/pubmed/25400662",
                "http://www.ncbi.nlm.nih.gov/pubmed/25385046",
                "http://www.ncbi.nlm.nih.gov/pubmed/25519680",
                "http://www.ncbi.nlm.nih.gov/pubmed/25429913",
                "http://www.ncbi.nlm.nih.gov/pubmed/25150498"
            ],
            "ideal_answer": [
                "PMP22 is the common gene found mutated through a duplication in CMT1A. Other genes are\nMPZ and SH3TC2"
            ],
            "exact_answer": [
                [
                    "PMP22"
                ],
                [
                    "MPZ"
                ],
                [
                    "SH3TC2"
                ]
            ],
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:10595",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002607"
            ],
            "type": "list",
            "id": "54d65b6b3706e8952800000c",
            "snippets": [
                {
                    "offsetInBeginSection": 26,
                    "offsetInEndSection": 77,
                    "text": "Most cases of CMT are caused by mutations in PMP22,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25522693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 164,
                    "offsetInEndSection": 196,
                    "text": " structural myelin protein PMP22",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25519680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "text": "Duplication of the gene encoding the peripheral myelin protein of 22 kDa (PMP22) underlies the most common inherited neuropathy, Charcot-Marie-Tooth 1A (CMT1A), a disease without a known cure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25150498",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1085,
                    "text": ". Two patients showed rearrangements in the PMP22 gene, which is commonly associated with CMT1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24819634",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 290,
                    "text": "Many PMP22 mutants accumulate in excess in the endoplasmic reticulum (ER) and lead to the inherited neuropathies of Charcot-Marie-Tooth (CMT) disease. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "The T118M mutation in PMP22 gene is associated with Charcot Marie Tooth, type 1A (CMT1A).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400662",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 644,
                    "offsetInEndSection": 794,
                    "text": "In CMT1, PMP22 duplication was the most common mutation while the second gene in order of frequency was MPZ in familial and SH3TC2 in isolated cases. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25429913",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 739,
                    "offsetInEndSection": 762,
                    "text": "CMT1A/PMP22 duplication",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430934",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 287,
                    "text": "he most frequent subtype is type 1A (CMT1A) caused by duplication in chromosome 17p12 that includes PMP22.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25500726",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which genes have been found mutated in Gray platelet syndrome patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23861251",
                "http://www.ncbi.nlm.nih.gov/pubmed/24325358",
                "http://www.ncbi.nlm.nih.gov/pubmed/17209061",
                "http://www.ncbi.nlm.nih.gov/pubmed/21765411",
                "http://www.ncbi.nlm.nih.gov/pubmed/21765413",
                "http://www.ncbi.nlm.nih.gov/pubmed/21765412",
                "http://www.ncbi.nlm.nih.gov/pubmed/23100277"
            ],
            "ideal_answer": [
                "The genetic defects responsible for gray platelet syndrome are mutations in the genes NBEAL2, GATA1 and GFI1B.",
                "The genetic defect responsible for gray platelet syndrome was recently identified in biallelic mutations in the NBEAL2 gene.\nA nonsense mutation in the gene encoding the transcription factor GFI1B (growth factor independent 1B) that causes autosomal dominant gray platelet syndrome.\nX-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation."
            ],
            "exact_answer": [
                [
                    "neurobeachin-like 2",
                    "NBEAL2"
                ],
                [
                    "GATA1"
                ],
                [
                    "GFI1B"
                ]
            ],
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:225",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0030220",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0036345",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
                "http://www.disease-ontology.org/api/metadata/DOID:2218",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0036344",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055652"
            ],
            "type": "list",
            "id": "52f89f4f2059c6d71c00004e",
            "snippets": [
                {
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 315,
                    "text": "We detected a nonsense mutation in the gene encoding the transcription factor GFI1B (growth factor independent 1B) that causes autosomal dominant gray platelet syndrome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325358",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 279,
                    "text": "The genetic defect responsible for gray platelet syndrome was recently identified in biallelic mutations in the NBEAL2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100277",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 370,
                    "text": "Here we show that mutations in NBEAL2 (neurobeachin-like 2), which encodes a BEACH/ARM/WD40 domain protein, cause GPS and that megakaryocytes and platelets from individuals with GPS express a unique combination of NBEAL2 transcripts. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21765412",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 385,
                    "offsetInEndSection": 665,
                    "text": "Linkage analysis revealed a 63 cM region on the X chromosome between markers G10578 and DXS6797, which segregated with the platelet phenotype and included the GATA1 gene. Sequencing of GATA1 revealed a G-to-A mutation at position 759 corresponding to amino acid change Arg216Gln. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209061",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "We identified a family with gray platelet syndrome (GPS) segregating as a sex-linked trait. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209061",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209061",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "List signaling molecules (ligands) that interact with the receptor EGFR?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23959273",
                "http://www.ncbi.nlm.nih.gov/pubmed/21514161",
                "http://www.ncbi.nlm.nih.gov/pubmed/23212918",
                "http://www.ncbi.nlm.nih.gov/pubmed/23888072",
                "http://www.ncbi.nlm.nih.gov/pubmed/23821377",
                "http://www.ncbi.nlm.nih.gov/pubmed/23099994",
                "http://www.ncbi.nlm.nih.gov/pubmed/22260327",
                "http://www.ncbi.nlm.nih.gov/pubmed/24204699",
                "http://www.ncbi.nlm.nih.gov/pubmed/24323361",
                "http://www.ncbi.nlm.nih.gov/pubmed/23089711",
                "http://www.ncbi.nlm.nih.gov/pubmed/23399900",
                "http://www.ncbi.nlm.nih.gov/pubmed/23382875",
                "http://www.ncbi.nlm.nih.gov/pubmed/23729230",
                "http://www.ncbi.nlm.nih.gov/pubmed/23787814",
                "http://www.ncbi.nlm.nih.gov/pubmed/24124521",
                "http://www.ncbi.nlm.nih.gov/pubmed/22247333"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q9QX70",
                    "o": "http://linkedlifedata.com/resource/#_5139515837300022"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_5139515837300022",
                    "o": "Egfr"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/intact/EBI-1256812",
                    "o": "http://purl.uniprot.org/uniprot/Q9QX70"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/intact/EBI-1256812",
                    "o": "Egfr"
                }
            ],
            "ideal_answer": [
                "The 7 known EGFR ligands  are: epidermal growth factor (EGF), betacellulin (BTC), epiregulin (EPR), heparin-binding EGF (HB-EGF), transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin (AREG) and epigen (EPG)."
            ],
            "exact_answer": [
                [
                    "epidermal growth factor"
                ],
                [
                    "betacellulin"
                ],
                [
                    "epiregulin"
                ],
                [
                    "heparin-binding epidermal growth factor"
                ],
                [
                    "transforming growth factor-\u03b1"
                ],
                [
                    "amphiregulin"
                ],
                [
                    "epigen"
                ]
            ],
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005154",
                "http://www.uniprot.org/uniprot/EGFR_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005488",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042058",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018773",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008024",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045741",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007173",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005006",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007175",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007176",
                "http://www.uniprot.org/uniprot/EGFR_CHICK"
            ],
            "type": "list",
            "id": "55046d5ff8aee20f27000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1085,
                    "offsetInEndSection": 1199,
                    "text": "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24323361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1139,
                    "offsetInEndSection": 1247,
                    "text": " EGFR ligands epidermal growth factor (EGF), amphiregulin (AREG) and transforming growth factor alpha (TGF\u03b1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 97,
                    "text": " EGFR and its ligand EGF ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959273",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1058,
                    "text": "Among EGFR ligands, heparin-binding EGF-like growth factor, TGF-\u03b1 and Betacellulin (BTC) are produced in the tumor microenvironment of FDC-S at RNA level. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888072",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 493,
                    "text": ". Plasma amphiregulin (AR), epidermal growth factor (EGF), transforming growth factor-\u03b1, and heparin binding-EGF were assessed by ELISA in 45 chemorefractory mCRC patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821377",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 346,
                    "offsetInEndSection": 414,
                    "text": "Among EGFR ligands, heparin-binding epidermal growth factor (HB-EGF)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 357,
                    "offsetInEndSection": 521,
                    "text": " Of the six known EGFR ligands, transforming growth factor alpha (TGF\u03b1) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729230",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 923,
                    "text": "the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin, and epigen) ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23399900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1393,
                    "offsetInEndSection": 1472,
                    "text": "EGFR ligands based on the two affinity classes: EGF>HB-EGF>TGF-\u03b1>BTC>EPR>EPG>AR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382875",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 320,
                    "text": "In this article, however, we demonstrate that PEPD directly binds to and activates epidermal growth factor receptor (EGFR),",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212918",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1559,
                    "offsetInEndSection": 1607,
                    "text": "four EGFR ligands (AR, HB-EGF, TGF-\u03b1, and EREG) ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099994",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Epidermal growth factor (EGF) family peptides are ligands for the EGF receptor (EGFR). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22260327",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 240,
                    "offsetInEndSection": 490,
                    "text": "oluble amphiregulin (AR), transforming growth factor alpha (TGF\u03b1), neuregulin 2 beta, and epigen stimulate greater EGFR coupling to cell proliferation and DNA synthesis than do EGF, betacellulin, heparin-binding EGF-like growth factor, and epiregulin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22260327",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 563,
                    "text": "Here, we demonstrate that histamine releases 2 EGFR ligands, amphiregulin and heparin-binding epidermal growth factor-like growth factor (HB-EGF), from airway epithelial cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247333",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 231,
                    "text": "mammalian EGFR ligands including EGF, TGF-\u03b1 (TGF\u03b1), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin, epiregulin, and epigen.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514161",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List available circular RNA prediction tools.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26657634"
            ],
            "ideal_answer": [
                "circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice."
            ],
            "exact_answer": [
                [
                    "circRNA_finder"
                ],
                [
                    "find_circ"
                ],
                [
                    "CIRCexplorer"
                ],
                [
                    "CIRI"
                ],
                [
                    "MapSplice"
                ]
            ],
            "type": "list",
            "id": "588f220e3b87a8a73800000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1119,
                    "text": "CircRNAs are novel members of the non-coding RNA family. For several decades circRNAs have been known to exist, however only recently the widespread abundance has become appreciated. Annotation of circRNAs depends on sequencing reads spanning the backsplice junction and therefore map as non-linear reads in the genome. Several pipelines have been developed to specifically identify these non-linear reads and consequently predict the landscape of circRNAs based on deep sequencing datasets. Here, we use common RNAseq datasets to scrutinize and compare the output from five different algorithms; circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice and evaluate the levels of bona fide and false positive circRNAs based on RNase R resistance. By this approach, we observe surprisingly dramatic differences between the algorithms specifically regarding the highly expressed circRNAs and the circRNAs derived from proximal splice sites. Collectively, this study emphasizes that circRNA annotation should be handled with care and that several algorithms should ideally be combined to achieve reliable predictions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657634",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "List types of avoided words in bacterial genomes",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12762852",
                "http://www.ncbi.nlm.nih.gov/pubmed/9171096"
            ],
            "ideal_answer": [
                "Short palindromic sequences (4, 5 and 6 bp palindromes) are avoided at a statistically significant level in the genomes of several bacteria, including the completely sequenced Haemophilus influenzae and Synechocystis sp. genomes and in the complete genome of the archaeon Methanococcus jannaschii. Palindromes corresponding to sites for restriction enzymes from other species are also avoided, albeit less significantly, suggesting that in the course of evolution bacterial DNA has been exposed to a wide spectrum of restriction enzymes, probably as the result of lateral transfer mediated by mobile genetic elements, such as plasmids and prophages. Palindromic words appear to accumulate in DNA once it becomes isolated from restriction-modification systems, as demonstrated by the case of organellar genomes."
            ],
            "exact_answer": [
                [
                    "Short palindromic sequences (4, 5 and 6 bp palindromes)"
                ],
                [
                    "Palindromes corresponding to sites for restriction enzymes from other species"
                ]
            ],
            "type": "list",
            "id": "56a37e33496b62f23f000003",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Avoidance of palindromic words in bacterial and archaeal genomes: a close connection with restriction enzymes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9171096",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "Short palindromic sequences (4, 5 and 6 bp palindromes) are avoided at a statistically significant level in the genomes of several bacteria, including the completely sequenced Haemophilus influenzae and Synechocystis sp. genomes and in the complete genome of the archaeon Methanococcus jannaschii.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9171096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 804,
                    "offsetInEndSection": 1154,
                    "text": "Palindromes corresponding to sites for restriction enzymes from other species are also avoided, albeit less significantly, suggesting that in the course of evolution bacterial DNA has been exposed to a wide spectrum of restriction enzymes, probably as the result of lateral transfer mediated by mobile genetic elements, such as plasmids and prophages",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9171096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1156,
                    "offsetInEndSection": 1315,
                    "text": "Palindromic words appear to accumulate in DNA once it becomes isolated from restriction-modification systems, as demonstrated by the case of organellar genomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9171096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1496,
                    "offsetInEndSection": 1642,
                    "text": "In certain cases, a comparison of avoided palindromic words in taxonomically related bacteria shows a pattern of relatedness of their R-M systems.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762852",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Recognition sites for type II restriction and modification enzymes in genomes of several bacteria are recognized as semi-palindromic motifs and are avoided at a significant degree.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762852",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1200,
                    "offsetInEndSection": 1506,
                    "text": "On the basis of the set of most avoided words, and in accordance to the IUPAC coding standards, suggestions are made regarding potential recognition sequences. In certain cases, a comparison of avoided palindromic words in taxonomically related bacteria shows a pattern of relatedness of their R-M systems.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762852",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which tissues express the ACE2 protein?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15221932",
                "http://www.ncbi.nlm.nih.gov/pubmed/24564768",
                "http://www.ncbi.nlm.nih.gov/pubmed/19014390",
                "http://www.ncbi.nlm.nih.gov/pubmed/19333547"
            ],
            "ideal_answer": [
                "Abundant ACE2 immunostaining was found in lung, kidney, heart, and islets of pancreas, but not in hepatocytes"
            ],
            "exact_answer": [
                [
                    "lung"
                ],
                [
                    "kidney"
                ],
                [
                    "heart"
                ],
                [
                    "pancreas"
                ]
            ],
            "type": "list",
            "id": "5e80e449835f4e477700002c",
            "snippets": [
                {
                    "offsetInBeginSection": 1409,
                    "offsetInEndSection": 1487,
                    "text": "in keeping with the variability of ACE2 expression we have observed previously",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564768",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 441,
                    "text": "ACE2 has been identified in various tissues and is supposed to be a modulator of cardiovascular function. Decreases in ACE2 expression and activity have been reported in models of hypertension, heart failure, atherosclerosis, diabetic nephropathy and others. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19014390",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 675,
                    "offsetInEndSection": 814,
                    "text": "ACE2 is expressed at high level in the primary target cells of SARS-CoV, namely pneumocytes and surface enterocytes of the small intestine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15221932",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1100,
                    "text": "endothelial cells, which express ACE2 to a high level,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15221932",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1090,
                    "offsetInEndSection": 1199,
                    "text": "Abundant ACE2 immunostaining was found in lung, kidney, heart, and islets of pancreas, but not in hepatocytes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19333547",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which protein complexes contain mitofilin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24030101",
                "http://www.ncbi.nlm.nih.gov/pubmed/23676277",
                "http://www.ncbi.nlm.nih.gov/pubmed/22252321",
                "http://www.ncbi.nlm.nih.gov/pubmed/21987634",
                "http://www.ncbi.nlm.nih.gov/pubmed/22575891",
                "http://www.ncbi.nlm.nih.gov/pubmed/22014515",
                "http://www.ncbi.nlm.nih.gov/pubmed/21944719",
                "http://www.ncbi.nlm.nih.gov/pubmed/22496419",
                "http://www.ncbi.nlm.nih.gov/pubmed/22918945",
                "http://www.ncbi.nlm.nih.gov/pubmed/23704930"
            ],
            "ideal_answer": [
                "mitochondrial inter-membrane space bridging (MIB) complex \nmitochondrial inner membrane organizing system (MINOS)\nMitOS for mitochondrial organizing structure"
            ],
            "exact_answer": [
                [
                    "MIB",
                    "mitochondrial inter-membrane space bridging complex"
                ],
                [
                    "MINOS",
                    "mitochondrial inner membrane organizing system"
                ],
                [
                    "MitOS"
                ]
            ],
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016592",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0043234",
                "http://www.uniprot.org/uniprot/FCJ1_LODEL",
                "http://www.uniprot.org/uniprot/FCJ1_SCLS1",
                "http://www.uniprot.org/uniprot/FCJ1_CANAL",
                "http://www.uniprot.org/uniprot/FCJ1_AJECN",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D046912",
                "http://www.uniprot.org/uniprot/FCJ1_CANTT"
            ],
            "type": "list",
            "id": "53215fca9b2d7acc7e000005",
            "snippets": [
                {
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1062,
                    "text": " and the mitochondrial structural proteins-components of mitochondrial inter-membrane space bridging (MIB) complex (Mitofilin, Sam50, and ChChd3), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030101",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 330,
                    "offsetInEndSection": 362,
                    "text": "Mitofilin/MINOS protein complex ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 879,
                    "offsetInEndSection": 989,
                    "text": " APOOL physically interacts with several subunits of the MINOS complex, namely Mitofilin, MINOS1, and SAMM50. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1054,
                    "offsetInEndSection": 1086,
                    "text": "Mitofilin/MINOS protein complex ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 662,
                    "text": "MINOS subunits (mitofilin, MINOS1, and CHCHD3)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23676277",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 918,
                    "offsetInEndSection": 950,
                    "text": "mitofilin, a core MINOS subunit,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23676277",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 239,
                    "text": "The mitochondrial inner membrane organizing system (MINOS) is a large protein complex required for maintaining inner membrane architecture. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22918945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 731,
                    "offsetInEndSection": 795,
                    "text": "Mitochondria lacking mitofilin, the large core subunit of MINOS,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22918945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "The mitochondrial inner membrane contains a large protein complex crucial for membrane architecture, the mitochondrial inner membrane organizing system (MINOS).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22575891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 557,
                    "text": " To study if outer membrane interactions and maintenance of cristae morphology are directly coupled, we generated mutant forms of mitofilin/Fcj1 (formation of crista junction protein 1), a core component of MINOS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22575891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "The C-terminal domain of Fcj1 is required for formation of crista junctions and interacts with the TOB/SAM complex in mitochondria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496419",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 291,
                    "text": "Mitofilin/Fcj1, the central component of the MINOS complex,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014515",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 648,
                    "text": "We provide evidence that the SAM components exist in a large protein complex together with the IMM proteins mitofilin and CHCHD3, which we term the mitochondrial intermembrane space bridging (MIB) complex.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22252321",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 680,
                    "text": "which we term MitOS for mitochondrial organizing structure, comprised of Fcj1/Mitofilin, a conserved inner membrane protein, and five additional components. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21987634",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 599,
                    "text": "Mitofilin is part of a large inner membrane complex, and we identify five partner proteins as constituents of the mitochondrial inner membrane organizing system (MINOS) that is required for keeping cristae membranes connected to the inner boundary membrane.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21944719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 813,
                    "text": " Our findings indicate that mitofilin is a central component\u00a0of MINOS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21944719",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Which miRNAs could be used as potential biomarkers for epithelial ovarian cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21345725",
                "http://www.ncbi.nlm.nih.gov/pubmed/22246341",
                "http://www.ncbi.nlm.nih.gov/pubmed/23836287",
                "http://www.ncbi.nlm.nih.gov/pubmed/20035894",
                "http://www.ncbi.nlm.nih.gov/pubmed/23542579",
                "http://www.ncbi.nlm.nih.gov/pubmed/19074899",
                "http://www.ncbi.nlm.nih.gov/pubmed/21971665",
                "http://www.ncbi.nlm.nih.gov/pubmed/23978303",
                "http://www.ncbi.nlm.nih.gov/pubmed/18954897",
                "http://www.ncbi.nlm.nih.gov/pubmed/21571355",
                "http://www.ncbi.nlm.nih.gov/pubmed/23888941",
                "http://www.ncbi.nlm.nih.gov/pubmed/23918241",
                "http://www.ncbi.nlm.nih.gov/pubmed/23272653",
                "http://www.ncbi.nlm.nih.gov/pubmed/23621186"
            ],
            "ideal_answer": [
                "miR-200a, miR-100, miR-141, miR-200b, miR-200c, miR-203, miR-510, miR-509-5p, miR-132, miR-26a, let-7b, miR-145, miR-182, miR-152, miR-148a, let-7a, let-7i, miR-21, miR-92 and miR-93 could be used as potential biomarkers for epithelial ovarian cancer."
            ],
            "exact_answer": [
                [
                    "let-7a"
                ],
                [
                    "let-7b"
                ],
                [
                    "let-7i"
                ],
                [
                    "miR-21"
                ],
                [
                    "miR-26a"
                ],
                [
                    "miR-92"
                ],
                [
                    "miR-93"
                ],
                [
                    "miR-100"
                ],
                [
                    "miR-132"
                ],
                [
                    "miR-141"
                ],
                [
                    "miR-145"
                ],
                [
                    "miR-148a"
                ],
                [
                    "miR-152"
                ],
                [
                    "miR-182"
                ],
                [
                    "miR-200a"
                ],
                [
                    "miR-200b"
                ],
                [
                    "miR-200c"
                ],
                [
                    "miR-203"
                ],
                [
                    "miR-509-5p"
                ],
                [
                    "miR-510"
                ]
            ],
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010051",
                "http://www.disease-ontology.org/api/metadata/DOID:2394"
            ],
            "type": "list",
            "id": "553fa78b1d53b76422000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1388,
                    "text": "Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies. MiR-200a, miR-200b, miR-200c, and miR-141, all of them belong to miR-200 family, were reported with consistently up-regulated in at least 4 studies, whereas miR-100 was reported with down-regulated in 4 studies",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23978303",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918241",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1418,
                    "text": "multivariate analysis showed that the status of miR-203 expression was an independent predictor for both overall survival and progression-free survival in EOC. These findings provide the convincing evidence for the first time that the upregulation of miR-203 may serve as a novel molecular marker to predict the aggressive tumor progression and unfavorable prognosis of EOC patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918241",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 493,
                    "offsetInEndSection": 773,
                    "text": "Some, but not all, of the data indicated that the miR-200 family was dysregulated in a variety of malignancies. In this study, we demonstrated that miR-200a and E-cadherin were significantly upregulated in EOC compared to benign epithelial ovarian cysts and normal ovarian tissues",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888941",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1324,
                    "offsetInEndSection": 1656,
                    "text": "There was a significantly positive correlation between miR-200a and E-cadherin in EOC. The biphasic expression pattern suggested that miR-200a levels may serve as novel biomarkers for the early detection of EOC, and miR-200a and E-cadherin are candidate targets for the development of new treatment modalities against ovarian cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888941",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1385,
                    "offsetInEndSection": 1771,
                    "text": "Kaplan-Meier analysis showed low miR-510 expression, low miR-509-5p expression, and advanced FIGO stage, and chemotherapy resistance were significantly associated with poorer overall survival (P < 0.05). Our results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1383,
                    "text": "The qRT-PCR results showed that miR-510, miR-509-5p, and miR-508-3p were significantly downregulated and that miR-483-5p was upregulated in stage III OSC compared with stage I, which was consistent with the microarray results",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 704,
                    "text": "In this study, we examined serum miR-21 levels in epithelial ovarian cancer (EOC) patients, and explored its association with clinicopathological factors and prognosis. The results showed significantly higher serum miR-21 levels in EOC patients than in healthy controls. In addition, increased serum miR-21 expression was correlated with advanced FIGO stage, high tumor grade, and shortened overall survival. These findings indicate that serum miR-21 may serve as a novel diagnostic and prognostic marker, and be used as a therapeutic target for the treatment of EOC",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23621186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23621186",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1680,
                    "offsetInEndSection": 1813,
                    "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1173,
                    "offsetInEndSection": 1665,
                    "text": "Among the miRNAs that showed a consistent regulation tendency through all specimens and showed more than a 2-fold difference in serum, 5 miRNAs (miR-132, miR-26a, let-7b, miR-145, and miR-143) were determined as the 5 most markedly down-regulated miRNAs in the serum from ovarian cancer patients with respect to those of controls. Four miRNAs (miR-132, miR-26a, let-7b, and miR-145) out of 5 selected miRNAs were significantly underexpressed in the serum of ovarian cancer patients in qRT-PCR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 739,
                    "offsetInEndSection": 968,
                    "text": " microRNA (miR)-182, miR-200a, miR-200b and miR-200c were highly overexpressed in the SEOC cell lines relative to normal human ovarian surface epithelial cells and were assessed in RNA extracted from serum as candidate biomarkers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272653",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1633,
                    "text": "Together, these results suggest that low miR-100 expression             may be an independent poor prognostic factor and miR-100 can function as a tumor             suppressor by targeting PLK1 in human EOCs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246341",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Prognostic implications of microRNA-100 and its functional roles in             human epithelial ovarian cancer",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246341",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1476,
                    "offsetInEndSection": 1738,
                    "text": "Taken together, miR-152 and miR-148a may be involved             in the carcinogenesis of ovarian cancer through deregulation of cell proliferation.             They may be novel biomarkers for early detection or therapeutic targets of ovarian             cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21971665",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571355",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1988,
                    "offsetInEndSection": 2236,
                    "text": " The study suggests that the beneficial impact of the addition of paclitaxel on EOC survival was significantly linked to let-7a levels, and that miRNAs such as let-7a may be a useful marker for selection of chemotherapeutic agents in EOC management",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571355",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2573,
                    "offsetInEndSection": 2669,
                    "text": "miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21345725",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074899",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1507,
                    "offsetInEndSection": 1723,
                    "text": " our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074899",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1560,
                    "offsetInEndSection": 1641,
                    "text": "miRNAs-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18954897",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1641,
                    "offsetInEndSection": 1773,
                    "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}